<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Kidney dialysis</title><meta name="description" content="Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury. The procedure mimics the kidneys&#x27; natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences. The two main..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="dialysis, renal dialysis"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Kidney_dialysis"/><meta property="og:title" content="Kidney dialysis"/><meta property="og:description" content="Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury. The procedure mimics the kidneys&#x27; natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences. The two main..."/><meta property="og:url" content="https://grokipedia.com/page/Kidney_dialysis"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Kidney dialysis"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:43.233Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Kidney dialysis"/><meta name="twitter:description" content="Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury. The procedure mimics the kidneys&#x27; natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences. The two main..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="e4ed0605247d336f7d62cb7be0627372-a4c86afeec2962a2-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=e4ed0605247d336f7d62cb7be0627372,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.056448766706321596,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#kidney-dialysis" class="transition-opacity hover:opacity-100 opacity-50">Kidney dialysis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fundamentals" class="transition-opacity hover:opacity-100 opacity-50">Fundamentals</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#definition-and-principles" class="transition-opacity hover:opacity-100 opacity-50">Definition and Principles</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dialysate-composition-and-substance-removal" class="transition-opacity hover:opacity-100 opacity-50">Dialysate Composition and Substance Removal</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#types-of-dialysis" class="transition-opacity hover:opacity-100 opacity-50">Types of Dialysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hemodialysis" class="transition-opacity hover:opacity-100 opacity-50">Hemodialysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#peritoneal-dialysis" class="transition-opacity hover:opacity-100 opacity-50">Peritoneal Dialysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#continuous-renal-replacement-therapies" class="transition-opacity hover:opacity-100 opacity-50">Continuous Renal Replacement Therapies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#emerging-and-experimental-modalities" class="transition-opacity hover:opacity-100 opacity-50">Emerging and Experimental Modalities</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-applications" class="transition-opacity hover:opacity-100 opacity-50">Clinical Applications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#indications-for-acute-kidney-injury" class="transition-opacity hover:opacity-100 opacity-50">Indications for Acute Kidney Injury</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#indications-for-chronic-kidney-disease" class="transition-opacity hover:opacity-100 opacity-50">Indications for Chronic Kidney Disease</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#contraindications-and-conservative-management-alternatives" class="transition-opacity hover:opacity-100 opacity-50">Contraindications and Conservative Management Alternatives</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment-procedures" class="transition-opacity hover:opacity-100 opacity-50">Treatment Procedures</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#vascular-and-peritoneal-access-methods" class="transition-opacity hover:opacity-100 opacity-50">Vascular and Peritoneal Access Methods</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#session-protocols-and-monitoring" class="transition-opacity hover:opacity-100 opacity-50">Session Protocols and Monitoring</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#home-versus-in-center-delivery" class="transition-opacity hover:opacity-100 opacity-50">Home versus In-Center Delivery</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-outcomes" class="transition-opacity hover:opacity-100 opacity-50">Clinical Outcomes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#survival-rates-and-mortality-data" class="transition-opacity hover:opacity-100 opacity-50">Survival Rates and Mortality Data</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#quality-of-life-and-functional-impacts" class="transition-opacity hover:opacity-100 opacity-50">Quality of Life and Functional Impacts</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#comparisons-to-kidney-transplantation-and-no-treatment" class="transition-opacity hover:opacity-100 opacity-50">Comparisons to Kidney Transplantation and No Treatment</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#complications-and-risks" class="transition-opacity hover:opacity-100 opacity-50">Complications and Risks</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#acute-complications" class="transition-opacity hover:opacity-100 opacity-50">Acute Complications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-complications" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Complications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#economic-and-systemic-factors" class="transition-opacity hover:opacity-100 opacity-50">Economic and Systemic Factors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment-costs-and-cost-effectiveness" class="transition-opacity hover:opacity-100 opacity-50">Treatment Costs and Cost-Effectiveness</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#industry-structure-and-market-dynamics" class="transition-opacity hover:opacity-100 opacity-50">Industry Structure and Market Dynamics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#access-disparities-and-policy-influences" class="transition-opacity hover:opacity-100 opacity-50">Access Disparities and Policy Influences</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#special-populations" class="transition-opacity hover:opacity-100 opacity-50">Special Populations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pediatric-dialysis" class="transition-opacity hover:opacity-100 opacity-50">Pediatric Dialysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dialysis-in-the-elderly-and-frail" class="transition-opacity hover:opacity-100 opacity-50">Dialysis in the Elderly and Frail</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#historical-development" class="transition-opacity hover:opacity-100 opacity-50">Historical Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#early-innovations-and-ethical-challenges" class="transition-opacity hover:opacity-100 opacity-50">Early Innovations and Ethical Challenges</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#modern-advancements-and-milestones" class="transition-opacity hover:opacity-100 opacity-50">Modern Advancements and Milestones</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#controversies-and-debates" class="transition-opacity hover:opacity-100 opacity-50">Controversies and Debates</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#resource-allocation-and-rationing" class="transition-opacity hover:opacity-100 opacity-50">Resource Allocation and Rationing</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#optimal-timing-of-dialysis-initiation" class="transition-opacity hover:opacity-100 opacity-50">Optimal Timing of Dialysis Initiation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#barriers-to-home-dialysis-adoption" class="transition-opacity hover:opacity-100 opacity-50">Barriers to Home Dialysis Adoption</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#future-directions" class="transition-opacity hover:opacity-100 opacity-50">Future Directions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#technological-innovations" class="transition-opacity hover:opacity-100 opacity-50">Technological Innovations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research-and-potential-breakthroughs" class="transition-opacity hover:opacity-100 opacity-50">Research and Potential Breakthroughs</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="kidney-dialysis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Kidney dialysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The procedure mimics the kidneys&#x27; natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The two main types are hemodialysis, which involves diverting blood through an external machine equipped with a dialyzer to perform the filtration, typically three times per week for several hours per session, and peritoneal dialysis, which utilizes the peritoneal membrane in the abdomen as the filter by infusing and draining dialysate fluid.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Hemodialysis requires vascular access such as an arteriovenous fistula or graft, while peritoneal dialysis employs a catheter into the peritoneal cavity, allowing for more frequent, shorter treatments often performed at home.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Both modalities sustain life in the absence of kidney function but do not restore it, serving as a bridge to potential transplantation or long-term management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pioneered by Dutch physician Willem Kolff, who constructed the first functional artificial kidney in 1943 using a rotating drum of cellophane tubing amid wartime scarcity, dialysis marked a breakthrough in treating otherwise fatal uremia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Subsequent advancements, including Kolff&#x27;s twin-coil dialyzer in the 1950s, enabled widespread clinical use and improved efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> In the United States, where end-stage kidney disease affects hundreds of thousands, dialysis patients exhibit a five-year survival rate of approximately 35%, influenced by factors such as age, comorbidities like diabetes, and treatment adherence, though outcomes remain inferior to kidney transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Despite its life-extending role, dialysis is associated with significant complications, including vascular access failures that drive 12-25% of hospitalizations and annual costs exceeding billions, alongside debates over surveillance protocols&#x27; efficacy in preventing thrombosis and stenosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_101qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_141qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h2 id="fundamentals" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Fundamentals<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="definition-and-principles" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Definition and Principles<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Dialysis constitutes a renal replacement therapy that artificially emulates select excretory functions of the kidneys by extracting metabolic waste products, excess electrolytes, and superfluous fluid from the bloodstream when renal function is profoundly impaired. This process is essential for sustaining life in individuals with acute kidney injury or end-stage renal disease, where glomerular filtration rates fall below viable thresholds, typically under 10-15 mL/min/1.73 mÂ². Unlike native kidneys, which integrate filtration, reabsorption, secretion, and endocrine regulation, dialysis primarily achieves solute clearance and volume control through engineered physicochemical mechanisms, without replicating active transport or hormonal outputs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The core principles of dialysis hinge on transmembrane transport across a semipermeable membrane, exploiting gradients in concentration, pressure, and osmolarity to facilitate diffusion, convection, and osmosis. Diffusion drives the passive movement of small-molecular-weight solutesâ€”such as urea (molecular weight 60 Da), creatinine (113 Da), and potassium ionsâ€”from regions of higher concentration in blood to lower concentrations in the dialysate solution, governed by Fick&#x27;s law of diffusion, where flux is proportional to the concentration differential and membrane permeability. Convection, or ultrafiltration, entails bulk fluid removal via hydrostatic pressure gradients across the membrane, akin to glomerular capillary dynamics, with rates controlled by transmembrane pressure differences typically ranging from 100-500 mmHg in intermittent hemodialysis sessions. Osmotic forces, induced by hypertonic dialysate components like glucose (up to 4.25% in peritoneal variants), supplement ultrafiltration by drawing water from blood into the dialysate compartment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Efficiency in solute removal is enhanced by countercurrent flow configurations in extracorporeal systems, where blood and dialysate traverse the membrane in opposing directions, preserving a maximal trans-membrane concentration gradient along the dialyzer length and thereby optimizing diffusive clearance; this principle, rooted in heat exchanger engineering, can elevate urea removal rates by up to 20-30% compared to cocurrent setups. Membrane biocompatibility and pore size distribution further dictate selectivity, with high-flux synthetic polymers (e.g., polysulfone) permitting passage of middle molecules (500-60,000 Da) like Î²2-microglobulin, reducing long-term complications such as dialysis-related amyloidosis. However, dialysis incompletely substitutes renal physiology, as evidenced by persistent uremic toxicity from protein-bound toxins (e.g., indoxyl sulfate) that evade diffusive clearance due to plasma protein binding and low dialysate solubility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<h3 id="dialysate-composition-and-substance-removal" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dialysate Composition and Substance Removal<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The dialysate in kidney dialysis is an aqueous electrolyte solution formulated to mimic key aspects of plasma composition while excluding uremic toxins, thereby creating concentration gradients for solute removal. In hemodialysis (HD), dialysate is prepared by mixing purified water with concentrates containing sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, and sometimes glucose or acetate as buffers or osmotic agents. Standard concentrations include sodium at 135â€“145 mmol/L to maintain osmotic stability and prevent disequilibrium syndrome, potassium at 1â€“3 mmol/L to avoid hypokalemia while correcting hyperkalemia, calcium at 1.25â€“1.75 mmol/L (2.5â€“3.5 mEq/L) to support cardiac function and bone health, magnesium at 0.25â€“0.5 mmol/L (0.5â€“1 mEq/L) to minimize post-dialysis hypomagnesemia, and bicarbonate at 32â€“40 mmol/L to buffer acidosis without risking alkalosis or vascular calcification. Glucose is often included at 5.5â€“11 mmol/L (100â€“200 mg/dL) to prevent hypoglycemia, though its absence in some formulations relies on patient glucose levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">In peritoneal dialysis (PD), dialysate composition differs to leverage the peritoneal membrane, featuring sodium at approximately 132 mmol/L, chloride at 95â€“105 mmol/L, calcium at 1.25â€“1.75 mmol/L, magnesium at 0.25â€“0.5 mmol/L, and a buffer such as lactate (35â€“40 mmol/L) or bicarbonate, with glucose concentrations varying from 1.5% to 4.25% (82â€“231 mmol/L) to drive ultrafiltration via osmosis. These formulations are sterilized in plastic bags and lack potassium to facilitate its removal from peritoneal effluent. Adjustments to dialysate composition, such as varying potassium or calcium levels, are individualized based on predialysis serum values to achieve target post-dialysis concentrations, with evidence indicating that dialysate potassium below 2 mmol/L correlates with increased arrhythmia risk, while bicarbonate exceeding 35 mmol/L may elevate mortality via metabolic shifts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Substance removal in dialysis relies on the dialysate&#x27;s composition to establish diffusive and convective gradients across a semipermeable membrane, which permits passage of small solutes (e.g., urea &lt;60 Da, creatinine &lt;113 Da, potassium) but restricts larger molecules like albumin (&gt;66 kDa). Diffusion drives passive transfer of uremic toxins from blood (higher concentration) to dialysate (near-zero for wastes), enhanced by countercurrent flow maximizing gradient efficiency; clearance rates for urea, for instance, depend on dialysate flow (typically 500 mL/min) and membrane surface area, yielding Kt/V values &gt;1.2 per session for adequacy. Electrolyte removal or addition is modulated by dialysate concentrationsâ€”for example, low-potassium dialysate (2 mmol/L) removes excess serum potassium via gradient-driven diffusion, reducing predialysis hyperkalemia from 5.6â€“8 mmol/L.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Excess fluid removal occurs via ultrafiltration (UF), a convective process where hydrostatic pressure gradients force water across the membrane, dragging solutes (solvent drag) in high-flux HD or hemodiafiltration; in standard HD, UF is independent of dialysate solutes but relies on transmembrane pressure (20â€“50 mmHg), targeting 2â€“4 L/session to correct interdialytic weight gain. In PD, hypertonic glucose in dialysate creates an osmotic gradient (344â€“500 mOsm/L), drawing water into the peritoneal cavity for removal, though aquaporin-mediated free water transport predominates initially before sodium sieving reduces efficacy over dwell time. Bicarbonate buffering in modern dialysates improves tolerance over acetate by minimizing inflammation, indirectly supporting sustained removal efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h2 id="types-of-dialysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Types of Dialysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="hemodialysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Hemodialysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hemodialysis is an extracorporeal renal replacement therapy that removes waste products, excess electrolytes, and fluid from the blood of patients with kidney failure by circulating blood through an external dialyzer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> The dialyzer functions as an artificial kidney, utilizing principles of diffusion for solute removalâ€”where metabolic wastes like urea move from higher concentration in blood to lower in dialysateâ€”and convection via ultrafiltration for fluid and larger solute clearance, driven by transmembrane pressure gradients across a semipermeable membrane composed of hollow fibers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> This process mimics glomerular filtration and tubular reabsorption but requires anticoagulation, typically with heparin, to prevent clotting in the extracorporeal circuit.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The foundational hemodialysis device was invented by Dutch physician Willem Kolff in 1943, using cellophane tubing as the semipermeable membrane in a rotating drum apparatus to treat acute uremia amid wartime shortages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Clinical adoption expanded post-1960 with improvements like the Scribner shunt for repeated access, enabling chronic therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Modern systems employ volumetric control for precise fluid removal and bicarbonate-based dialysate to correct acidosis, with blood flow rates of 300-500 mL/min and dialysate countercurrent flow enhancing efficiency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Sessions, usually conducted thrice weekly for 3-5 hours each, aim to achieve a Kt/V urea clearance target of at least 1.2 per treatment, a dimensionless measure of dialysis adequacy correlating with survival.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Vascular access is critical, with autogenous arteriovenous fistulas (AVF) recommended as first choice due to superior patency (primary failure rate 20-40% but long-term survival up to 60-80% at 1 year) and lower infection risk compared to synthetic grafts or catheters.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> AVF creation involves surgical anastomosis of artery to vein, typically radial-cephalic at the wrist, maturing over 6-12 weeks via arterialization-induced vein remodeling for repeated needling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_obabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Central venous catheters serve for urgent starts but carry 10-20 times higher bacteremia risk, limiting use to &lt;10% of prevalent patients per guidelines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Common intradialytic complications include hypotension (affecting 20-30% of sessions, linked to rapid fluid shifts and cardiac instability) and muscle cramps, while interdialytic risks encompass hyperkalemia and volume overload, with cardiovascular events causing 40-50% of deaths in dialysis populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Extended-duration or more frequent treatments (e.g., &gt;5 hours/session or &gt;3/week) associate with 20-30% mortality reductions in observational cohorts, though randomized evidence remains limited.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_obqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> Home hemodialysis variants, using portable machines, permit daily short or nocturnal long sessions, improving quality of life and potentially adequacy via increased weekly clearance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<h3 id="peritoneal-dialysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Peritoneal Dialysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Peritoneal dialysis employs the peritoneum, a vascularized serous membrane lining the abdominal cavity, as a semipermeable barrier to facilitate the removal of uremic solutes and excess fluid from the blood. A hypertonic dialysate solution, typically containing glucose as the primary osmotic agent, is infused into the peritoneal cavity through an indwelling catheter, creating concentration gradients that drive diffusion of waste products like urea and creatinine from peritoneal capillaries into the dialysate, alongside osmosis-induced ultrafiltration of water.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup>  The process relies on the peritoneum&#x27;s large surface area, estimated at 1-2 mÂ² in adults, and its permeability properties, which enable efficient small-molecule clearance but limit removal of larger toxins compared to hemodialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Two primary modalities exist: continuous ambulatory peritoneal dialysis (CAPD), which involves 3-5 manual exchanges per day with dwells lasting 4-6 hours each, and automated peritoneal dialysis (APD), which uses a cycler machine to perform shorter, more frequent exchanges, often nocturnally, allowing daytime freedom.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> CAPD provides continuous solute clearance approximating 7-10 liters of dialysate daily, while APD emphasizes higher volume exchanges to enhance ultrafiltration, particularly in patients with high peritoneal transport rates. Catheter placement, typically via laparoscopic or percutaneous methods under local anesthesia, is essential for access; complications during insertion occur in less than 5% of cases when performed by experienced surgeons.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The procedure begins with priming the catheter to prevent air embolism, followed by instillation of 2-2.5 liters of warmed dialysate (1.5-4.25% glucose concentration based on fluid status), a dwell period for equilibration, and drainage, with effluent inspected for clarity and volume to assess adequacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Biocompatible dialysates with icodextrin or amino acids are used in select cases to mitigate glucose-related metabolic effects like hyperglycemia and peritoneal fibrosis, though standard glucose-based solutions remain predominant due to cost and availability. Prescription adequacy targets a weekly Kt/V urea of at least 1.7 and creatinine clearance of 50 L/week/1.73 mÂ², adjusted via peritoneal equilibration tests measuring solute transport rates.00848-4/fulltext)</span>
<span class="mb-4 block break-words text-[1em] leading-7">Advantages include home-based delivery promoting patient autonomy, continuous therapy preserving hemodynamic stability, and preserved residual kidney function longer than in hemodialysis, with initial survival benefits in non-diabetic patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> However, peritoneal dialysis yields lower clearance rates (8-10 mL/min for urea versus 200-300 mL/min in hemodialysis), necessitating patient adherence and limiting suitability for large or catabolic individuals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Technique survival averages 50-60% at 2 years, with dropout due to membrane failure or infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Major complications encompass peritonitis, occurring at rates of 0.2-0.5 episodes per patient-year, primarily from touch contamination or catheter-related biofilms, treatable with intraperitoneal antibiotics but risking sclerosing peritonitis in recurrent cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup>  Exit-site and tunnel infections affect 0.3-0.6 episodes per patient-year, often managed with oral or topical agents, while mechanical issues like hernias or leaks arise from increased intra-abdominal pressure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Ultrafiltration failure, linked to high glucose absorption and membrane hyperpermeability, develops in 30-40% of long-term patients, accelerating transition to hemodialysis.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Survival outcomes show peritoneal dialysis conferring similar or superior adjusted mortality to hemodialysis in the first 1-2 years (hazard ratio 0.83-1.0), attributed to gentler solute removal and lifestyle factors, but diverging thereafter with higher long-term risks in elderly or comorbid populations (hazard ratio 1.17 for those over 65).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> Five-year survival rates hover at 40-50%, influenced by age, diabetes, and residual function preservation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ofqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Incremental approaches starting with fewer exchanges in early chronic kidney disease preserve membrane longevity but require monitoring for underdialysis.</span>
<h3 id="continuous-renal-replacement-therapies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Continuous Renal Replacement Therapies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">![Continuous Veno-Venous Hemofiltration (CVVH)](./<em>assets</em>/Continuous_Venon_Venous_Haemofiltration_with_pre_and_post_dilution_<span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>V</mi><mi>V</mi><mi>H</mi></mrow><annotation encoding="application/x-tex">CVVH</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:0.6833em"></span><span class="mord mathnormal" style="margin-right:0.07153em">C</span><span class="mord mathnormal" style="margin-right:0.22222em">VV</span><span class="mord mathnormal" style="margin-right:0.08125em">H</span></span></span></span>
Continuous renal replacement therapies (CRRT) encompass extracorporeal blood purification techniques designed to provide slow, continuous solute and fluid removal over 24 hours, primarily for critically ill patients with acute kidney injury (AKI) in intensive care settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ogqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> These modalities simulate native kidney function by employing convection, diffusion, or a combination thereof across a semipermeable membrane, allowing for gradual clearance of uremic toxins, electrolytes, and excess volume without the rapid shifts associated with intermittent hemodialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> CRRT is typically venovenous, relying on vascular access via dual-lumen catheters, and requires anticoagulation to prevent circuit clotting, though evidence supports individualized dosing based on patient factors rather than fixed protocols.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Principal modalities include continuous venovenous hemofiltration (CVVH), which relies on convective clearance using replacement fluids; continuous venovenous hemodialysis (CVVHD), emphasizing diffusive solute removal via dialysate; and continuous venovenous hemodiafiltration (CVVHDF), combining both mechanisms for enhanced middle-molecule clearance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> CVVHDF is often preferred for its versatility in managing diverse solute sizes, with studies indicating superior removal of cytokines in septic patients compared to pure diffusive methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ghabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> Effluent doses are standardized at 20-25 mL/kg/hour per KDIGO recommendations, though delivered doses frequently fall short due to downtime from filter clotting or interruptions, averaging 25-30% less in practice.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ohabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Indications center on hemodynamically unstable patients with AKI stage 3 (KDIGO criteria), refractory fluid overload, severe acidosis, or uremic complications unresponsive to conservative measures, particularly when intermittent therapies risk exacerbating instability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> CRRT facilitates precise volume control and metabolic stability in multi-organ failure, but initiation should be deferred beyond 72 hours in non-emergent cases to allow potential renal recovery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ghqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Meta-analyses of randomized trials reveal no mortality advantage over intermittent hemodialysis, with pooled odds ratios approximating 1.0, though CRRT may shorten hospital stays in select cohorts by enabling earlier enteral nutrition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ohqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Complications include circuit-related issues such as clotting (occurring in 20-40% of sessions despite anticoagulation), hypothermia from heat loss, and bleeding risks from heparin or citrate use, with citrate preferred in renal failure for regional effects minimizing systemic exposure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Nutrient losses necessitate supplementation, particularly for amino acids and glucose, while vascular access infections and hypotension from ultrafiltration persist as concerns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Resource demands are high, with CRRT circuits lasting 24-48 hours on average, contributing to costs 1.5-2 times those of intermittent dialysis, yet no evidence supports routine superiority in survival outcomes across large trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> Ongoing research emphasizes hybrid approaches and biomarker-guided timing to optimize efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<h3 id="emerging-and-experimental-modalities" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Emerging and Experimental Modalities<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Wearable artificial kidneys represent an experimental advancement aimed at providing continuous, ambulatory dialysis without reliance on large stationary machines. These devices typically employ sorbent-based dialysate regeneration to miniaturize the system, allowing patients to move freely during treatment. A prototype wearable artificial kidney (WAK), developed by Victor Gura and tested in an FDA-approved human trial in 2016, demonstrated effective solute clearance and ultrafiltration comparable to conventional hemodialysis over 24-hour periods, with participants reporting improved mobility and quality of life.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> Further iterations, including those in ongoing clinical evaluations like the wearable filtrating artificial kidney device initiated in 2023, focus on precision, safety, and operability for end-stage renal disease patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Implantable bioartificial kidneys seek to replicate native kidney functions through integrated filtration and bio-reabsorption components, potentially eliminating the need for repeated vascular access or external devices. The Kidney Project, a collaboration between UCSF and Vanderbilt University, has developed a prototype implantable bioartificial kidney (iBAK) featuring silicon nanopore membranes for hemofiltration and a bioreactor with renal tubule cells for active transport, successfully tested in large animal models as of 2021 to achieve metabolic homeostasis without immunosuppression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> In 2023, the project received a $1 million KidneyX prize for prototype advancements, with preclinical studies continuing toward human trials expected in the coming years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> Similarly, UCLA&#x27;s implantable artificial kidney employs novel glomerular filtration mimicry without dialysis fluid, advancing through animal proof-of-concept phases as of 2024, prioritizing waterless operation to reduce infection risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ojqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hybrid and regenerative dialysis modalities are also under investigation to enhance efficiency and patient independence. Intermittent infusion hemodiafiltration (I-HDF), a technique combining standard hemodialysis with cyclic infusions, emerged in clinical reviews by 2025 as a potential bridge modality, offering improved middle-molecule clearance while minimizing hemodynamic instability in select patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Portable peritoneal dialysis systems, such as the AWAK-PD device, utilize automated sorbent regeneration for extended dwell times and reduced fluid volumes; pivotal U.S. clinical trials were planned as of 2024 to assess efficacy against traditional peritoneal dialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> These approaches prioritize empirical validation through randomized trials, addressing limitations like biocompatibility and long-term durability observed in early prototypes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_okabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<h2 id="clinical-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="indications-for-acute-kidney-injury" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Indications for Acute Kidney Injury<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Dialysis, or renal replacement therapy (RRT), is initiated in acute kidney injury (AKI) primarily to address life-threatening complications arising from impaired kidney function, rather than solely based on biomarkers such as serum creatinine or estimated glomerular filtration rate (eGFR).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_glqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize emergent RRT for severe disruptions in fluid balance, electrolytes, or acid-base status that cannot be managed conservatively.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_olqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> Randomized trials, including the STARRT-AKI study involving 2,927 critically ill patients with AKI, have demonstrated no mortality benefit from early initiation (within 8 hours of KDIGO stage 2 AKI) compared to delayed initiation (after complications develop), with early RRT associated with more dialysis dependence at 90 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> Similarly, the AKIKI trial in 620 ICU patients found delayed RRT (started only for severe acidosis, hyperkalemia, pulmonary edema, or uremia) reduced circuit clotting and transfusions without increasing mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key clinical indications include:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]"><strong>Refractory hyperkalemia</strong>: Serum potassium exceeding 6.5 mmol/L or persistent levels above 6 mmol/L despite medical interventions such as insulin, beta-agonists, sodium bicarbonate, and calcium gluconate, due to risk of fatal arrhythmias.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></li>
<li class="text-[1em]"><strong>Severe metabolic acidosis</strong>: Arterial pH below 7.15-7.20, particularly with hypercapnia (PaCO2 &gt;50 mmHg) or in the absence of respiratory compensation, unresponsive to bicarbonate therapy, to prevent hemodynamic instability and organ dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6gmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_agmqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></li>
<li class="text-[1em]"><strong>Volume overload</strong>: Pulmonary edema or fluid accumulation causing hypoxemia or hemodynamic compromise, refractory to diuretics or ultrafiltration alternatives, often defined as &gt;10% body weight gain or central venous pressure &gt;12-15 mmHg without response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6omqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aomqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></li>
<li class="text-[1em]"><strong>Uremic complications</strong>: Symptomatic uremia manifesting as encephalopathy, pericarditis, or coagulopathy, typically with blood urea nitrogen (BUN) &gt;80-112 mg/dL (28-40 mmol/L), though BUN thresholds alone are insufficient without clinical signs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b0mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></li>
<li class="text-[1em]"><strong>Toxin removal</strong>: Specific intoxications where dialysis effectively clears dialyzable toxins, such as methanol, ethylene glycol, lithium, or salicylates, guided by toxicokinetics rather than AKI stage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">In ICU settings, where AKI affects up to 50% of patients and carries a 20-50% mortality risk, continuous RRT (CRRT) modalities are often preferred for hemodynamic stability, though intermittent hemodialysis remains viable in stable patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> Delaying RRT until absolute indications avoids unnecessary exposure to complications like hypotension (occurring in 30-40% of early starts) and infection, supported by meta-analyses showing equivalent 28-day survival rates between strategies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> Patient-specific factors, including sepsis or multiorgan failure, may necessitate individualized thresholds, but prophylactic RRT based on anticipated worsening lacks empirical support.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_onabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup></span>
<h3 id="indications-for-chronic-kidney-disease" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Indications for Chronic Kidney Disease<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Dialysis for chronic kidney disease (CKD) is typically initiated in patients with end-stage renal disease (ESRD), corresponding to CKD stage 5 with an estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 mÂ², when symptoms or complications cannot be adequately managed through conservative measures such as dietary restrictions, medications, or fluid management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Guidelines emphasize that initiation should not rely solely on eGFR thresholds, as randomized trials like the Initiating Dialysis Early and Late (IDEAL) study, published in 2010, demonstrated no survival benefit from starting dialysis at higher eGFR levels (10-14 mL/min/1.73 mÂ²) compared to lower levels (5-7 mL/min/1.73 mÂ²), with late initiation potentially reducing complications like infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key indications include uremic symptoms such as persistent nausea, vomiting, fatigue, pruritus, cognitive impairment, or uremic pericarditis, which arise from the accumulation of uremic toxins when renal clearance fails.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Refractory hyperkalemia (serum potassium &gt;6.0 mEq/L despite medical therapy), severe metabolic acidosis (bicarbonate &lt;15 mEq/L unresponsive to bicarbonate supplementation), and volume overload leading to pulmonary edema or hypertension not controllable by diuretics also necessitate dialysis to prevent cardiac arrhythmias, respiratory failure, or accelerated cardiovascular disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ooqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Additional criteria encompass uremia-related malnutrition (evidenced by declining serum albumin &lt;3.5 g/dL or unintentional weight loss &gt;10% despite nutritional support), progressive neuropathy, or bleeding diathesis due to platelet dysfunction, as these reflect irreversible toxin buildup that dialysis can mitigate by removing middle- and large-molecular-weight uremic solutes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> In asymptomatic patients with eGFR &lt;10 mL/min/1.73 mÂ², initiation may be deferred with close monitoring, but rapid eGFR decline (&gt;0.5 mL/min/month) or patient-specific factors like frailty or preference for preemptive transplant preparation can prompt earlier vascular access planning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_opabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> National Kidney Foundation-KDOQI guidelines reinforce that uremia-driven clinical judgment supersedes arbitrary GFR cutoffs, avoiding unnecessary early dialysis that increases hospitalization risks without improving mortality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<h3 id="contraindications-and-conservative-management-alternatives" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Contraindications and Conservative Management Alternatives<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Dialysis initiation lacks strict absolute contraindications in most cases, with the primary exception being the inability to establish vascular access for hemodialysis due to extensive vascular disease or prohibitive hemodynamic instability that precludes safe treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> Relative contraindications often revolve around patient-specific factors where the burdens of therapyâ€”such as frequent sessions, infection risks, and vascular complicationsâ€”may exceed benefits, particularly in individuals with advanced age, multiple severe comorbidities (e.g., frailty, dementia, or metastatic cancer), or limited life expectancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> For instance, in patients with end-stage renal disease (ESRD) accompanied by irreversible multi-organ failure or profound functional impairment, dialysis may not meaningfully extend survival or improve quality of life, leading clinicians to weigh these elements through shared decision-making rather than proceeding automatically.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_oqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Conservative kidney management (CKM), also termed maximum conservative management, serves as a non-dialytic alternative for select patients with advanced chronic kidney disease (CKD stage 5) or ESRD, emphasizing symptom palliation, nutritional support, and medical optimization without renal replacement therapy. This approach typically involves rigorous control of fluid and electrolyte imbalances via diuretics and dietary restrictions, anemia management with erythropoiesis-stimulating agents, bone-mineral disorder treatment, and advance care planning to address uremic symptoms like fatigue, pruritus, and nausea.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> CKM is particularly considered for elderly patients (often over 75 years) with high comorbidity burdens, where dialysis-associated interventions could accelerate functional decline or hospitalizations without proportional survival gains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Empirical data indicate that CKM generally yields shorter median survival compared to dialysis in broader ESRD populations, with dialysis reducing overall mortality risk by addressing uremia and fluid overload more effectively. For example, a 2022 analysis found patients opting for dialysis had lower mortality hazard ratios than those choosing conservative care, even after adjusting for age and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> However, in frail elderly subgroups with significant comorbidities, survival differences narrow; a seminal 2007 study reported median survival of approximately 6-23 months under conservative management versus 13-37 months with dialysis, but without clear net benefit from dialysis after accounting for treatment downtime and complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_orabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> Quality-of-life metrics often favor CKM in these cohorts, showing reduced hospitalization frequency, preserved time at home, and lower symptom burden from dialysis procedures, though data remain heterogeneous due to selection bias in observational studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Patient Group</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Median Survival (CKM)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Median Survival (Dialysis)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Considerations</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">General ESRD adults</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6-12 months</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2-5 years</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dialysis extends life via solute clearance; CKM suits those declining therapy.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18orqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Elderly (&gt;75 years) with comorbidities</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6-23 months</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">13-37 months</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Comparable in frail subsets; CKM prioritizes QoL over marginal gains.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_198rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Decisions for CKM versus dialysis should integrate patient preferences, prognostic tools (e.g., surprise question for 12-month mortality prediction), and multidisciplinary input, as dialysis does not universally equate to prolonged healthy life in advanced disease states.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> Long-term cohort studies underscore that while dialysis dominates as the default, CKM uptake remains low (under 20% in many regions), potentially reflecting under-discussion of alternatives despite evidence of its viability for quality-focused care.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup></span>
<h2 id="treatment-procedures" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Treatment Procedures<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="vascular-and-peritoneal-access-methods" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Vascular and Peritoneal Access Methods<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Vascular access for hemodialysis enables the extracorporeal circulation of blood through the dialyzer, with arteriovenous fistulas (AVFs), arteriovenous grafts (AVGs), and central venous catheters (CVCs) as the primary methods.31137-0/fulltext) The KDOQI Clinical Practice Guideline recommends AV access (AVF or AVG) over CVC for most incident and prevalent patients due to reduced infection risk and improved long-term patency.31137-0/fulltext) AVFs are created by surgically anastomosing a native artery to a vein, typically the radial artery to cephalic vein at the wrist (radiocephalic fistula), allowing vein maturation through arterialization for repeated needle punctures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> AVFs exhibit lower rates of infection (0.5-1.5% per patient-year) and thrombosis compared to alternatives, though they require 2-3 months for maturation in 60-70% of cases.31137-0/fulltext) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">AVGs involve interposing synthetic materials, such as polytetrafluoroethylene, between artery and vein when native vessels are inadequate, offering faster usability (2-3 weeks) but higher thrombosis rates (0.8-1.8 events per patient-year) and interventions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> CVCs, including non-tunneled for acute use and tunneled cuffed for chronic, provide immediate access via jugular, subclavian, or femoral veins but carry the highest bacteremia risk (0.5-6.0 episodes per 1,000 catheter-days) and are associated with increased mortality.31137-0/fulltext) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> Guidelines advocate minimizing CVC duration, targeting less than 10% prevalent use, with ultrasound guidance for insertion to reduce complications like pneumothorax.31137-0/fulltext)</span>
<span class="mb-4 block break-words text-[1em] leading-7">Peritoneal access for peritoneal dialysis utilizes specialized catheters to infuse and drain dialysate into the peritoneal cavity, with Tenckhoff cathetersâ€”straight or curled tip, often double-cuffedâ€”being the most common type for secure fixation and reduced migration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> Insertion techniques include open surgical (midline laparotomy under general anesthesia), laparoscopic (with visualization for adhesiolysis), and percutaneous (Seldinger method under local anesthesia or fluoroscopy), each with comparable long-term success but varying procedural risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> Guidelines recommend a 2-week break post-insertion before full dialysis to minimize early complications like dialysate leakage (5-10% incidence).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ovabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Common peritoneal catheter complications encompass early issues such as bowel perforation (1%), bleeding, and malpositioning, alongside late problems including exit-site infections (0.4-0.6 episodes per patient-year), tunnel infections, and outflow obstruction from fibrin or omental plugging, potentially necessitating removal in 10-20% of cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> Prophylactic measures, like burying the external cuff initially or using antibiotic creams, reduce infection rates, while imaging or laparoscopy aids in dysfunction management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> Patient selection, including avoidance in cases of abdominal adhesions or obesity, optimizes outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ovqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<h3 id="session-protocols-and-monitoring" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Session Protocols and Monitoring<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hemodialysis sessions typically occur three times per week, with each session lasting 3.5 to 5 hours to achieve a minimum of 12 hours weekly dialysis time in patients with minimal residual kidney function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> Protocols begin with vascular access preparation, including cannulation of arteriovenous fistula or graft, administration of anticoagulation such as unfractionated heparin to prevent clotting, and programming the dialysis machine for blood flow rates of 300-500 mL/min and dialysate flow of 500-800 mL/min.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Ultrafiltration rates are prescribed to remove excess fluid while minimizing hemodynamic instability, often targeting a single-pool Kt/V of at least 1.2 per session.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_111abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Intra-session monitoring includes continuous assessment of machine parameters such as arterial and venous pressures, transmembrane pressure, blood pump speed, and conductivity alarms, alongside patient vital signs checked every 30 minutes, encompassing blood pressure, heart rate, and temperature to detect complications like hypotension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Pre-dialysis evaluations involve recording dry weight, blood pressure, and access patency, while post-dialysis protocols confirm target weight achievement, final vital signs, and access site hemostasis to prevent bleeding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Adequacy is verified monthly via equilibrated Kt/V measurements, with adjustments for residual renal function assessed quarterly if present.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For peritoneal dialysis, protocols differ by modality: continuous ambulatory peritoneal dialysis (CAPD) involves 3-5 manual exchanges daily with dwell times of 4-6 hours, while automated peritoneal dialysis (APD) uses cyclic machine-driven exchanges overnight, typically 8-10 cycles with shorter dwells of 1.5-3 hours for high transporters.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> Monitoring emphasizes daily self-assessment of body weight, blood pressure, and dialysate effluent for clarity and volume to ensure ultrafiltration of at least 750 mL/day in anuric adults, with peritoneal equilibration testing performed at 6 weeks post-initiation and annually thereafter to evaluate membrane function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> Solute clearance targets include a weekly Kt/V urea of 1.7 or creatinine clearance of 50 L/1.73 mÂ², measured semiannually, alongside residual renal function tracking to guide prescription adjustments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></span>
<h3 id="home-versus-in-center-delivery" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Home versus In-Center Delivery<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Home hemodialysis (HHD) and peritoneal dialysis (PD), the primary home-based modalities, enable patients to perform treatments independently or with caregiver assistance after extensive training, contrasting with in-center hemodialysis (ICHD), which occurs under professional supervision at facilities three times weekly for approximately four hours per session. HHD training typically spans 4-8 weeks, covering vascular access management, dialysate preparation, and complication recognition, while PD requires instruction in catheter care and manual or automated dialysate exchanges performed daily.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Aspect</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Home Dialysis (HHD/PD) Advantages/Outcomes</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">In-Center HD Advantages/Outcomes</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Evidence/Limitations</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Survival</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Lower all-cause mortality (e.g., 3.76 vs. 6.27 deaths/100 patient-years for extended HHD vs. ICHD; HR 0.60, 95% CI 0.45-0.80); PD advantage persists 1.5-2 years before equalizing.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Higher standardized mortality in observational data, though supervised care mitigates acute issues.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Selection bias favors healthier home patients (younger, fewer comorbidities); no RCTs due to recruitment challenges.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gp3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3gp3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gp3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Quality of Life</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Greater flexibility reduces travel (up to 52 days/year saved), enables more frequent/shorter sessions, improves life participation and satisfaction.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Structured social interaction; immediate staff intervention for complications.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mixed results on mental/physical components; home burnout or isolation possible.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2h93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3h93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Clinical Control</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Better blood pressure, phosphate, and nutrition management; fewer hospitalizations.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Consistent monitoring reduces procedural errors.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Home requires patient adherence; PD peritonitis risk higher if hygiene lapses.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2hp3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><strong>Costs</strong></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">More cost-effective (e.g., PD yields higher QALYs at lower cost than ICHD); potential savings from reduced facility overhead.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Higher overall due to staffing/transport; initial home setup offset by long-term gains.</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Upfront home equipment/training barriers; PD consumables ongoing.30271-5/fulltext)</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2i93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Home dialysis demands reliable home infrastructure, electricity, and water quality, with HHD often necessitating nocturnal or daily regimens for optimal clearance, whereas ICHD adheres to standardized protocols minimizing patient burden but limiting personalization. Risks in home settings include technique failure (e.g., PD peritonitis rates ~0.2-0.5 episodes/year despite improvements) and vascular access issues without immediate oversight, though ICHD exposes patients to facility-acquired infections. Empirical data favor home modalities for suitable candidatesâ€”those with adequate support and dexterityâ€”due to causal links between treatment frequency/intensity and cardiovascular stability, yet broader adoption is hindered by training demands and socioeconomic factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup></span>
<h2 id="clinical-outcomes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Outcomes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="survival-rates-and-mortality-data" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Survival Rates and Mortality Data<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">For patients with end-stage renal disease (ESRD) initiating dialysis in the United States, the five-year survival probability after starting hemodialysis (HD) was 40.7% for the 2018 incident cohort, showing minimal improvement from 40.4% in the 2008 cohort.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Similarly, five-year survival after peritoneal dialysis (PD) initiation stood at 42.5% for the 2018 cohort, down slightly from 44.5% in 2008.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> These figures reflect persistent challenges, with overall one-year mortality rates for dialysis patients estimated at 15-20%, driven primarily by cardiovascular events, infections, and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Adjusted all-cause mortality rates for prevalent HD patients averaged 185.7 deaths per 1,000 patient-years in 2022, following a spike to 195.9 in 2021 amid the COVID-19 pandemic, which eroded prior declines observed from 179.4 in 2012 to 166.0 in 2019.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> For PD patients, rates were lower at 149.5 per 1,000 patient-years in 2022 but exhibited a similar pandemic-related increase from 132.1 in 2019.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Survival varies markedly by age, with HD mortality rates rising from 92.1 per 1,000 patient-years in those aged 18-44 to 318.3 in those 75 and older in 2022; analogous age-stratified elevations occur in PD cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup></span>























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Modality</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">5-Year Survival (2008 Cohort)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">5-Year Survival (2018 Cohort)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">2022 Mortality Rate (per 1,000 patient-years)</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hemodialysis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">40.4%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">40.7%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">185.7</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Peritoneal Dialysis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">44.5%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">42.5%</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">149.5</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Data from USRDS 2024 Annual Data Report.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Comorbidities exacerbate mortality, with dialysis patients aged 66-74 exhibiting rates four times higher than those with cancer and three times higher than heart failure in 2022 comparisons.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Meta-analyses indicate comparable long-term survival between HD and PD overall, though PD may confer early advantages in select non-diabetic or urgent-start populations, while HD predominates for extended survival in others.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> Global trends mirror these patterns, with chronic kidney disease-related mortality influenced by access to dialysis and regional healthcare disparities, though high-income countries report 15-20% one-year mortality post-initiation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> Survival has stagnated over decades despite procedural advances, attributable to rising patient age, diabetes prevalence, and non-renal comorbidities at ESRD onset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_157qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup></span>
<h3 id="quality-of-life-and-functional-impacts" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Quality of Life and Functional Impacts<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Patients undergoing kidney dialysis experience substantially diminished health-related quality of life (HRQoL) compared to the general population, with reductions particularly pronounced in physical and mental domains as assessed by standardized tools like the SF-36 questionnaire.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> A 2024 study of hemodialysis (HD) patients reported average QoL scores lower than those of healthy individuals, correlating with the presence of complications such as anemia and cardiovascular issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup> Longitudinal analyses indicate progressive declines in both physical and mental HRQoL over time for patients on institutional HD or peritoneal dialysis (PD), though PD may preserve slightly better initial HRQoL due to greater scheduling flexibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_118qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Functional impacts are marked by chronic fatigue, reduced exercise capacity, and limitations in daily activities stemming from uremic symptoms, fluid and dietary restrictions, and the treatment burden itself. Approximately 27% of patients initiating dialysis develop significant functional impairment within the first year, often requiring assistance with activities of daily living.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> HD sessions, typically lasting 3-5 hours three times weekly, impose substantial time constraints, disrupting employment and social engagements; employment rates among dialysis patients remain low at around 20-30%, influenced by physical debility and session logistics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup> In contrast, PD allows home-based treatment but demands rigorous adherence to sterile techniques and may exacerbate abdominal discomfort or hernias, limiting mobility in some cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Psychological burdens further erode QoL, with depression prevalence ranging from 20% to 45% among end-stage renal disease patients on dialysis, exceeding rates in other chronic conditions and linked to biological factors like inflammation alongside psychosocial stressors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> Anxiety co-occurs frequently, affecting up to 50% in some cohorts, and correlates with poorer adherence and higher hospitalization risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> These mental health challenges, compounded by body image concerns from vascular access and dependency on machines, underscore dialysis&#x27;s holistic toll, though interventions like exercise programs can modestly improve physical function and mood.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> Overall, while dialysis sustains life, its functional restrictions often confine patients to a narrowed sphere of activity, with younger cohorts facing amplified disruptions to career and family roles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_159qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup></span>
<h3 id="comparisons-to-kidney-transplantation-and-no-treatment" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Comparisons to Kidney Transplantation and No Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Kidney transplantation generally confers superior long-term survival compared to remaining on dialysis for patients with end-stage renal disease (ESRD). A systematic review of observational studies found that transplantation is associated with lower all-cause mortality rates than chronic dialysis, with adjusted hazard ratios indicating a 50-70% reduction in mortality risk post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> Similarly, a meta-analysis of 48 studies reported that 92% demonstrated a survival benefit for transplantation over dialysis beyond one year, with the advantage persisting across age groups and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> However, one-year post-transplant survival rates may approximate those on dialysis (94% versus 95%), as surgical risks and early immunosuppression complications offset initial gains, after which divergence favors transplantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_paqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> Deceased-donor transplants extend median survival by years across all candidate ages, even after accounting for waiting times up to five years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Health-related quality of life (HRQoL) also improves markedly after successful kidney transplantation relative to dialysis. Multiple studies, including prospective cohorts, show transplant recipients experiencing higher scores in physical functioning, vitality, and social domains on validated instruments like the SF-36, attributable to freedom from frequent treatments and reduced uremic symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> For older recipients (over 65), transplantation yields significantly better HRQoL than remaining waitlisted on dialysis, with gains in mobility and emotional well-being persisting long-term.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup> These benefits stem from restored renal function enabling dietary liberalization and employment resumption, though lifelong immunosuppression introduces infection and malignancy risks not present in dialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In contrast to conservative management without dialysis or transplantation, dialysis extends survival for most ESRD patients, particularly those under 80 or without severe frailty. A 2024 analysis of over 10,000 patients found dialysis initiation reduced all-cause mortality risk by 40-60% compared to conservative care in advanced chronic kidney disease (CKD5), with median survival on dialysis exceeding conservative management by 12-24 months.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> Meta-analyses confirm this survival edge where patients explicitly choose dialysis, though conservative care avoids procedural burdens like vascular access infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> For patients over 80 or with life expectancy under six months, survival differences narrow, and conservative managementâ€”focusing on symptom palliation and holistic supportâ€”may preserve HRQoL by preventing dialysis-related fatigue and hospitalizations without meaningfully prolonging life.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> Untreated ESRD typically leads to uremic death within weeks to months, underscoring dialysis as a bridge to transplantation or stabilization when feasible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1hbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup></span>
<h2 id="complications-and-risks" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Complications and Risks<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="acute-complications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Acute Complications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Intradialytic hypotension, defined as a drop in systolic blood pressure by at least 20 mm Hg or to below 90 mm Hg during hemodialysis, represents the most frequent acute complication, occurring in 10-30% of sessions and linked to increased cardiovascular mortality and hospitalization risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> This event arises primarily from rapid fluid removal via ultrafiltration exceeding vascular refilling, compounded by autonomic neuropathy common in end-stage renal disease, left ventricular dysfunction, and dialysate composition factors such as low sodium levels.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ldabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Symptomatic episodes manifest as dizziness, nausea, or syncope, with severe cases precipitating ischemia or arrhythmias; preventive strategies include adjusted ultrafiltration rates and midodrine administration, though evidence for long-term outcome improvement remains limited.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Muscle cramps, affecting up to 20% of hemodialysis sessions, typically occur in the lower extremities during the latter half of treatment and correlate strongly with predialysis fluid overload and intradialytic hypotension.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> These cramps stem from electrolyte shifts, particularly hypocalcemia or hypomagnesemia induced by diffusive losses, and muscle ischemia from hypoperfusion; interventions such as hypertonic saline boluses or quinine have shown variable efficacy, with cramps resolving post-session in most cases but contributing to treatment discontinuation in 1-2% of patients annually.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other intradialytic events in hemodialysis include nausea and vomiting (5-15% incidence), often tied to rapid urea removal causing osmotic disequilibrium, and pruritus from residual uremia or mast cell degranulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup> Arrhythmias, encompassing ventricular ectopy or atrial fibrillation, arise in 10-20% of sessions among at-risk patients with underlying cardiac disease, exacerbated by electrolyte fluctuations like hyperkalemia reversal or hypocalcemia; continuous ECG monitoring detects these, with beta-blockers or pacing as acute management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> Rare but critical complications encompass air embolism from venous air ingress (mortality up to 20% if untreated) and hemolysis from hypotonic dialysate or overheated solutions, both necessitating immediate session termination and supportive care.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_peabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In peritoneal dialysis, acute complications predominantly involve infectious peritonitis, with an incidence of 0.2-0.5 episodes per patient-year, presenting as abdominal pain, cloudy effluent, and fever within hours of contamination during catheter exchanges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> Mechanical issues, such as dialysate leaks or catheter malposition, occur in 5-10% of early sessions, leading to subcutaneous edema, reduced ultrafiltration, or hydrothorax from pleuroperitoneal communication, often requiring temporary cessation and surgical revision.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_heqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> Exit-site bleeding or hypotension from excessive fluid shifts can also emerge acutely, though less frequently than in hemodialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_peqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> Overall, acute events in both modalities heighten session interruptions and underscore the need for vigilant monitoring, with hemodialysis exhibiting higher cardiovascular acuity while peritoneal dialysis risks center on access integrity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup></span>
<h3 id="long-term-complications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Complications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term complications of kidney dialysis arise primarily from the incomplete replication of native kidney function, leading to persistent uremia, fluid and electrolyte imbalances, and chronic inflammation, despite regular treatments. Cardiovascular disease remains the predominant cause of morbidity and mortality, accounting for approximately 40-50% of deaths in dialysis patients, driven by accelerated atherosclerosis, left ventricular hypertrophy, and arrhythmias due to factors such as hypertension, anemia, and hyperphosphatemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> Dialysis patients exhibit 10-20 times higher cardiovascular mortality compared to the general population, with risks exacerbated by intradialytic hypotension, which promotes regional myocardial ischemia and long-term cardiac remodeling.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Mineral and bone disorder (CKD-MBD)</strong> manifests as renal osteodystrophy, characterized by high-turnover bone disease from secondary hyperparathyroidism, adynamic bone disease, or osteomalacia, resulting from phosphate retention, vitamin D deficiency, and disrupted calcium homeostasis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup> Long-term dialysis intensifies vascular calcification, linking CKD-MBD to increased cardiovascular events and fracture risk, with bone-specific alkaline phosphatase levels at dialysis initiation predicting higher hospitalization rates for cardiovascular, cerebrovascular, and peripheral arterial disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup> In hemodialysis patients surviving over 20 years, uremic osteodystrophy persists as a key issue, often requiring parathyroidectomy for severe hyperparathyroidism.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Infections pose a sustained threat, with vascular access sites in hemodialysis predisposing to bacteremia and sepsis, while peritoneal dialysis carries risks of peritonitis and encapsulating peritoneal sclerosis after prolonged use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> Defects in cellular immunity inherent to uremia compound these risks, elevating overall infection rates beyond those attributable to access alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> Neurological complications, including peripheral neuropathy and dialysis-related amyloidosis from beta-2 microglobulin accumulation, emerge after years of therapy, impairing quality of life and mobility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> Acquired cystic kidney disease also develops in long-term patients, increasing malignancy risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_19gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Comparisons between hemodialysis and peritoneal dialysis reveal modality-specific patterns: hemodialysis associates more with cardiovascular and access-related issues, while peritoneal dialysis heightens encapsulating sclerosis risk after 5-10 years, though both share systemic burdens like fatigue and reduced survival linked to dialysis vintage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup> These complications underscore dialysis&#x27;s role as a bridge therapy, with cumulative risks rising with treatment duration, often necessitating multimodal management including phosphate binders, erythropoietin, and access revisions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_phabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h2 id="economic-and-systemic-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Economic and Systemic Factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="treatment-costs-and-cost-effectiveness" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Treatment Costs and Cost-Effectiveness<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, the average annual Medicare expenditure per patient for in-center hemodialysis was approximately $99,000 in 2021, while peritoneal dialysis averaged $87,000 per patient, reflecting differences in facility utilization, supply requirements, and associated hospitalizations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup> These figures encompass bundled payments under the End-Stage Renal Disease Prospective Payment System, which covers dialysis treatments, medications, and laboratory services, but exclude supplemental costs such as physician fees or extended hospital stays for complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> Peritoneal dialysis generally incurs lower direct costs due to reduced need for clinic infrastructure and transportation, though initial training and home setup expenses can offset some savings in the first year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_piqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup></span>

























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Modality</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Average Annual Cost per Patient (US, 2021 Medicare)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Cost Drivers</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">In-Center Hemodialysis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$99,000</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Facility operations, frequent sessions (3x/week), higher drug expenditures (e.g., $20,000/year for injectables)</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mpjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Peritoneal Dialysis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$87,000</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Home-based supplies, training, lower facility dependency</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Kidney Transplantation (first year)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">$100,000â€“$130,000 (variable by donor type)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Surgery, immunosuppression; subsequent years ~$20,000â€“$30,000</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term cost-effectiveness analyses indicate peritoneal dialysis yields superior value compared to hemodialysis, with 10-year cumulative costs averaging $336,000 for peritoneal dialysis versus $353,000 for in-center hemodialysis, driven by fewer hospitalizations and lower overhead.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup> Incremental cost-effectiveness ratios for dialysis modalities often exceed $50,000â€“$100,000 per quality-adjusted life year (QALY) gained relative to conservative management, reflecting modest survival extensions (median 3â€“5 years on dialysis) amid high complication rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> In contrast, kidney transplantation demonstrates dominant cost-effectiveness over dialysis, with first-year costs comparable or higher but lifetime savings of $50,000â€“$70,000 per patient due to improved QALYs (e.g., 0.72 QALYs for transplant vs. 0.55 for hemodialysis in one-year models) and reduced ongoing therapy needs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Factors influencing cost-effectiveness include patient comorbidities, which elevate hospitalization expenses (up to 40% of total dialysis costs), and payer mix, as Medicare covers most end-stage renal disease patients but private insurers face 20â€“30% higher reimbursements for hemodialysis sessions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup> Home-based peritoneal dialysis enhances cost savings in resource-constrained settings by minimizing indirect expenses like lost productivity, though adoption remains low (under 10% of US dialysis patients) due to training barriers and peritonitis risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> Overall, while dialysis sustains life short-term, its economic burdenâ€”totaling over $50 billion annually in Medicare spendingâ€”underscores the imperative for transplantation prioritization, as evidenced by models showing net QALY gains and cost neutrality after 2â€“3 years post-transplant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup></span>
<h3 id="industry-structure-and-market-dynamics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Industry Structure and Market Dynamics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The dialysis industry exhibits a highly concentrated oligopolistic structure, particularly in the United States, where two dominant providersâ€”Fresenius Medical Care AG &amp; Co. KGaA and DaVita Inc.â€”control approximately 77% of dialysis facilities and account for over 90% of industry revenue as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[149]</sup> This consolidation has intensified over the past two decades, with their combined market share rising from 59% to 77% between the early 2000s and recent years, driven by acquisitions and economies of scale that have marginalized independent centers, whose share fell from 20% to 11%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_llabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[148]</sup> Globally, the market includes additional players like Baxter International Inc. and B. Braun Melsungen AG, but vertical integration by leadersâ€”spanning equipment manufacturing, consumables, and service provisionâ€”reinforces barriers to entry for smaller competitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[150]</sup> Dialysis chains overall dominate U.S. centers with an 83% share in 2024, benefiting from standardized operations and extensive networks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_15labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[151]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Market dynamics are shaped by steady demand growth amid structural rigidities. The global dialysis market reached $98.51 billion in 2024 and is forecasted to expand to $181.16 billion by 2032 at a compound annual growth rate (CAGR) of 8.4%, propelled by rising chronic kidney disease (CKD) and end-stage renal disease (ESRD) incidence linked to diabetes, hypertension, and aging demographics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[152]</sup> In the U.S., where Medicare covers nearly all ESRD patients via the bundled Prospective Payment System (PPS), total payments to facilities are projected to rise with a 2025 base rate adjustment to $273.82 per treatment, though this has incentivized cost containment measures like reduced ancillary services.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[153]</sup> Reimbursement policies have facilitated consolidation by favoring large chains capable of negotiating higher commercial ratesâ€”up to three times Medicare levelsâ€”while bundling expansions since 2011 have correlated with shifts in care practices, such as anemia management variations by market competition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_plqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[154]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_tlqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[155]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key trends include a gradual pivot toward home-based dialysis, supported by portable technologies, though in-center treatments still comprise the majority due to patient adherence barriers and infrastructure costs in emerging markets.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[156]</sup> Barriers persist from high capital requirements for equipment and regulatory compliance, alongside policy-driven pressures like Medicare&#x27;s PPS, which prioritize efficiency but risk technique failures in peritoneal dialysis promotion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[157]</sup> Innovations in dialyzer membranes and continuous therapies offer growth potential, yet oligopolistic pricing power sustains elevated commercial reimbursements, with limited antitrust intervention despite facility divestitures in concentrated areas.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[158]</sup> Overall, while prevalence-driven expansion sustains revenueâ€”U.S. centers at $31.3 billion in 2025â€”systemic dependencies on public funding underscore vulnerabilities to policy reforms targeting over-concentration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[159]</sup></span>
<h3 id="access-disparities-and-policy-influences" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Access Disparities and Policy Influences<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, the Medicare End-Stage Renal Disease (ESRD) program, enacted in 1972 as an amendment to the Social Security Act, entitles individuals with ESRD who are fully or currently insured under Social Securityâ€”or their spouses or dependentsâ€”to Medicare coverage for dialysis services, regardless of age or disability status, with benefits typically starting on the first day of the fourth month of dialysis treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[160]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[161]</sup> This policy has substantially expanded access since its inception, covering all ESRD-related services and contributing to near-universal treatment availability for eligible patients by 1980, when annual expenditures reached $1.2 billion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[162]</sup> However, implementation through the prospective payment system (PPS), updated annuallyâ€”such as the 2025 revisionsâ€”aims to control costs via bundled reimbursements but has not eliminated disparities in treatment modality and quality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[163]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Racial, ethnic, and socioeconomic disparities persist within this framework. Non-Hispanic Black and Hispanic patients initiate dialysis at younger ages and face barriers to home-based modalities, with large gaps in access to home dialysis and living donor kidney transplantation compared to non-Hispanic White patients, as documented in the US Renal Data System 2023 and 2024 reports.00048-9/fulltext) 00703-6/fulltext) Low socioeconomic status correlates with higher chronic kidney disease incidence, faster progression to ESRD, inadequate predialysis nephrology care, and reliance on central venous catheters rather than optimal arteriovenous fistulas, exacerbating infection risks and outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[164]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[165]</sup> Black, Hispanic, and Asian patients with advanced chronic kidney disease also encounter limited specialist access, influenced by social determinants like education and income, which policy expansions such as Medicare Advantage enrollment under the 21st Century Cures Act (effective 2021) have only partially addressed amid rising dual enrollment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_pnqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[166]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_11nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[167]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Globally, access disparities are more pronounced, driven by policy and funding variations. In 2023, an estimated 3.57 million people received dialysis worldwide, but availability at kidney failure onset exceeds 50% of needs in only 74% of countries with services, dropping to 32% in low-income countries (LICs) where private out-of-pocket funding predominates and temporary catheters comprise over 75% of hemodialysis initiations in 57% of cases.00198-6/fulltext) 00570-3/fulltext) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[168]</sup> Men are 47% more likely than women to access dialysis or transplantation, reflecting gender biases in resource allocation across regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> High-income countries achieve broader coverage through public funding models akin to the U.S. ESRD program, while LICs&#x27; limited infrastructure and cost barriers lead to treatment withdrawal and higher mortality from access-related infections.01737-6/fulltext) The International Society of Nephrology&#x27;s 2023 Global Kidney Health Atlas highlights how national policies prioritizing universal kidney replacement therapy correlate with reduced inequities, though only 6% of responding countries fully cover all needs at onset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_poabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[169]</sup></span>
<h2 id="special-populations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Special Populations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pediatric-dialysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pediatric Dialysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Pediatric dialysis refers to renal replacement therapy administered to children with end-stage renal disease (ESRD), typically those under 18 years of age, to remove waste products and excess fluid from the blood when kidneys fail. In the United States, approximately 1,500 children younger than 18 receive dialysis annually, with congenital anomalies of the kidney and urinary tract accounting for about 50% of cases, followed by glomerular diseases. Peritoneal dialysis (PD) is often the initial modality for infants and young children due to its feasibility for home use and continuous nature, which supports growth and minimizes hemodynamic instability compared to intermittent hemodialysis (HD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[170]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[171]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Vascular access poses significant challenges in pediatric HD, as small vessel sizes complicate arteriovenous fistula (AVF) creation, leading to reliance on central venous catheters (CVCs) in up to 70-80% of cases initially, which increases infection risks and thrombosis. Guidelines from the American Society of Pediatric Nephrology recommend AVF as the preferred permanent access for maintenance HD when feasible, but maturation rates are lower in children under 10 years due to anatomical limitations. PD avoids vascular access issues but carries risks of peritonitis (incidence 0.5-1 episode per patient-year) and mechanical complications like catheter malfunction, particularly in active toddlers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[172]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[173]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[174]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Outcomes in pediatric dialysis vary by age, modality, and comorbidities, with 1-year patient survival rates ranging from 82-96% and 5-year rates from 51-84%, influenced by factors such as effluent flow adequacy in continuous therapies and timely transition to transplantation. Cardiovascular complications remain the leading cause of mortality, accounting for up to 30% of deaths, while non-infectious issues like growth impairment and neurocognitive delays affect long-term quality of life. Psychosocial burdens are pronounced, with children on PD experiencing higher rates of anxiety (up to 40%) and academic disruption due to treatment demands on families. Multidisciplinary care, including nutritional support and psychological interventions, is essential to mitigate these effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[175]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[176]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[177]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[178]</sup></span>
<h3 id="dialysis-in-the-elderly-and-frail" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dialysis in the Elderly and Frail<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Elderly patients initiating dialysis, typically defined as those aged 75 years and older, exhibit substantially reduced survival compared to younger cohorts. A 2019 analysis of U.S. Medicare data for adults aged 65 and older found one-year mortality rates of 54.5% following dialysis start, with 22.5% dying within 30 days and 44.2% within 180 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[179]</sup> For patients over 80 on chronic hemodialysis, approximately one-third survive 12-24 months and another third 24-60 months, influenced by comorbidities such as cardiovascular disease and diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hrqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[180]</sup> Peritoneal dialysis in this group yields even lower survival, with rates of 79% at one year and 30% at five years, versus 97% and 73% in younger patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_prqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[181]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Frailty, characterized by diminished strength, endurance, and physiologic reserve, profoundly worsens prognosis in dialysis-dependent elderly patients. Frail individuals face 2- to 6-fold higher risks of mortality, hospitalization, infections, cardiovascular events, and dialysis-related complications like technique failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[182]</sup> Prevalence of frailty exceeds 70% in advanced chronic kidney disease progressing to dialysis, escalating with age and correlating with accelerated functional decline post-initiation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[183]</sup> A 2009 New England Journal of Medicine study of patients aged 70 and older documented marked deterioration in functional statusâ€”measured by activities of daily livingâ€”within one year of starting dialysis, independent of age or baseline function, attributing this to treatment burdens including vascular access issues and fatigue.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_psabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[184]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Quality of life often diminishes rather than improves with dialysis in frail elderly patients, due to procedural demands, frequent hospitalizations, and symptom persistence. Longitudinal assessments show no significant gains in health-related quality of life metrics post-dialysis initiation, with frail patients reporting higher pain, reduced mobility, and dependency.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[185]</sup> A 2024 Stanford-led study of frail older adults with kidney failure indicated that delaying or forgoing dialysis resulted in only nine days shorter median survival but substantially more days spent at home versus in facilities, highlighting dialysis&#x27;s limited life-prolonging benefit against its logistical strains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hsqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[186]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Conservative kidney managementâ€”focusing on symptom palliation, blood pressure control, and anemia correction without dialysisâ€”emerges as a viable alternative for frail elderly with end-stage renal disease. Median survival under conservative care ranges from 1 to 45 months, with one-year rates of 29-82%, often comparable to dialysis in highly comorbid subgroups where treatment intensity yields marginal gains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[187]</sup> While dialysis may confer a slight overall mortality advantage in selected elderly cohorts, conservative approaches preserve quality of life by avoiding dialysis-associated disruptions, with evidence from comparative studies showing equivalent or superior symptom control in frail patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_htabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Shared decision-making, incorporating frailty indices like the Fried phenotype, is essential, as patient preferences for longevity versus autonomy influence outcomes; guidelines emphasize discussing these trade-offs pre-initiation to align with realistic expectations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ptabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[188]</sup></span>
<h2 id="historical-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Historical Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="early-innovations-and-ethical-challenges" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Early Innovations and Ethical Challenges<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 1913, American physiologist John Jacob Abel, collaborating with Leonard G. Rowntree and Benjamin B. Turner, developed the first experimental artificial kidney apparatus. This device employed semipermeable collodion tubes as dialysis membranes and hirudin derived from leeches as an anticoagulant to remove urea and other waste from animal blood ex vivo, marking the initial demonstration of diffusive clearance mimicking renal filtration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[189]</sup> The system operated by circulating blood through the tubes immersed in a saline bath, achieving measurable toxin reduction but limited by clotting and membrane fragility, restricting it to short-term laboratory use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_huqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[190]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Building on these principles, German physician Georg G. Haas conducted the first human dialysis experiments in 1924 at the University of Giessen. Haas adapted collodion tubing and hirudin anticoagulation to treat uremic patients, performing sessions that reduced blood urea levels, though outcomes were hampered by inconsistent anticoagulation, membrane rupture, and patient comorbidities, with no long-term survivals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[191]</sup> These efforts highlighted technical barriers like biocompatibility and vascular access but established dialysis as a feasible, albeit rudimentary, intervention for acute uremia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Practical advancements accelerated during World War II under Dutch physician Willem J. Kolff, who in 1943 constructed the first functional hemodialyzerâ€”a rotating drum machine using 30 meters of cellophane sausage casing wrapped around a wooden cylinder rotating in a dialysate bath. Kolff treated 16 patients with acute kidney injury in Nazi-occupied Netherlands, sustaining one leather tanner for 24 hours beyond expectations, though most succumbed to underlying conditions or complications like hemorrhage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Postwar refinements, including distribution of Kolff&#x27;s designs to centers like the U.S. Naval Medical Center, enabled broader acute applications, with survival rates improving to 10-50% in selected cases by the late 1940s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[192]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Ethical challenges emerged concurrently as dialysis transitioned from experimental salvage therapy to potential life-sustaining treatment, raising questions of consent, futility, and equitable access amid resource scarcity. Early human trials involved terminal patients with minimal informed consent protocols, prioritizing physiological restoration over quality-of-life assessments, which later drew scrutiny for overlooking psychological burdens like dependency and survival with disabilities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup> By the early 1960s, innovations such as Belding Scribner&#x27;s external arteriovenous shunt in 1960 permitted repeated access for chronic therapy, but limited machinesâ€”often one per centerâ€”necessitated selection criteria favoring younger, employed, socially stable individuals, as determined by ad hoc hospital committees.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[194]</sup> These &quot;God committees&quot; provoked public outcry, exemplified by a 1962 Life magazine feature and 1965 NBC documentary &quot;Who Shall Live?&quot;, exposing utilitarian judgments on human worth and catalyzing bioethics discourse on rationing without democratic oversight.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[195]</sup> Such practices underscored causal tensions between technological promise and societal capacity, influencing later policy shifts toward universal access under the 1972 U.S. End-Stage Renal Disease program.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_120abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup></span>
<h3 id="modern-advancements-and-milestones" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Modern Advancements and Milestones<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The introduction of <strong>continuous ambulatory peritoneal dialysis (CAPD)</strong> in 1976 by Popovich and colleagues marked a pivotal shift toward outpatient and home-based renal replacement therapy, enabling patients to perform exchanges manually without specialized equipment, thereby reducing reliance on hospital-based hemodialysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[196]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[197]</sup> This modality expanded access for chronic kidney disease patients, with widespread adoption in the 1980s demonstrating improved quality of life through greater flexibility, though peritonitis rates initially posed challenges addressed via refined connection systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_121abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[198]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Building on CAPD, <strong>automated peritoneal dialysis (APD)</strong> emerged in 1981, utilizing cyclers to automate fluid exchanges overnight, which minimized daytime disruptions and suited patients with physical limitations or high transporters.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[199]</sup> Baxter&#x27;s APD cycler, introduced in 1984, facilitated programmed regimens like continuous cycling PD, enhancing solute clearance and ultrafiltration while lowering infection risks compared to manual methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[200]</sup> Concurrently, hemodialysis advanced with <strong>high-flux dialyzers</strong> in the early 1980s, such as the 1980 F60 polysulfone model, which permitted greater removal of middle-molecular-weight toxins like beta-2 microglobulin, reducing amyloidosis incidence and improving long-term outcomes over low-flux predecessors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[201]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A landmark pharmacological milestone occurred on June 1, 1989, when the U.S. FDA approved recombinant human erythropoietin (epoetin alfa) for treating anemia in dialysis patients, dramatically decreasing transfusion dependence from over 50% to under 10% in the first years of use by stimulating endogenous red blood cell production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[202]</sup> This innovation addressed a core complication of end-stage renal disease, with studies confirming hemoglobin stabilization and reduced cardiovascular strain, though later dose adjustments were needed to mitigate risks like thrombosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[203]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the 2000s, <strong>portable home hemodialysis systems</strong> like the NxStage System One gained traction, cleared for home use to enable short, frequent sessions (e.g., 2.5-3 hours, 5-6 times weekly), yielding superior phosphate control and vascular access preservation versus conventional thrice-weekly in-center treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[204]</sup> Recent developments include sorbent-based regeneration for reduced fluid volumes and wearable prototypes, such as the AWAK PD device, which recycles peritoneal dialysate for continuous ambulatory use; clinical trials since 2018 have shown feasibility for mobility, though scalability and regulatory hurdles persist.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[205]</sup> These innovations collectively extend survivalâ€”dialysis patient life expectancy rose from under 5 years in the 1980s to over 10 years by the 2020sâ€”driven by iterative engineering and biocompatibility gains, albeit with ongoing needs for infection mitigation and personalization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_122qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[206]</sup></span>
<h2 id="controversies-and-debates" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Controversies and Debates<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="resource-allocation-and-rationing" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Resource Allocation and Rationing<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the early 1960s, scarcity of hemodialysis machines in Seattle, Washington, led to the formation of an anonymous committee at Swedish Hospital, informally known as the &quot;God Committee,&quot; to allocate access to treatment among patients with end-stage renal disease (ESRD).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[194]</sup> The committee, comprising seven lay members including a minister, labor leader, housewife, and government official, evaluated candidates using criteria such as medical suitability, income, marital status, family responsibilities, community contributions, and perceived social worth, effectively deciding life-or-death outcomes for dozens of applicants amid only 10-16 available machines nationwide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[207]</sup> This process, initiated in 1962, sparked public outrage over subjective judgments and inspired journalistic scrutiny, including Shana Alexander&#x27;s 1962 <em>Life</em> magazine exposÃ©, which highlighted cases like the denial of treatment to a wheat farmer deemed insufficiently &quot;intellectually stimulating.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_124abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[208]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Seattle experience catalyzed broader policy reforms, culminating in the U.S. Social Security Amendments of 1972, which established Medicare entitlement for all ESRD patients regardless of age, effectively eliminating explicit rationing by federalizing funding for dialysis and transplantation at an initial cost of $240 million annually, rising to billions over decades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[193]</sup> This &quot;end-stage renal disease program&quot; prioritized universal access over cost containment, averting committee-style triage but straining resources, as demand exceeded supply projections; by 2023, over 550,000 U.S. patients received dialysis at costs exceeding $50 billion yearly.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[209]</sup> Critics argue this approach deferred rationing to implicit forms, such as withholding treatment from noncompliant or frail patients based on clinical futility, though empirical data show lower mortality benefits in elderly cohorts with comorbidities, raising stewardship questions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[210]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Globally, explicit rationing persists in low- and middle-income countries (LMICs), where dialysis capacity covers less than 10% of needs in sub-Saharan Africa and South Asia, often prioritizing younger patients or transplant candidates over the elderly or poor due to limited machines and funding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[211]</sup> In resource-constrained settings like Pakistan and parts of Africa, up to 60% of ESRD patients are denied treatment owing to poverty or social factors, with informal triage by clinicians leading to moral distress; for instance, a 2006 South African study found economic barriers excluded most applicants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[212]</sup> The 2023 International Society of Nephrology Global Kidney Health Atlas documents stark disparities, with only 20-30% of LMICs providing comprehensive kidney replacement therapy, necessitating rationing by ability to pay or prognostic utility rather than egalitarian principles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[213]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pandemic-induced shortages, as during COVID-19, exposed vulnerabilities even in high-income systems; in New York City hospitals in April 2020, machine and fluid deficits forced reductions in continuous renal replacement therapy sessions from 24 to 12 hours daily or outright triage, prioritizing acute over chronic cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[214]</sup> Advocates subsequently urged inclusion of dialysis equipment in U.S. national stockpiles, absent since the 1980s, to mitigate future crises, though no standardized ESRD-specific guidelines emerged, leaving decisions to ad hoc clinical judgment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[215]</sup> Ethical debates center on balancing utility (e.g., quality-adjusted life years gained) against equity, with evidence from LMICs indicating age- or comorbidity-based rationing maximizes population-level outcomes but risks discrimination, while high-income avoidance of explicit criteria may inflate costs without proportional survival gains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[216]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[217]</sup></span>
<h3 id="optimal-timing-of-dialysis-initiation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Optimal Timing of Dialysis Initiation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The optimal timing for initiating dialysis in patients with advanced chronic kidney disease (CKD) remains a topic of debate, with evidence indicating that decisions should prioritize clinical symptoms over glomerular filtration rate (GFR) thresholds alone. Randomized controlled trials, such as the Initiating Dialysis Early and Late (IDEAL) study published in 2010, demonstrated no survival benefit from starting dialysis at a higher eGFR (10-14 mL/min/1.73 mÂ²) compared to a lower threshold (5-7 mL/min/1.73 mÂ²), with median survival times of 6.0 years versus 5.8 years, respectively.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[218]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[218]</sup> This trial, involving 828 participants, also found no differences in cardiovascular events, infections, or quality of life, challenging prior observational data suggesting early initiation improved outcomes, which were likely confounded by lead-time and survivor biases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[218]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Subsequent analyses and guidelines reinforce a symptom-guided approach, recommending initiation when uremia impairs daily function, uncontrollable fluid overload occurs, or persistent hyperkalemia or acidosis develops, typically at eGFR levels below 10 mL/min/1.73 mÂ² in symptomatic patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> KDIGO controversies conference reports from 2019 explicitly advise against routine preemptive dialysis in asymptomatic individuals, as early starts do not reduce mortality or cardiac risks and may hasten residual renal function decline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[219]</sup> A 2023 systematic review of 23 studies confirmed that GFR at initiation does not independently predict mortality, with planned starts (versus urgent) associated with better survival due to better access preparation rather than timing per se.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_127abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[220]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Early initiation carries risks including higher rates of dialysis-related complications, such as infections from temporary catheters and accelerated loss of native kidney function, without offsetting gains in longevity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[221]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[218]</sup> In contrast, delayed initiation in carefully monitored patients allows for conservative management, potentially avoiding dialysis altogether in some with slow progression, though urgent starts risk higher short-term mortality from complications like volume overload.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[220]</sup> Patient-specific factors, including frailty, comorbidities, and access maturity (e.g., arteriovenous fistula formation requiring 6 months for maturation), must inform timing to minimize harm.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_127qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[222]</sup> Post-IDEAL practice shifts in regions like Canada showed reduced mean eGFR at start from 11.0 to 8.5 mL/min/1.73 mÂ² without worsening outcomes, supporting later, deliberate initiation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[223]</sup></span>
<h3 id="barriers-to-home-dialysis-adoption" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Barriers to Home Dialysis Adoption<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Despite evidence that home dialysis modalities, such as peritoneal dialysis and home hemodialysis, can improve patient quality of life and potentially reduce costs compared to in-center treatments, adoption remains low, comprising less than 10% of dialysis patients in the United States as of 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[224]</sup> Patient-level fears represent a primary obstacle, with surveys indicating that fear of self-performing dialysisâ€”particularly self-cannulation for home hemodialysisâ€”and concerns over handling medical emergencies at home rank as the top barriers cited by patients and caregivers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[225]</sup> These apprehensions are compounded by inadequate home space for equipment and supplies, which affects up to 20-30% of potential candidates in urban or low-income settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[226]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Caregiver and family burden further deters uptake, as home dialysis often requires assistance from relatives, imposing physical, emotional, and time demands that many households cannot sustain without support.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[227]</sup> Qualitative studies highlight psychosocial factors, including patients&#x27; physical limitations, cognitive impairments, and negative attitudes toward self-management, which systematically exclude frail or elderly individuals despite their potential eligibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[228]</sup> Deficient patient education exacerbates these issues; providers report that insufficient training programs and low awareness of home options lead patients to default to familiar in-center care, where professional oversight alleviates perceived risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[229]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">From a systemic perspective, reimbursement structures fail to adequately cover home modifications, ongoing support visits, or caregiver respite, even following policy incentives like the U.S. Advancing American Kidney Health Initiative launched in 2019, which aimed to boost home dialysis to 80% of new patients by 2025 but has seen limited progress.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[224]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[225]</sup> Economic disparities amplify this, with socioeconomically disadvantaged patients facing upfront costs for home setups and supply storage that in-center dialysis avoids, particularly in peritoneal dialysis where modality-specific infrastructure demands strain low-resource environments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[230]</sup> Providers also cite operational hurdles, such as the scarcity of dedicated home dialysis clinics with transitional care units, which are essential for initial training but absent in many regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_129qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[231]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In Europe and other regions, policy fragmentation contributes to inequities, with home dialysis often restricted to patients with high autonomy and financial stability, sidelining broader implementation despite modifiable barriers like standardized training protocols.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[232]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[233]</sup> Addressing these requires targeted interventions, including enhanced financial alignments and education, though entrenched provider preferences for in-center modelsâ€”driven by revenue stabilityâ€”persist as unaddressed incentives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[234]</sup></span>
<h2 id="future-directions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Future Directions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="technological-innovations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Technological Innovations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Efforts to develop wearable artificial kidneys focus on enhancing patient mobility and enabling more frequent, continuous treatment to mimic natural renal function. Devices like the Automated Wearable Artificial Kidney (AWAK) for peritoneal dialysis regenerate dialysate using sorbent technology, reducing fluid volume requirements and allowing ambulatory use under clothing, with prototypes demonstrating feasibility in preclinical models as of 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[235]</sup> Similarly, Seoul National University researchers advanced a portable peritoneal dialysis system in April 2025 that continuously purifies and reinfuses dialysate, potentially enabling home-based, water-efficient therapy without large infrastructure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ibqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[236]</sup> These innovations address limitations of stationary hemodialysis by prioritizing dialysate regeneration and miniaturization, though clinical trials remain ongoing to validate long-term efficacy and biocompatibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[237]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bioartificial kidneys represent a paradigm shift toward implantable devices integrating synthetic filtration with living cellular components for autonomous waste removal and metabolic regulation. The Kidney Project at the University of California, San Francisco, develops a silicon nanopore membrane-based hemofilter paired with a bioreactor of human renal tubule cells, aiming for 24/7 implantation without immunosuppression or anticoagulation; prototypes achieved proof-of-concept filtration in large animal models by 2023, earning a $1 million KidneyX prize in 2023 for milestone advancements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> The Implantable Bio-Artificial Kidney (iBAK), a soda-can-sized device with porcine renal cells, supports continuous ultrafiltration and reabsorption, with preclinical data from 2023 indicating stable function without dialysis dependency in animal studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_icabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[238]</sup> These hybrid approaches leverage tissue engineering to restore endocrine functions absent in conventional dialysis, but human trials are pending resolution of immune rejection and scaling challenges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[239]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Integration of artificial intelligence (AI) and machine learning promises precision dialysis through predictive analytics and automated adjustments. Machine learning models trained on intradialytic data predict hypotension episodes with high accuracy, enabling preemptive interventions to reduce cardiovascular risks during sessions, as demonstrated in systematic reviews of studies up to 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[240]</sup> AI-driven systems analyze real-time patient metrics like fluid status and urea levels to optimize dose adequacy, outperforming traditional Kt/V metrics in retrospective datasets from 2021 onward.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_icqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[241]</sup> Future smart dialyzers could incorporate AI for personalized regimens, learning from aggregated treatment data to minimize complications, though validation requires prospective trials to confirm causality beyond correlations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qcqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[242]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Nanotechnology enhances hemodialysis membranes by improving selectivity, antifouling, and biocompatibility. Incorporation of nanoparticles, such as gold or graphene oxide, into polymeric matrices boosts permeability for middle-molecule clearance while preventing protein adsorption and bacterial adhesion, with lab-tested membranes showing up to 50% higher flux without albumin loss as of 2021-2023 studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_adabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[243]</sup> Nano-porous alumina membranes exhibit superior solute rejection and hemocompatibility compared to polysulfone standards, enabling efficient uremic toxin removal in ex vivo setups reported in 2009 but refined in recent nanocomposites.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_idabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[244]</sup> These modifications support compact, high-efficiency filters for wearable applications, yet biocompatibility in chronic human use demands further randomized evidence to mitigate potential nanoparticle leaching risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[245]</sup></span>
<h3 id="research-and-potential-breakthroughs" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Research and Potential Breakthroughs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Ongoing research into kidney dialysis focuses on developing implantable and bioartificial kidneys to replace conventional hemodialysis and peritoneal dialysis, aiming to restore natural filtration without frequent sessions or vascular access complications. The Kidney Project, a collaboration between UCSF and Vanderbilt University, is advancing a bioartificial kidney that integrates silicon nanopore membranes for glomerular filtration and living kidney cells for bioactivity, with preclinical large-animal studies demonstrating sustained function as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[239]</sup> Similarly, UCLA&#x27;s Implantable Artificial Kidney program is engineering a waterless, dialysis-free device mimicking the renal glomerulus using silicon nanopore technology, which filters blood continuously without anticoagulants or pumps, supported by National Institutes of Health funding and entering advanced prototyping in 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> These efforts address dialysis limitations like infection risks and poor quality of life, with projections for human trials in the late 2020s if biocompatibility hurdles are overcome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[246]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Wearable and portable dialysis devices represent nearer-term innovations to enhance mobility and reduce clinic dependence. Devices like the Wearable Artificial Kidney (WAK), weighing about 2 kg and belt-mounted, perform sorbent-based hemodialysis using body fluids for regeneration, enabling continuous treatment with lower fluid volumes than standard machines; clinical trials in 2023-2024 confirmed safety and efficacy in small cohorts, though energy efficiency and membrane durability remain challenges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[205]</sup> Next-generation peritoneal dialysis systems, such as automated portable cyclers with sorbent technology, are under development to minimize dialysate use and infrastructure needs, with European prototypes tested in 2025 showing improved ultrafiltration rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[247]</sup> These technologies could expand home-based therapy, potentially lowering costsâ€”estimated at $90,000 annually per patient for in-center dialysisâ€”and cardiovascular strain from intermittent treatment, per modeling from the National Kidney Foundation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[248]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regenerative approaches, including stem cell and cell therapies, seek to repair kidney tissue and delay or obviate dialysis initiation. Mesenchymal stem cell infusions have shown promise in preclinical models for reducing inflammation and fibrosis in chronic kidney disease (CKD), with a 2024 review indicating improved glomerular filtration rates in rodent acute kidney injury studies, though human translation is limited by engraftment issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[249]</sup> A phase 1/2 trial launched by UC Davis Health in April 2025 tests allogeneic cell therapy in type 2 diabetes-associated CKD patients on or nearing dialysis, aiming to restore tubular function via paracrine effects; early data from similar mesenchymal trials report stabilized creatinine levels in 30-50% of participants after 12 months.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ifabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[250]</sup> Bioengineered kidney organoids from induced pluripotent stem cells offer platforms for disease modeling and potential transplantation, but scalability and vascularization barriers persist, with no clinical dialysis-alternative applications as of 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[251]</sup> These therapies complement dialysis by targeting underlying pathology, yet experts emphasize the need for randomized controlled trials to validate long-term outcomes amid risks like immune rejection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_12fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[252]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Integration of precision medicine, such as biomarkers like suPAR for predicting dialysis need, is accelerating through omics research, with NIH-funded studies in 2024-2025 identifying genetic variants influencing dialysis response to guide personalized regimens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[253]</sup> While xenotransplantation trials, including genetically modified pig kidneys sustaining function in brain-dead humans for over 60 days in 2023, primarily target transplantation, they indirectly inform bioartificial designs by validating cross-species compatibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ifqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[254]</sup> Overall, these advancements could transform end-stage renal disease management by 2050, potentially halving reliance on chronic dialysis through hybrid renal replacement therapies, contingent on regulatory approval and equitable access.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[255]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000707.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000707.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000707.htm</a></span></div></li><li id="https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK492981/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK492981/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK492981/</a></span></div></li><li id="https://www.nlm.nih.gov/medlineplus/dialysis.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nlm.nih.gov/medlineplus/dialysis.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nlm.nih.gov/medlineplus/dialysis.html</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK532006/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK532006/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK532006/</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK563296/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK563296/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK563296/</a></span></div></li><li id="https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/</a></span></div></li><li id="https://case.edu/ech/articles/k/kolff-willem-j" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://case.edu/ech/articles/k/kolff-willem-j" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://case.edu/ech/articles/k/kolff-willem-j</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK499861/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK499861/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK499861/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7529591/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7529591/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7529591/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2818%2930124-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2818%2930124-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2818%2930124-0/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5654453/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5654453/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5654453/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/ultrafiltration" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/ultrafiltration" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/ultrafiltration</a></span></div></li><li id="https://www.sciencedirect.com/topics/nursing-and-health-professions/countercurrent-flow" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/nursing-and-health-professions/countercurrent-flow" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/nursing-and-health-professions/countercurrent-flow</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7645386/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7645386/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7645386/</a></span></div></li><li id="https://academic.oup.com/ndt/article/19/4/785/1810632" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/19/4/785/1810632" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/19/4/785/1810632</a></span></div></li><li id="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/peritoneal-dialysis-fluid" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/peritoneal-dialysis-fluid" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/peritoneal-dialysis-fluid</a></span></div></li><li id="https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-111/diffusion-mechanism-solute-removal" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-111/diffusion-mechanism-solute-removal" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-111/diffusion-mechanism-solute-removal</a></span></div></li><li id="https://davita.com/treatment-options/articles/the-history-of-dialysis/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://davita.com/treatment-options/articles/the-history-of-dialysis/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://davita.com/treatment-options/articles/the-history-of-dialysis/</a></span></div></li><li id="https://nephrology.uw.edu/about/history" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nephrology.uw.edu/about/history" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nephrology.uw.edu/about/history</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8711766/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8711766/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8711766/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5618180/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5618180/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5618180/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2824%2900976-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2824%2900976-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2824%2900976-4/fulltext</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK493195/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK493195/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK493195/</a></span></div></li><li id="https://jamanetwork.com/journals/jama/article-abstract/2816266" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jama/article-abstract/2816266" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jama/article-abstract/2816266</a></span></div></li><li id="https://www.kidney.org/kidney-topics/hemodialysis-access" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/hemodialysis-access" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/hemodialysis-access</a></span></div></li><li id="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300823" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300823" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300823</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa1103313" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1103313" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa1103313</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0085253816303222" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0085253816303222" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0085253816303222</a></span></div></li><li id="https://academic.oup.com/ckj/article/14/2/665/6054266" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/14/2/665/6054266" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/14/2/665/6054266</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK532979/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK532979/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK532979/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/peritoneal-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/peritoneal-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/peritoneal-dialysis</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39675379/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39675379/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39675379/</a></span></div></li><li id="https://academic.oup.com/ckj/article/18/8/sfaf215/8193697" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/18/8/sfaf215/8193697" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/18/8/sfaf215/8193697</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7855236/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7855236/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7855236/</a></span></div></li><li id="https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus</a></span></div></li><li id="https://www.uptodate.com/contents/patient-survival-and-maintenance-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uptodate.com/contents/patient-survival-and-maintenance-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uptodate.com/contents/patient-survival-and-maintenance-dialysis</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK556028/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK556028/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK556028/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-63862401120-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-63862401120-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-63862401120-X/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6435902/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6435902/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6435902/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0034837625001639" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0034837625001639" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0034837625001639</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39417967/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39417967/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39417967/</a></span></div></li><li id="https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01517-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01517-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01517-0</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10125730/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10125730/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10125730/</a></span></div></li><li id="https://journals.lww.com/ccejournal/fulltext/2021/05000/comparing_renal_replacement_therapy_modalities_in.3.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/ccejournal/fulltext/2021/05000/comparing_renal_replacement_therapy_modalities_in.3.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/ccejournal/fulltext/2021/05000/comparing_renal_replacement_therapy_modalities_in.3.aspx</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1441277225000110" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1441277225000110" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1441277225000110</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/27398407/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/27398407/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/27398407/</a></span></div></li><li id="https://clinicaltrials.gov/study/NCT05906355" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://clinicaltrials.gov/study/NCT05906355" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://clinicaltrials.gov/study/NCT05906355</a></span></div></li><li id="https://pharm.ucsf.edu/kidney/device" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pharm.ucsf.edu/kidney/device" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pharm.ucsf.edu/kidney/device</a></span></div></li><li id="https://www.healio.com/news/nephrology/20241008/cell-therapy-new-pd-devices-bioartificial-kidneys-set-a-new-direction-for-kidney-care" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healio.com/news/nephrology/20241008/cell-therapy-new-pd-devices-bioartificial-kidneys-set-a-new-direction-for-kidney-care" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healio.com/news/nephrology/20241008/cell-therapy-new-pd-devices-bioartificial-kidneys-set-a-new-direction-for-kidney-care</a></span></div></li><li id="https://www.uclahealth.org/medical-services/nephrology/clinical-programs/implantable-artificial-kidney" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uclahealth.org/medical-services/nephrology/clinical-programs/implantable-artificial-kidney" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uclahealth.org/medical-services/nephrology/clinical-programs/implantable-artificial-kidney</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12474070/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12474070/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12474070/</a></span></div></li><li id="https://www.nature.com/articles/s41581-023-00726-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41581-023-00726-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41581-023-00726-9</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2000741" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2000741" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2000741</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa1803213" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1803213" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa1803213</a></span></div></li><li id="http://www.nephjc.com/news/2016/5/26/acute-kidney-injury-when-to-dialyze" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.nephjc.com/news/2016/5/26/acute-kidney-injury-when-to-dialyze" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">http://www.nephjc.com/news/2016/5/26/acute-kidney-injury-when-to-dialyze</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5066036/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5066036/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5066036/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11258500/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11258500/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11258500/</a></span></div></li><li id="https://www.atsjournals.org/doi/full/10.1164/rccm.201810-1906CP" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.atsjournals.org/doi/full/10.1164/rccm.201810-1906CP" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.atsjournals.org/doi/full/10.1164/rccm.201810-1906CP</a></span></div></li><li id="https://academic.oup.com/ndt/article/26/7/2082/1896753" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/26/7/2082/1896753" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/26/7/2082/1896753</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/30208820/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/30208820/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/30208820/</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf</a></span></div></li><li id="https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf</a></span></div></li><li id="https://www.kidney.org/news-when-should-i-start-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/news-when-should-i-start-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/news-when-should-i-start-dialysis</a></span></div></li><li id="https://doi.org/10.1093/ckj/sfad062" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1093/ckj/sfad062" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1093/ckj/sfad062</a></span></div></li><li id="https://www.aafp.org/pubs/afp/issues/2021/1100/p493.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aafp.org/pubs/afp/issues/2021/1100/p493.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aafp.org/pubs/afp/issues/2021/1100/p493.html</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790050" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790050" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790050</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/</a></span></div></li><li id="https://www.kidneymedicinejournal.org/article/S2590-0595%2820%2930268-5/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneymedicinejournal.org/article/S2590-0595%2820%2930268-5/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneymedicinejournal.org/article/S2590-0595%2820%2930268-5/fulltext</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6</a></span></div></li><li id="https://reports.mountsinai.org/article/neph2021-04-conservative-management-of-esrd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://reports.mountsinai.org/article/neph2021-04-conservative-management-of-esrd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://reports.mountsinai.org/article/neph2021-04-conservative-management-of-esrd</a></span></div></li><li id="https://academic.oup.com/ndt/article/37/Supplement_3/gfac071.013/6578311" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/37/Supplement_3/gfac071.013/6578311" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/37/Supplement_3/gfac071.013/6578311</a></span></div></li><li id="https://www.mdpi.com/2077-0383/13/1/41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2077-0383/13/1/41" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2077-0383/13/1/41</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2590059523001449" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2590059523001449" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2590059523001449</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/choosing-dialysis-which-type-right-me" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/choosing-dialysis-which-type-right-me" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/choosing-dialysis-which-type-right-me</a></span></div></li><li id="https://nephrology.medicine.ufl.edu/patient-care/renal-replacement-therpay/home-dialysis/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nephrology.medicine.ufl.edu/patient-care/renal-replacement-therpay/home-dialysis/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nephrology.medicine.ufl.edu/patient-care/renal-replacement-therpay/home-dialysis/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2468024923014845" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2468024923014845" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2468024923014845</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22098661/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22098661/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22098661/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6628511/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6628511/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6628511/</a></span></div></li><li id="https://www.kidney.org.uk/home-dialysis-the-advantages" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org.uk/home-dialysis-the-advantages" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org.uk/home-dialysis-the-advantages</a></span></div></li><li id="https://www.hsrd.research.va.gov/publications/esp/kidney-dialysis-REPORT.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hsrd.research.va.gov/publications/esp/kidney-dialysis-REPORT.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hsrd.research.va.gov/publications/esp/kidney-dialysis-REPORT.pdf</a></span></div></li><li id="https://link.springer.com/article/10.1007/s40258-025-00976-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s40258-025-00976-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s40258-025-00976-7</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03264-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03264-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03264-5</a></span></div></li><li id="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality</a></span></div></li><li id="https://pharm.ucsf.edu/kidney/need/statistics" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pharm.ucsf.edu/kidney/need/statistics" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pharm.ucsf.edu/kidney/need/statistics</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39675379" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39675379" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39675379</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12407124/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12407124/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12407124/</a></span></div></li><li id="https://www.nature.com/articles/s41581-024-00820-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41581-024-00820-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41581-024-00820-6</a></span></div></li><li id="https://www.cureus.com/articles/205740-quality-of-life-and-complications-among-hemodialysis-patients" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cureus.com/articles/205740-quality-of-life-and-complications-among-hemodialysis-patients" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cureus.com/articles/205740-quality-of-life-and-complications-among-hemodialysis-patients</a></span></div></li><li id="https://academic.oup.com/ckj/article/18/2/sfae420/7929882" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/18/2/sfae420/7929882" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/18/2/sfae420/7929882</a></span></div></li><li id="https://www.nature.com/articles/s41598-019-46744-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-019-46744-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-019-46744-1</a></span></div></li><li id="https://academic.oup.com/ndt/article/38/11/2528/7172141" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/38/11/2528/7172141" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/38/11/2528/7172141</a></span></div></li><li id="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1530465/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1530465/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1530465/full</a></span></div></li><li id="https://karger.com/kbr/article/43/6/1813/187988/Hemodialysis-or-Peritoneal-Dialysis-Which-Is" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/kbr/article/43/6/1813/187988/Hemodialysis-or-Peritoneal-Dialysis-Which-Is" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/kbr/article/43/6/1813/187988/Hemodialysis-or-Peritoneal-Dialysis-Which-Is</a></span></div></li><li id="https://www.mypcnow.org/fast-fact/depression-in-end-stage-renal-disease/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mypcnow.org/fast-fact/depression-in-end-stage-renal-disease/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mypcnow.org/fast-fact/depression-in-end-stage-renal-disease/</a></span></div></li><li id="https://www.kidney.org/sites/default/files/v40b_a4.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/sites/default/files/v40b_a4.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/sites/default/files/v40b_a4.pdf</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-03051-8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-03051-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-03051-8</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5856029/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5856029/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5856029/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/21883901/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/21883901/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/21883901/</a></span></div></li><li id="https://www.bmj.com/content/376/bmj-2021-068769" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bmj.com/content/376/bmj-2021-068769" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bmj.com/content/376/bmj-2021-068769</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S1600613523005786" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S1600613523005786" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S1600613523005786</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z</a></span></div></li><li id="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12071/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12071/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12071/full</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2590059525000226" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2590059525000226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2590059525000226</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39212241/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39212241/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39212241/</a></span></div></li><li id="https://academic.oup.com/ndt/article-abstract/37/8/1529/6534933" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article-abstract/37/8/1529/6534933" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article-abstract/37/8/1529/6534933</a></span></div></li><li id="https://www.capc.org/blog/rethinking-kidney-care-the-role-of-conservative-kidney-management/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.capc.org/blog/rethinking-kidney-care-the-role-of-conservative-kidney-management/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.capc.org/blog/rethinking-kidney-care-the-role-of-conservative-kidney-management/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790040" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790040" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790040</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2805%2900436-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2805%2900436-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2805%2900436-1/fulltext</a></span></div></li><li id="https://academic.oup.com/ckj/article/13/6/981/5868598" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/13/6/981/5868598" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/13/6/981/5868598</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7851674/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7851674/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7851674/</a></span></div></li><li id="https://www.intechopen.com/chapters/85615" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.intechopen.com/chapters/85615" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.intechopen.com/chapters/85615</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01806-9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01806-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01806-9</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2821%2900001-9/pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2821%2900001-9/pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2821%2900001-9/pdf</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2823%2900649-2/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2823%2900649-2/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2823%2900649-2/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11168815/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11168815/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11168815/</a></span></div></li><li id="https://www.merckmanuals.com/home/multimedia/table/some-common-complications-of-peritoneal-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merckmanuals.com/home/multimedia/table/some-common-complications-of-peritoneal-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merckmanuals.com/home/multimedia/table/some-common-complications-of-peritoneal-dialysis</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11952240/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11952240/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11952240/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6168816/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6168816/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6168816/</a></span></div></li><li id="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686</a></span></div></li><li id="https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2023.1198560/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2023.1198560/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2023.1198560/full</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK560742/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK560742/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK560742/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2214762414000140" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2214762414000140" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2214762414000140</a></span></div></li><li id="https://my.clevelandclinic.org/health/diseases/24006-renal-osteodystrophy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://my.clevelandclinic.org/health/diseases/24006-renal-osteodystrophy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://my.clevelandclinic.org/health/diseases/24006-renal-osteodystrophy</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8359961/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8359961/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8359961/</a></span></div></li><li id="https://www.kidney.org/kidney-topics/dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/kidney-topics/dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/kidney-topics/dialysis</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/8320909/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/8320909/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/8320909/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/</a></span></div></li><li id="https://www.cdc.gov/pcd/issues/2024/24_0052.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/pcd/issues/2024/24_0052.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/pcd/issues/2024/24_0052.htm</a></span></div></li><li id="https://www.cms.gov/newsroom/fact-sheets/calendar-year-2024-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1782-f" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-2024-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1782-f" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cms.gov/newsroom/fact-sheets/calendar-year-2024-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1782-f</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7873827/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7873827/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7873827/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10344940/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10344940/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10344940/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10060297/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10060297/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10060297/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2212109925000342" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2212109925000342" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2212109925000342</a></span></div></li><li id="https://www.nature.com/articles/s41598-023-37814-6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-023-37814-6" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-023-37814-6</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2342210" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2342210" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2342210</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794481" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794481" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794481</a></span></div></li><li id="https://www.medpac.gov/wp-content/uploads/2024/03/Mar24_Ch5_MedPAC_Report_To_Congress_SEC.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medpac.gov/wp-content/uploads/2024/03/Mar24_Ch5_MedPAC_Report_To_Congress_SEC.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medpac.gov/wp-content/uploads/2024/03/Mar24_Ch5_MedPAC_Report_To_Congress_SEC.pdf</a></span></div></li><li id="https://www.healio.com/news/nephrology/20250708/economic-analysis-dialysis-center-duopoly-keeps-commercial-insurance-payments-high" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healio.com/news/nephrology/20250708/economic-analysis-dialysis-center-duopoly-keeps-commercial-insurance-payments-high" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healio.com/news/nephrology/20250708/economic-analysis-dialysis-center-duopoly-keeps-commercial-insurance-payments-high</a></span></div></li><li id="https://lpeproject.org/blog/a-dialysis-duopoly-how-public-funding-entrenched-private-power/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://lpeproject.org/blog/a-dialysis-duopoly-how-public-funding-entrenched-private-power/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://lpeproject.org/blog/a-dialysis-duopoly-how-public-funding-entrenched-private-power/</a></span></div></li><li id="https://www.marketsandmarkets.com/ResearchInsight/dialysis-market.asp" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.marketsandmarkets.com/ResearchInsight/dialysis-market.asp" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.marketsandmarkets.com/ResearchInsight/dialysis-market.asp</a></span></div></li><li id="https://www.grandviewresearch.com/industry-analysis/us-dialysis-centers-market-report" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.grandviewresearch.com/industry-analysis/us-dialysis-centers-market-report" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.grandviewresearch.com/industry-analysis/us-dialysis-centers-market-report</a></span></div></li><li id="https://www.fortunebusinessinsights.com/dialysis-market-102367" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fortunebusinessinsights.com/dialysis-market-102367" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fortunebusinessinsights.com/dialysis-market-102367</a></span></div></li><li id="https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7985814/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7985814/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7985814/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10592119/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10592119/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10592119/</a></span></div></li><li id="https://meditechinsights.com/dialysis-market/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://meditechinsights.com/dialysis-market/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://meditechinsights.com/dialysis-market/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S016885102300101X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S016885102300101X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S016885102300101X</a></span></div></li><li id="https://som.yale.edu/sites/default/files/2024-05/Dialysis_Divestitures_6.2.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://som.yale.edu/sites/default/files/2024-05/Dialysis_Divestitures_6.2.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://som.yale.edu/sites/default/files/2024-05/Dialysis_Divestitures_6.2.pdf</a></span></div></li><li id="https://www.ibisworld.com/united-states/industry/dialysis-centers/4038/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ibisworld.com/united-states/industry/dialysis-centers/4038/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ibisworld.com/united-states/industry/dialysis-centers/4038/</a></span></div></li><li id="https://www.cms.gov/medicare/coordination-benefits-recovery/overview/end-stage-renal-disease-esrd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cms.gov/medicare/coordination-benefits-recovery/overview/end-stage-renal-disease-esrd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cms.gov/medicare/coordination-benefits-recovery/overview/end-stage-renal-disease-esrd</a></span></div></li><li id="https://www.medicare.gov/basics/end-stage-renal-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medicare.gov/basics/end-stage-renal-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medicare.gov/basics/end-stage-renal-disease</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11090145/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11090145/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11090145/</a></span></div></li><li id="https://www.federalregister.gov/documents/2024/11/12/2024-25486/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.federalregister.gov/documents/2024/11/12/2024-25486/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.federalregister.gov/documents/2024/11/12/2024-25486/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis</a></span></div></li><li id="https://www.nature.com/articles/nrneph.2012.117" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nrneph.2012.117" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nrneph.2012.117</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838512" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838512" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838512</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10593311/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10593311/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10593311/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823636" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823636" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823636</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03593-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03593-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03593-z</a></span></div></li><li id="https://www.theisn.org/wp-content/uploads/media/ISN%2520Atlas_2023%2520Digital.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.theisn.org/wp-content/uploads/media/ISN%2520Atlas_2023%2520Digital.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.theisn.org/wp-content/uploads/media/ISN%2520Atlas_2023%2520Digital.pdf</a></span></div></li><li id="https://www.healthychildren.org/English/health-issues/conditions/genitourinary-tract/Pages/dialysis-in-children.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.healthychildren.org/English/health-issues/conditions/genitourinary-tract/Pages/dialysis-in-children.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.healthychildren.org/English/health-issues/conditions/genitourinary-tract/Pages/dialysis-in-children.aspx</a></span></div></li><li id="https://link.springer.com/book/10.1007/978-3-030-66861-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/book/10.1007/978-3-030-66861-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/book/10.1007/978-3-030-66861-7</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/32891312/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/32891312/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/32891312/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2806%2900666-4/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2806%2900666-4/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2806%2900666-4/fulltext</a></span></div></li><li id="https://link.springer.com/article/10.1007/s00467-025-06713-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s00467-025-06713-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s00467-025-06713-5</a></span></div></li><li id="https://academic.oup.com/ndt/article/23/4/1336/1874466" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/23/4/1336/1874466" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/23/4/1336/1874466</a></span></div></li><li id="https://journals.lww.com/sjkd/fulltext/2023/34010/outcomes_of_maintenance_peritoneal_dialysis_in.6.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/sjkd/fulltext/2023/34010/outcomes_of_maintenance_peritoneal_dialysis_in.6.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/sjkd/fulltext/2023/34010/outcomes_of_maintenance_peritoneal_dialysis_in.6.aspx</a></span></div></li><li id="https://journaljpri.com/index.php/JPRI/article/view/7512" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journaljpri.com/index.php/JPRI/article/view/7512" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journaljpri.com/index.php/JPRI/article/view/7512</a></span></div></li><li id="https://journals.sagepub.com/doi/10.1177/08968608241273633" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/10.1177/08968608241273633" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/10.1177/08968608241273633</a></span></div></li><li id="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730766" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730766" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730766</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3998852/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3998852/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3998852/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4033330/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4033330/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4033330/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2468024923016455" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2468024923016455" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2468024923016455</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03303-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03303-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03303-1</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa0904655" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0904655" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa0904655</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/30922246/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/30922246/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/30922246/</a></span></div></li><li id="https://news.stanford.edu/stories/2024/08/for-some-older-adults-with-kidney-failure-dialysis-may-not-be-the-best-option" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.stanford.edu/stories/2024/08/for-some-older-adults-with-kidney-failure-dialysis-may-not-be-the-best-option" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.stanford.edu/stories/2024/08/for-some-older-adults-with-kidney-failure-dialysis-may-not-be-the-best-option</a></span></div></li><li id="https://www.kidneymedicinejournal.org/article/S2590-0595%2822%2900059-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneymedicinejournal.org/article/S2590-0595%2822%2900059-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneymedicinejournal.org/article/S2590-0595%2822%2900059-0/fulltext</a></span></div></li><li id="https://academic.oup.com/ndt/article/39/5/742/7281724" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ndt/article/39/5/742/7281724" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ndt/article/39/5/742/7281724</a></span></div></li><li id="https://karger.com/ajn/article/17/3-4/289/326285/History-of-the-Science-of-Dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/ajn/article/17/3-4/289/326285/History-of-the-Science-of-Dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/ajn/article/17/3-4/289/326285/History-of-the-Science-of-Dialysis</a></span></div></li><li id="https://edren.org/ren/unit/history/milestones-in-nephrology/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://edren.org/ren/unit/history/milestones-in-nephrology/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://edren.org/ren/unit/history/milestones-in-nephrology/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/9189249/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/9189249/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/9189249/</a></span></div></li><li id="https://freseniusmedicalcare.com/en/media/insights/company-features/the-history-of-dialysis/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://freseniusmedicalcare.com/en/media/insights/company-features/the-history-of-dialysis/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://freseniusmedicalcare.com/en/media/insights/company-features/the-history-of-dialysis/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/</a></span></div></li><li id="https://journalofethics.ama-assn.org/article/god-panels-and-history-hemodialysis-america-cautionary-tale/2012-11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journalofethics.ama-assn.org/article/god-panels-and-history-hemodialysis-america-cautionary-tale/2012-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journalofethics.ama-assn.org/article/god-panels-and-history-hemodialysis-america-cautionary-tale/2012-11</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2807%2900116-3/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2807%2900116-3/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2807%2900116-3/fulltext</a></span></div></li><li id="https://journals.lww.com/sjkd/fulltext/1995/06010/continuous_ambulatory_peritoneal_dialysis__capd_.8.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/sjkd/fulltext/1995/06010/continuous_ambulatory_peritoneal_dialysis__capd_.8.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/sjkd/fulltext/1995/06010/continuous_ambulatory_peritoneal_dialysis__capd_.8.aspx</a></span></div></li><li id="https://www.ccjm.org/content/ccjom/47/4/285.full.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ccjm.org/content/ccjom/47/4/285.full.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ccjm.org/content/ccjom/47/4/285.full.pdf</a></span></div></li><li id="https://karger.com/books/book/120/chapter/5059608/Historical-Milestones-in-Peritoneal-Dialysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://karger.com/books/book/120/chapter/5059608/Historical-Milestones-in-Peritoneal-Dialysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://karger.com/books/book/120/chapter/5059608/Historical-Milestones-in-Peritoneal-Dialysis</a></span></div></li><li id="https://clinicaltrials.gov/study/NCT01209273" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://clinicaltrials.gov/study/NCT01209273" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://clinicaltrials.gov/study/NCT01209273</a></span></div></li><li id="https://www.linkedin.com/posts/arun-bhim-singh-_apd-baxter-this-activity-7370391987830599680-G_pv" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.linkedin.com/posts/arun-bhim-singh-_apd-baxter-this-activity-7370391987830599680-G_pv" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.linkedin.com/posts/arun-bhim-singh-_apd-baxter-this-activity-7370391987830599680-G_pv</a></span></div></li><li id="https://www.researchgate.net/figure/Evolution-of-discoveries-enabling-development-of-hemodialysis-for-renal-failure-in-the_tbl1_5458717" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/figure/Evolution-of-discoveries-enabling-development-of-hemodialysis-for-renal-failure-in-the_tbl1_5458717" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/figure/Evolution-of-discoveries-enabling-development-of-hemodialysis-for-renal-failure-in-the_tbl1_5458717</a></span></div></li><li id="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK554547/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK554547/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK554547/</a></span></div></li><li id="https://ww3.nxstage.com/wp-content/uploads/2017/12/introducing_the_nxstage_system_one.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ww3.nxstage.com/wp-content/uploads/2017/12/introducing_the_nxstage_system_one.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ww3.nxstage.com/wp-content/uploads/2017/12/introducing_the_nxstage_system_one.pdf</a></span></div></li><li id="https://journals.lww.com/imna/fulltext/2024/06000/wearable_artificial_kidneys__the_first_choice_for.9.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/imna/fulltext/2024/06000/wearable_artificial_kidneys__the_first_choice_for.9.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/imna/fulltext/2024/06000/wearable_artificial_kidneys__the_first_choice_for.9.aspx</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7391926/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7391926/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7391926/</a></span></div></li><li id="https://www.aei.org/articles/the-god-committee/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aei.org/articles/the-god-committee/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aei.org/articles/the-god-committee/</a></span></div></li><li id="https://www.realclearpolicy.com/2020/12/09/the_god_committee_652383.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.realclearpolicy.com/2020/12/09/the_god_committee_652383.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.realclearpolicy.com/2020/12/09/the_god_committee_652383.html</a></span></div></li><li id="https://www.kidney.org/sites/default/files/v36b_a4.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/sites/default/files/v36b_a4.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/sites/default/files/v36b_a4.pdf</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK234421/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK234421/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK234421/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11296549/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11296549/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11296549/</a></span></div></li><li id="https://www.researchgate.net/publication/6904071_The_dangers_of_rationing_dialysis_treatment_The_dilemma_facing_a_developing_country" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/6904071_The_dangers_of_rationing_dialysis_treatment_The_dilemma_facing_a_developing_country" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/6904071_The_dangers_of_rationing_dialysis_treatment_The_dilemma_facing_a_developing_country</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11010612/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11010612/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11010612/</a></span></div></li><li id="https://www.npr.org/2020/04/19/837727691/doctors-at-hard-hit-hospitals-say-theyre-facing-shortage-of-dialysis-equipment" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.npr.org/2020/04/19/837727691/doctors-at-hard-hit-hospitals-say-theyre-facing-shortage-of-dialysis-equipment" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.npr.org/2020/04/19/837727691/doctors-at-hard-hit-hospitals-say-theyre-facing-shortage-of-dialysis-equipment</a></span></div></li><li id="https://www.statnews.com/2023/08/07/kidney-failure-dialysis-stockpile/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statnews.com/2023/08/07/kidney-failure-dialysis-stockpile/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statnews.com/2023/08/07/kidney-failure-dialysis-stockpile/</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.1080/15265161.2020.1777346" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.1080/15265161.2020.1777346" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.1080/15265161.2020.1777346</a></span></div></li><li id="https://www.nature.com/articles/s41581-021-00404-8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41581-021-00404-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41581-021-00404-8</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa1000552" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1000552" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa1000552</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2017/02/10.-Harris-DialysisInitiationKDIGO1216a.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2017/02/10.-Harris-DialysisInitiationKDIGO1216a.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2017/02/10.-Harris-DialysisInitiationKDIGO1216a.pdf</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03184-4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03184-4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03184-4</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/36158157/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/36158157/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/36158157/</a></span></div></li><li id="https://kdigo.org/wp-content/uploads/2017/02/Polkinghorne_KDIGO-Dialysis-Initiation-Presentation.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://kdigo.org/wp-content/uploads/2017/02/Polkinghorne_KDIGO-Dialysis-Initiation-Presentation.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://kdigo.org/wp-content/uploads/2017/02/Polkinghorne_KDIGO-Dialysis-Initiation-Presentation.pdf</a></span></div></li><li id="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2733562" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2733562" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2733562</a></span></div></li><li id="https://www.renalandurologynews.com/news/home-dialysis-hampered-by-barriers-despite-financial-incentives/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.renalandurologynews.com/news/home-dialysis-hampered-by-barriers-despite-financial-incentives/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.renalandurologynews.com/news/home-dialysis-hampered-by-barriers-despite-financial-incentives/</a></span></div></li><li id="https://www.ajkd.org/article/S0272-6386%2824%2900790-X/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajkd.org/article/S0272-6386%2824%2900790-X/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajkd.org/article/S0272-6386%2824%2900790-X/fulltext</a></span></div></li><li id="https://ldi.upenn.edu/our-work/research-updates/6-major-barriers-that-stop-patients-from-doing-home-dialysis/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ldi.upenn.edu/our-work/research-updates/6-major-barriers-that-stop-patients-from-doing-home-dialysis/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ldi.upenn.edu/our-work/research-updates/6-major-barriers-that-stop-patients-from-doing-home-dialysis/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/hdi.13213?af=R" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/hdi.13213?af=R" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/hdi.13213?af=R</a></span></div></li><li id="https://www.kidney.org/sites/default/files/v36a_a1.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/sites/default/files/v36a_a1.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/sites/default/files/v36a_a1.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12531936/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12531936/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12531936/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9161798/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9161798/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9161798/</a></span></div></li><li id="https://www.mdpi.com/2673-8236/5/2/18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/2673-8236/5/2/18" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/2673-8236/5/2/18</a></span></div></li><li id="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04188-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04188-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04188-y</a></span></div></li><li id="https://academic.oup.com/ckj/article/17/7/sfae180/7705608" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ckj/article/17/7/sfae180/7705608" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ckj/article/17/7/sfae180/7705608</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0272638611011437" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0272638611011437" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0272638611011437</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0272638625000538" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0272638625000538" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0272638625000538</a></span></div></li><li id="https://www.eurekalert.org/news-releases/1079258" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.eurekalert.org/news-releases/1079258" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.eurekalert.org/news-releases/1079258</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7812841/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7812841/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7812841/</a></span></div></li><li id="https://www.kidneyx.org/prize-winners/implantable-bioartificial-kidney/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidneyx.org/prize-winners/implantable-bioartificial-kidney/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidneyx.org/prize-winners/implantable-bioartificial-kidney/</a></span></div></li><li id="https://www.kidney.org/news-stories/future-artificial-kidneys" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/news-stories/future-artificial-kidneys" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/news-stories/future-artificial-kidneys</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11344373/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11344373/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11344373/</a></span></div></li><li id="https://www.nature.com/articles/s41598-021-94964-1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41598-021-94964-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41598-021-94964-1</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2590059524000797" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2590059524000797" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2590059524000797</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S1383586625023159" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1383586625023159" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S1383586625023159</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/19293709/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/19293709/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/19293709/</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.1080/15583724.2025.2512945" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.1080/15583724.2025.2512945" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.1080/15583724.2025.2512945</a></span></div></li><li id="https://www.preprints.org/manuscript/202505.1959/v1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.preprints.org/manuscript/202505.1959/v1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.preprints.org/manuscript/202505.1959/v1</a></span></div></li><li id="https://www.kidney.org.uk/news/kidney-technologies-on-the-horizon" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org.uk/news/kidney-technologies-on-the-horizon" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org.uk/news/kidney-technologies-on-the-horizon</a></span></div></li><li id="https://www.kidney.org/news-stories/dream-starting-to-come-true-wearable-kidneys" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kidney.org/news-stories/dream-starting-to-come-true-wearable-kidneys" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kidney.org/news-stories/dream-starting-to-come-true-wearable-kidneys</a></span></div></li><li id="https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01751-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01751-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01751-2</a></span></div></li><li id="https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11669058/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11669058/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11669058/</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1619291/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1619291/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1619291/full</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/</a></span></div></li><li id="https://www.uab.edu/news/health-medicine/new-study-pig-kidneys-for-the-first-time-demonstrate-life-sustaining-kidney-function-in-a-human" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uab.edu/news/health-medicine/new-study-pig-kidneys-for-the-first-time-demonstrate-life-sustaining-kidney-function-in-a-human" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uab.edu/news/health-medicine/new-study-pig-kidneys-for-the-first-time-demonstrate-life-sustaining-kidney-function-in-a-human</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11998293/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11998293/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11998293/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy" id="_R_" async=""></script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Kidney_dialysis\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Kidney_dialysis\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Kidney_dialysis\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T1cc16,"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"# Kidney dialysis\n\n![Hemodialysis machine](./_assets_/Hemodialysismachine.jpg)  \nKidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury.[](https://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000707.htm)[](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis) The procedure mimics the kidneys' natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences.[](https://www.ncbi.nlm.nih.gov/books/NBK492981/)  \n\nThe two main types are hemodialysis, which involves diverting blood through an external machine equipped with a dialyzer to perform the filtration, typically three times per week for several hours per session, and peritoneal dialysis, which utilizes the peritoneal membrane in the abdomen as the filter by infusing and draining dialysate fluid.[](https://www.nlm.nih.gov/medlineplus/dialysis.html)[](https://www.ncbi.nlm.nih.gov/books/NBK532006/) Hemodialysis requires vascular access such as an arteriovenous fistula or graft, while peritoneal dialysis employs a catheter into the peritoneal cavity, allowing for more frequent, shorter treatments often performed at home.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/) Both modalities sustain life in the absence of kidney function but do not restore it, serving as a bridge to potential transplantation or long-term management.[](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis)  \n\nPioneered by Dutch physician Willem Kolff, who constructed the first functional artificial kidney in 1943 using a rotating drum of cellophane tubing amid wartime scarcity, dialysis marked a breakthrough in treating otherwise fatal uremia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/) Subsequent advancements, including Kolff's twin-coil dialyzer in the 1950s, enabled widespread clinical use and improved efficiency.[](https://case.edu/ech/articles/k/kolff-willem-j) In the United States, where end-stage kidney disease affects hundreds of thousands, dialysis patients exhibit a five-year survival rate of approximately 35%, influenced by factors such as age, comorbidities like diabetes, and treatment adherence, though outcomes remain inferior to kidney transplantation.[](https://www.ncbi.nlm.nih.gov/books/NBK499861/) Despite its life-extending role, dialysis is associated with significant complications, including vascular access failures that drive 12-25% of hospitalizations and annual costs exceeding billions, alongside debates over surveillance protocols' efficacy in preventing thrombosis and stenosis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7529591/)[](https://www.ajkd.org/article/S0272-6386%2818%2930124-0/fulltext)\n\n## Fundamentals\n\n### Definition and Principles\n\n![Semipermeable membrane](./_assets_/Semipermeable_membrane_\\(svg\\))\n\nDialysis constitutes a renal replacement therapy that artificially emulates select excretory functions of the kidneys by extracting metabolic waste products, excess electrolytes, and superfluous fluid from the bloodstream when renal function is profoundly impaired. This process is essential for sustaining life in individuals with acute kidney injury or end-stage renal disease, where glomerular filtration rates fall below viable thresholds, typically under 10-15 mL/min/1.73 mÂ². Unlike native kidneys, which integrate filtration, reabsorption, secretion, and endocrine regulation, dialysis primarily achieves solute clearance and volume control through engineered physicochemical mechanisms, without replicating active transport or hormonal outputs.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5654453/)\n\nThe core principles of dialysis hinge on transmembrane transport across a semipermeable membrane, exploiting gradients in concentration, pressure, and osmolarity to facilitate diffusion, convection, and osmosis. Diffusion drives the passive movement of small-molecular-weight solutesâ€”such as urea (molecular weight 60 Da), creatinine (113 Da), and potassium ionsâ€”from regions of higher concentration in blood to lower concentrations in the dialysate solution, governed by Fick's law of diffusion, where flux is proportional to the concentration differential and membrane permeability. Convection, or ultrafiltration, entails bulk fluid removal via hydrostatic pressure gradients across the membrane, akin to glomerular capillary dynamics, with rates controlled by transmembrane pressure differences typically ranging from 100-500 mmHg in intermittent hemodialysis sessions. Osmotic forces, induced by hypertonic dialysate components like glucose (up to 4.25% in peritoneal variants), supplement ultrafiltration by drawing water from blood into the dialysate compartment.[](https://www.ncbi.nlm.nih.gov/books/NBK492981/)[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)[](https://www.kidney.org/kidney-topics/ultrafiltration)\n\nEfficiency in solute removal is enhanced by countercurrent flow configurations in extracorporeal systems, where blood and dialysate traverse the membrane in opposing directions, preserving a maximal trans-membrane concentration gradient along the dialyzer length and thereby optimizing diffusive clearance; this principle, rooted in heat exchanger engineering, can elevate urea removal rates by up to 20-30% compared to cocurrent setups. Membrane biocompatibility and pore size distribution further dictate selectivity, with high-flux synthetic polymers (e.g., polysulfone) permitting passage of middle molecules (500-60,000 Da) like Î²2-microglobulin, reducing long-term complications such as dialysis-related amyloidosis. However, dialysis incompletely substitutes renal physiology, as evidenced by persistent uremic toxicity from protein-bound toxins (e.g., indoxyl sulfate) that evade diffusive clearance due to plasma protein binding and low dialysate solubility.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)[](https://www.sciencedirect.com/topics/nursing-and-health-professions/countercurrent-flow)\n\n![Key principles of dialysis](./_assets_/Osmosis_Diffusion_Ultrafiltration_and_Dialysis.svg.png)\n\n### Dialysate Composition and Substance Removal\n\nThe dialysate in kidney dialysis is an aqueous electrolyte solution formulated to mimic key aspects of plasma composition while excluding uremic toxins, thereby creating concentration gradients for solute removal. In hemodialysis (HD), dialysate is prepared by mixing purified water with concentrates containing sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, and sometimes glucose or acetate as buffers or osmotic agents. Standard concentrations include sodium at 135â€“145 mmol/L to maintain osmotic stability and prevent disequilibrium syndrome, potassium at 1â€“3 mmol/L to avoid hypokalemia while correcting hyperkalemia, calcium at 1.25â€“1.75 mmol/L (2.5â€“3.5 mEq/L) to support cardiac function and bone health, magnesium at 0.25â€“0.5 mmol/L (0.5â€“1 mEq/L) to minimize post-dialysis hypomagnesemia, and bicarbonate at 32â€“40 mmol/L to buffer acidosis without risking alkalosis or vascular calcification. Glucose is often included at 5.5â€“11 mmol/L (100â€“200 mg/dL) to prevent hypoglycemia, though its absence in some formulations relies on patient glucose levels.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7645386/)[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)[](https://academic.oup.com/ndt/article/19/4/785/1810632)\n\n![Illustration of dialysis mechanisms](./_assets_/Osmosis_Diffusion_Ultrafiltration_and_Dialysis.svg.png)\n\nIn peritoneal dialysis (PD), dialysate composition differs to leverage the peritoneal membrane, featuring sodium at approximately 132 mmol/L, chloride at 95â€“105 mmol/L, calcium at 1.25â€“1.75 mmol/L, magnesium at 0.25â€“0.5 mmol/L, and a buffer such as lactate (35â€“40 mmol/L) or bicarbonate, with glucose concentrations varying from 1.5% to 4.25% (82â€“231 mmol/L) to drive ultrafiltration via osmosis. These formulations are sterilized in plastic bags and lack potassium to facilitate its removal from peritoneal effluent. Adjustments to dialysate composition, such as varying potassium or calcium levels, are individualized based on predialysis serum values to achieve target post-dialysis concentrations, with evidence indicating that dialysate potassium below 2 mmol/L correlates with increased arrhythmia risk, while bicarbonate exceeding 35 mmol/L may elevate mortality via metabolic shifts.[](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/peritoneal-dialysis-fluid)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7645386/)\n\nSubstance removal in dialysis relies on the dialysate's composition to establish diffusive and convective gradients across a semipermeable membrane, which permits passage of small solutes (e.g., urea \u003c60 Da, creatinine \u003c113 Da, potassium) but restricts larger molecules like albumin (\u003e66 kDa). Diffusion drives passive transfer of uremic toxins from blood (higher concentration) to dialysate (near-zero for wastes), enhanced by countercurrent flow maximizing gradient efficiency; clearance rates for urea, for instance, depend on dialysate flow (typically 500 mL/min) and membrane surface area, yielding Kt/V values \u003e1.2 per session for adequacy. Electrolyte removal or addition is modulated by dialysate concentrationsâ€”for example, low-potassium dialysate (2 mmol/L) removes excess serum potassium via gradient-driven diffusion, reducing predialysis hyperkalemia from 5.6â€“8 mmol/L.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)[](https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-111/diffusion-mechanism-solute-removal)\n\nExcess fluid removal occurs via ultrafiltration (UF), a convective process where hydrostatic pressure gradients force water across the membrane, dragging solutes (solvent drag) in high-flux HD or hemodiafiltration; in standard HD, UF is independent of dialysate solutes but relies on transmembrane pressure (20â€“50 mmHg), targeting 2â€“4 L/session to correct interdialytic weight gain. In PD, hypertonic glucose in dialysate creates an osmotic gradient (344â€“500 mOsm/L), drawing water into the peritoneal cavity for removal, though aquaporin-mediated free water transport predominates initially before sodium sieving reduces efficacy over dwell time. Bicarbonate buffering in modern dialysates improves tolerance over acetate by minimizing inflammation, indirectly supporting sustained removal efficiency.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)[](https://www.kidney.org/kidney-topics/ultrafiltration)[](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/peritoneal-dialysis-fluid)\n\n## Types of Dialysis\n\n### Hemodialysis\n\n![Hemodialysis schematic](./_assets_/Hemodialysis-en.svg.png)\n\nHemodialysis is an extracorporeal renal replacement therapy that removes waste products, excess electrolytes, and fluid from the blood of patients with kidney failure by circulating blood through an external dialyzer.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/) The dialyzer functions as an artificial kidney, utilizing principles of diffusion for solute removalâ€”where metabolic wastes like urea move from higher concentration in blood to lower in dialysateâ€”and convection via ultrafiltration for fluid and larger solute clearance, driven by transmembrane pressure gradients across a semipermeable membrane composed of hollow fibers.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/) [](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis) This process mimics glomerular filtration and tubular reabsorption but requires anticoagulation, typically with heparin, to prevent clotting in the extracorporeal circuit.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)\n\nThe foundational hemodialysis device was invented by Dutch physician Willem Kolff in 1943, using cellophane tubing as the semipermeable membrane in a rotating drum apparatus to treat acute uremia amid wartime shortages.[](https://davita.com/treatment-options/articles/the-history-of-dialysis/) Clinical adoption expanded post-1960 with improvements like the Scribner shunt for repeated access, enabling chronic therapy.[](https://nephrology.uw.edu/about/history) Modern systems employ volumetric control for precise fluid removal and bicarbonate-based dialysate to correct acidosis, with blood flow rates of 300-500 mL/min and dialysate countercurrent flow enhancing efficiency.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8711766/) Sessions, usually conducted thrice weekly for 3-5 hours each, aim to achieve a Kt/V urea clearance target of at least 1.2 per treatment, a dimensionless measure of dialysis adequacy correlating with survival.[](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618180/)\n\nVascular access is critical, with autogenous arteriovenous fistulas (AVF) recommended as first choice due to superior patency (primary failure rate 20-40% but long-term survival up to 60-80% at 1 year) and lower infection risk compared to synthetic grafts or catheters.[](https://www.ajkd.org/article/S0272-6386%2824%2900976-4/fulltext) [](https://www.ncbi.nlm.nih.gov/books/NBK493195/) AVF creation involves surgical anastomosis of artery to vein, typically radial-cephalic at the wrist, maturing over 6-12 weeks via arterialization-induced vein remodeling for repeated needling.[](https://jamanetwork.com/journals/jama/article-abstract/2816266) [](https://www.kidney.org/kidney-topics/hemodialysis-access) Central venous catheters serve for urgent starts but carry 10-20 times higher bacteremia risk, limiting use to \u003c10% of prevalent patients per guidelines.[](https://www.ajkd.org/article/S0272-6386%2824%2900976-4/fulltext)\n\nCommon intradialytic complications include hypotension (affecting 20-30% of sessions, linked to rapid fluid shifts and cardiac instability) and muscle cramps, while interdialytic risks encompass hyperkalemia and volume overload, with cardiovascular events causing 40-50% of deaths in dialysis populations.[](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300823) [](https://www.nejm.org/doi/full/10.1056/NEJMoa1103313) Extended-duration or more frequent treatments (e.g., \u003e5 hours/session or \u003e3/week) associate with 20-30% mortality reductions in observational cohorts, though randomized evidence remains limited.[](https://www.sciencedirect.com/science/article/pii/S0085253816303222) [](https://academic.oup.com/ckj/article/14/2/665/6054266) Home hemodialysis variants, using portable machines, permit daily short or nocturnal long sessions, improving quality of life and potentially adequacy via increased weekly clearance.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618180/)\n\n![Hemodialysis machine](./_assets_/Hemodialysismachine.jpg)\n\n### Peritoneal Dialysis\n\n![Peritoneal dialysis exchange](./_assets_/Peritoneal_dialysis.gif)\nPeritoneal dialysis employs the peritoneum, a vascularized serous membrane lining the abdominal cavity, as a semipermeable barrier to facilitate the removal of uremic solutes and excess fluid from the blood. A hypertonic dialysate solution, typically containing glucose as the primary osmotic agent, is infused into the peritoneal cavity through an indwelling catheter, creating concentration gradients that drive diffusion of waste products like urea and creatinine from peritoneal capillaries into the dialysate, alongside osmosis-induced ultrafiltration of water.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/)  The process relies on the peritoneum's large surface area, estimated at 1-2 mÂ² in adults, and its permeability properties, which enable efficient small-molecule clearance but limit removal of larger toxins compared to hemodialysis.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/)\n\nTwo primary modalities exist: continuous ambulatory peritoneal dialysis (CAPD), which involves 3-5 manual exchanges per day with dwells lasting 4-6 hours each, and automated peritoneal dialysis (APD), which uses a cycler machine to perform shorter, more frequent exchanges, often nocturnally, allowing daytime freedom.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/) CAPD provides continuous solute clearance approximating 7-10 liters of dialysate daily, while APD emphasizes higher volume exchanges to enhance ultrafiltration, particularly in patients with high peritoneal transport rates. Catheter placement, typically via laparoscopic or percutaneous methods under local anesthesia, is essential for access; complications during insertion occur in less than 5% of cases when performed by experienced surgeons.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/)\n\nThe procedure begins with priming the catheter to prevent air embolism, followed by instillation of 2-2.5 liters of warmed dialysate (1.5-4.25% glucose concentration based on fluid status), a dwell period for equilibration, and drainage, with effluent inspected for clarity and volume to assess adequacy.[](https://www.kidney.org/kidney-topics/peritoneal-dialysis) Biocompatible dialysates with icodextrin or amino acids are used in select cases to mitigate glucose-related metabolic effects like hyperglycemia and peritoneal fibrosis, though standard glucose-based solutions remain predominant due to cost and availability. Prescription adequacy targets a weekly Kt/V urea of at least 1.7 and creatinine clearance of 50 L/week/1.73 mÂ², adjusted via peritoneal equilibration tests measuring solute transport rates.00848-4/fulltext)\n\nAdvantages include home-based delivery promoting patient autonomy, continuous therapy preserving hemodynamic stability, and preserved residual kidney function longer than in hemodialysis, with initial survival benefits in non-diabetic patients.[](https://www.kidney.org/kidney-topics/peritoneal-dialysis) [](https://pubmed.ncbi.nlm.nih.gov/39675379/) However, peritoneal dialysis yields lower clearance rates (8-10 mL/min for urea versus 200-300 mL/min in hemodialysis), necessitating patient adherence and limiting suitability for large or catabolic individuals.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/) Technique survival averages 50-60% at 2 years, with dropout due to membrane failure or infections.[](https://academic.oup.com/ckj/article/18/8/sfaf215/8193697)\n\nMajor complications encompass peritonitis, occurring at rates of 0.2-0.5 episodes per patient-year, primarily from touch contamination or catheter-related biofilms, treatable with intraperitoneal antibiotics but risking sclerosing peritonitis in recurrent cases.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/)  Exit-site and tunnel infections affect 0.3-0.6 episodes per patient-year, often managed with oral or topical agents, while mechanical issues like hernias or leaks arise from increased intra-abdominal pressure.[](https://www.ncbi.nlm.nih.gov/books/NBK532979/) Ultrafiltration failure, linked to high glucose absorption and membrane hyperpermeability, develops in 30-40% of long-term patients, accelerating transition to hemodialysis.\n\nSurvival outcomes show peritoneal dialysis conferring similar or superior adjusted mortality to hemodialysis in the first 1-2 years (hazard ratio 0.83-1.0), attributed to gentler solute removal and lifestyle factors, but diverging thereafter with higher long-term risks in elderly or comorbid populations (hazard ratio 1.17 for those over 65).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7855236/) [](https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus) Five-year survival rates hover at 40-50%, influenced by age, diabetes, and residual function preservation.[](https://www.uptodate.com/contents/patient-survival-and-maintenance-dialysis) Incremental approaches starting with fewer exchanges in early chronic kidney disease preserve membrane longevity but require monitoring for underdialysis.\n\n### Continuous Renal Replacement Therapies\n\n![Continuous Veno-Venous Hemofiltration (CVVH)](./_assets_/Continuous_Venon_Venous_Haemofiltration_with_pre_and_post_dilution_\\(CVVH\\)\nContinuous renal replacement therapies (CRRT) encompass extracorporeal blood purification techniques designed to provide slow, continuous solute and fluid removal over 24 hours, primarily for critically ill patients with acute kidney injury (AKI) in intensive care settings.[](https://www.ncbi.nlm.nih.gov/books/NBK556028/) These modalities simulate native kidney function by employing convection, diffusion, or a combination thereof across a semipermeable membrane, allowing for gradual clearance of uremic toxins, electrolytes, and excess volume without the rapid shifts associated with intermittent hemodialysis.[](https://www.ajkd.org/article/S0272-63862401120-X/fulltext) CRRT is typically venovenous, relying on vascular access via dual-lumen catheters, and requires anticoagulation to prevent circuit clotting, though evidence supports individualized dosing based on patient factors rather than fixed protocols.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6435902/)\n\nPrincipal modalities include continuous venovenous hemofiltration (CVVH), which relies on convective clearance using replacement fluids; continuous venovenous hemodialysis (CVVHD), emphasizing diffusive solute removal via dialysate; and continuous venovenous hemodiafiltration (CVVHDF), combining both mechanisms for enhanced middle-molecule clearance.[](https://www.ncbi.nlm.nih.gov/books/NBK556028/) CVVHDF is often preferred for its versatility in managing diverse solute sizes, with studies indicating superior removal of cytokines in septic patients compared to pure diffusive methods.[](https://www.sciencedirect.com/science/article/pii/S0034837625001639) Effluent doses are standardized at 20-25 mL/kg/hour per KDIGO recommendations, though delivered doses frequently fall short due to downtime from filter clotting or interruptions, averaging 25-30% less in practice.[](https://pubmed.ncbi.nlm.nih.gov/39417967/)\n\nIndications center on hemodynamically unstable patients with AKI stage 3 (KDIGO criteria), refractory fluid overload, severe acidosis, or uremic complications unresponsive to conservative measures, particularly when intermittent therapies risk exacerbating instability.[](https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01517-0) CRRT facilitates precise volume control and metabolic stability in multi-organ failure, but initiation should be deferred beyond 72 hours in non-emergent cases to allow potential renal recovery.[](https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01517-0) Meta-analyses of randomized trials reveal no mortality advantage over intermittent hemodialysis, with pooled odds ratios approximating 1.0, though CRRT may shorten hospital stays in select cohorts by enabling earlier enteral nutrition.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10125730/) [](https://journals.lww.com/ccejournal/fulltext/2021/05000/comparing_renal_replacement_therapy_modalities_in.3.aspx)\n\nComplications include circuit-related issues such as clotting (occurring in 20-40% of sessions despite anticoagulation), hypothermia from heat loss, and bleeding risks from heparin or citrate use, with citrate preferred in renal failure for regional effects minimizing systemic exposure.[](https://www.ncbi.nlm.nih.gov/books/NBK556028/) Nutrient losses necessitate supplementation, particularly for amino acids and glucose, while vascular access infections and hypotension from ultrafiltration persist as concerns.[](https://www.ajkd.org/article/S0272-63862401120-X/fulltext) Resource demands are high, with CRRT circuits lasting 24-48 hours on average, contributing to costs 1.5-2 times those of intermittent dialysis, yet no evidence supports routine superiority in survival outcomes across large trials.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10125730/) Ongoing research emphasizes hybrid approaches and biomarker-guided timing to optimize efficacy.[](https://www.sciencedirect.com/science/article/pii/S1441277225000110)\n\n### Emerging and Experimental Modalities\n\nWearable artificial kidneys represent an experimental advancement aimed at providing continuous, ambulatory dialysis without reliance on large stationary machines. These devices typically employ sorbent-based dialysate regeneration to miniaturize the system, allowing patients to move freely during treatment. A prototype wearable artificial kidney (WAK), developed by Victor Gura and tested in an FDA-approved human trial in 2016, demonstrated effective solute clearance and ultrafiltration comparable to conventional hemodialysis over 24-hour periods, with participants reporting improved mobility and quality of life.[](https://pubmed.ncbi.nlm.nih.gov/27398407/) Further iterations, including those in ongoing clinical evaluations like the wearable filtrating artificial kidney device initiated in 2023, focus on precision, safety, and operability for end-stage renal disease patients.[](https://clinicaltrials.gov/study/NCT05906355)\n\nImplantable bioartificial kidneys seek to replicate native kidney functions through integrated filtration and bio-reabsorption components, potentially eliminating the need for repeated vascular access or external devices. The Kidney Project, a collaboration between UCSF and Vanderbilt University, has developed a prototype implantable bioartificial kidney (iBAK) featuring silicon nanopore membranes for hemofiltration and a bioreactor with renal tubule cells for active transport, successfully tested in large animal models as of 2021 to achieve metabolic homeostasis without immunosuppression.[](https://pharm.ucsf.edu/kidney/device) In 2023, the project received a $1 million KidneyX prize for prototype advancements, with preclinical studies continuing toward human trials expected in the coming years.[](https://www.healio.com/news/nephrology/20241008/cell-therapy-new-pd-devices-bioartificial-kidneys-set-a-new-direction-for-kidney-care) Similarly, UCLA's implantable artificial kidney employs novel glomerular filtration mimicry without dialysis fluid, advancing through animal proof-of-concept phases as of 2024, prioritizing waterless operation to reduce infection risks.[](https://www.uclahealth.org/medical-services/nephrology/clinical-programs/implantable-artificial-kidney)\n\nHybrid and regenerative dialysis modalities are also under investigation to enhance efficiency and patient independence. Intermittent infusion hemodiafiltration (I-HDF), a technique combining standard hemodialysis with cyclic infusions, emerged in clinical reviews by 2025 as a potential bridge modality, offering improved middle-molecule clearance while minimizing hemodynamic instability in select patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12474070/) Portable peritoneal dialysis systems, such as the AWAK-PD device, utilize automated sorbent regeneration for extended dwell times and reduced fluid volumes; pivotal U.S. clinical trials were planned as of 2024 to assess efficacy against traditional peritoneal dialysis.[](https://www.healio.com/news/nephrology/20241008/cell-therapy-new-pd-devices-bioartificial-kidneys-set-a-new-direction-for-kidney-care) These approaches prioritize empirical validation through randomized trials, addressing limitations like biocompatibility and long-term durability observed in early prototypes.[](https://www.nature.com/articles/s41581-023-00726-9)\n\n## Clinical Applications\n\n### Indications for Acute Kidney Injury\n\nDialysis, or renal replacement therapy (RRT), is initiated in acute kidney injury (AKI) primarily to address life-threatening complications arising from impaired kidney function, rather than solely based on biomarkers such as serum creatinine or estimated glomerular filtration rate (eGFR).[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/) The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize emergent RRT for severe disruptions in fluid balance, electrolytes, or acid-base status that cannot be managed conservatively.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) Randomized trials, including the STARRT-AKI study involving 2,927 critically ill patients with AKI, have demonstrated no mortality benefit from early initiation (within 8 hours of KDIGO stage 2 AKI) compared to delayed initiation (after complications develop), with early RRT associated with more dialysis dependence at 90 days.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2000741) Similarly, the AKIKI trial in 620 ICU patients found delayed RRT (started only for severe acidosis, hyperkalemia, pulmonary edema, or uremia) reduced circuit clotting and transfusions without increasing mortality.[](https://www.nejm.org/doi/full/10.1056/NEJMoa1803213)\n\nKey clinical indications include:\n\n- **Refractory hyperkalemia**: Serum potassium exceeding 6.5 mmol/L or persistent levels above 6 mmol/L despite medical interventions such as insulin, beta-agonists, sodium bicarbonate, and calcium gluconate, due to risk of fatal arrhythmias.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/)\n- **Severe metabolic acidosis**: Arterial pH below 7.15-7.20, particularly with hypercapnia (PaCO2 \u003e50 mmHg) or in the absence of respiratory compensation, unresponsive to bicarbonate therapy, to prevent hemodynamic instability and organ dysfunction.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) [](http://www.nephjc.com/news/2016/5/26/acute-kidney-injury-when-to-dialyze)\n- **Volume overload**: Pulmonary edema or fluid accumulation causing hypoxemia or hemodynamic compromise, refractory to diuretics or ultrafiltration alternatives, often defined as \u003e10% body weight gain or central venous pressure \u003e12-15 mmHg without response.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC5066036/)\n- **Uremic complications**: Symptomatic uremia manifesting as encephalopathy, pericarditis, or coagulopathy, typically with blood urea nitrogen (BUN) \u003e80-112 mg/dL (28-40 mmol/L), though BUN thresholds alone are insufficient without clinical signs.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/)\n- **Toxin removal**: Specific intoxications where dialysis effectively clears dialyzable toxins, such as methanol, ethylene glycol, lithium, or salicylates, guided by toxicokinetics rather than AKI stage.[](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf)\n\nIn ICU settings, where AKI affects up to 50% of patients and carries a 20-50% mortality risk, continuous RRT (CRRT) modalities are often preferred for hemodynamic stability, though intermittent hemodialysis remains viable in stable patients.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2000741) Delaying RRT until absolute indications avoids unnecessary exposure to complications like hypotension (occurring in 30-40% of early starts) and infection, supported by meta-analyses showing equivalent 28-day survival rates between strategies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11258500/) Patient-specific factors, including sepsis or multiorgan failure, may necessitate individualized thresholds, but prophylactic RRT based on anticipated worsening lacks empirical support.[](https://www.atsjournals.org/doi/full/10.1164/rccm.201810-1906CP)\n\n### Indications for Chronic Kidney Disease\n\nDialysis for chronic kidney disease (CKD) is typically initiated in patients with end-stage renal disease (ESRD), corresponding to CKD stage 5 with an estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 mÂ², when symptoms or complications cannot be adequately managed through conservative measures such as dietary restrictions, medications, or fluid management.[](https://www.ncbi.nlm.nih.gov/books/NBK499861/) [](https://academic.oup.com/ndt/article/26/7/2082/1896753) Guidelines emphasize that initiation should not rely solely on eGFR thresholds, as randomized trials like the Initiating Dialysis Early and Late (IDEAL) study, published in 2010, demonstrated no survival benefit from starting dialysis at higher eGFR levels (10-14 mL/min/1.73 mÂ²) compared to lower levels (5-7 mL/min/1.73 mÂ²), with late initiation potentially reducing complications like infections.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409/) [](https://pubmed.ncbi.nlm.nih.gov/30208820/)\n\nKey indications include uremic symptoms such as persistent nausea, vomiting, fatigue, pruritus, cognitive impairment, or uremic pericarditis, which arise from the accumulation of uremic toxins when renal clearance fails.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf) [](https://academic.oup.com/ndt/article/26/7/2082/1896753) Refractory hyperkalemia (serum potassium \u003e6.0 mEq/L despite medical therapy), severe metabolic acidosis (bicarbonate \u003c15 mEq/L unresponsive to bicarbonate supplementation), and volume overload leading to pulmonary edema or hypertension not controllable by diuretics also necessitate dialysis to prevent cardiac arrhythmias, respiratory failure, or accelerated cardiovascular disease.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf) [](https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf)\n\nAdditional criteria encompass uremia-related malnutrition (evidenced by declining serum albumin \u003c3.5 g/dL or unintentional weight loss \u003e10% despite nutritional support), progressive neuropathy, or bleeding diathesis due to platelet dysfunction, as these reflect irreversible toxin buildup that dialysis can mitigate by removing middle- and large-molecular-weight uremic solutes.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf) [](https://pubmed.ncbi.nlm.nih.gov/30208820/) In asymptomatic patients with eGFR \u003c10 mL/min/1.73 mÂ², initiation may be deferred with close monitoring, but rapid eGFR decline (\u003e0.5 mL/min/month) or patient-specific factors like frailty or preference for preemptive transplant preparation can prompt earlier vascular access planning.[](https://www.kidney.org/news-when-should-i-start-dialysis) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409/) National Kidney Foundation-KDOQI guidelines reinforce that uremia-driven clinical judgment supersedes arbitrary GFR cutoffs, avoiding unnecessary early dialysis that increases hospitalization risks without improving mortality.[](https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf)\n\n### Contraindications and Conservative Management Alternatives\n\nDialysis initiation lacks strict absolute contraindications in most cases, with the primary exception being the inability to establish vascular access for hemodialysis due to extensive vascular disease or prohibitive hemodynamic instability that precludes safe treatment.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf) Relative contraindications often revolve around patient-specific factors where the burdens of therapyâ€”such as frequent sessions, infection risks, and vascular complicationsâ€”may exceed benefits, particularly in individuals with advanced age, multiple severe comorbidities (e.g., frailty, dementia, or metastatic cancer), or limited life expectancy.[](https://doi.org/10.1093/ckj/sfad062) For instance, in patients with end-stage renal disease (ESRD) accompanied by irreversible multi-organ failure or profound functional impairment, dialysis may not meaningfully extend survival or improve quality of life, leading clinicians to weigh these elements through shared decision-making rather than proceeding automatically.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)\n\nConservative kidney management (CKM), also termed maximum conservative management, serves as a non-dialytic alternative for select patients with advanced chronic kidney disease (CKD stage 5) or ESRD, emphasizing symptom palliation, nutritional support, and medical optimization without renal replacement therapy. This approach typically involves rigorous control of fluid and electrolyte imbalances via diuretics and dietary restrictions, anemia management with erythropoiesis-stimulating agents, bone-mineral disorder treatment, and advance care planning to address uremic symptoms like fatigue, pruritus, and nausea.[](https://www.aafp.org/pubs/afp/issues/2021/1100/p493.html) CKM is particularly considered for elderly patients (often over 75 years) with high comorbidity burdens, where dialysis-associated interventions could accelerate functional decline or hospitalizations without proportional survival gains.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790050)\n\nEmpirical data indicate that CKM generally yields shorter median survival compared to dialysis in broader ESRD populations, with dialysis reducing overall mortality risk by addressing uremia and fluid overload more effectively. For example, a 2022 analysis found patients opting for dialysis had lower mortality hazard ratios than those choosing conservative care, even after adjusting for age and comorbidities.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/) [](https://www.kidneymedicinejournal.org/article/S2590-0595%2820%2930268-5/fulltext) However, in frail elderly subgroups with significant comorbidities, survival differences narrow; a seminal 2007 study reported median survival of approximately 6-23 months under conservative management versus 13-37 months with dialysis, but without clear net benefit from dialysis after accounting for treatment downtime and complications.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6) Quality-of-life metrics often favor CKM in these cohorts, showing reduced hospitalization frequency, preserved time at home, and lower symptom burden from dialysis procedures, though data remain heterogeneous due to selection bias in observational studies.[](https://reports.mountsinai.org/article/neph2021-04-conservative-management-of-esrd) [](https://academic.oup.com/ndt/article/37/Supplement_3/gfac071.013/6578311)\n\n| Patient Group | Median Survival (CKM) | Median Survival (Dialysis) | Key Considerations |\n|---------------|-----------------------|----------------------------|-------------------|\n| General ESRD adults | 6-12 months | 2-5 years | Dialysis extends life via solute clearance; CKM suits those declining therapy.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/) |\n| Elderly (\u003e75 years) with comorbidities | 6-23 months | 13-37 months | Comparable in frail subsets; CKM prioritizes QoL over marginal gains.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6) |\n\nDecisions for CKM versus dialysis should integrate patient preferences, prognostic tools (e.g., surprise question for 12-month mortality prediction), and multidisciplinary input, as dialysis does not universally equate to prolonged healthy life in advanced disease states.[](https://www.mdpi.com/2077-0383/13/1/41) Long-term cohort studies underscore that while dialysis dominates as the default, CKM uptake remains low (under 20% in many regions), potentially reflecting under-discussion of alternatives despite evidence of its viability for quality-focused care.[](https://www.sciencedirect.com/science/article/pii/S2590059523001449)\n\n## Treatment Procedures\n\n### Vascular and Peritoneal Access Methods\n\n![Arteriovenous fistula in the arm](./_assets_/Dialysis_-_arm_-_01.jpg)\n\nVascular access for hemodialysis enables the extracorporeal circulation of blood through the dialyzer, with arteriovenous fistulas (AVFs), arteriovenous grafts (AVGs), and central venous catheters (CVCs) as the primary methods.31137-0/fulltext) The KDOQI Clinical Practice Guideline recommends AV access (AVF or AVG) over CVC for most incident and prevalent patients due to reduced infection risk and improved long-term patency.31137-0/fulltext) AVFs are created by surgically anastomosing a native artery to a vein, typically the radial artery to cephalic vein at the wrist (radiocephalic fistula), allowing vein maturation through arterialization for repeated needle punctures.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/) AVFs exhibit lower rates of infection (0.5-1.5% per patient-year) and thrombosis compared to alternatives, though they require 2-3 months for maturation in 60-70% of cases.31137-0/fulltext) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/)\n\nAVGs involve interposing synthetic materials, such as polytetrafluoroethylene, between artery and vein when native vessels are inadequate, offering faster usability (2-3 weeks) but higher thrombosis rates (0.8-1.8 events per patient-year) and interventions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/) CVCs, including non-tunneled for acute use and tunneled cuffed for chronic, provide immediate access via jugular, subclavian, or femoral veins but carry the highest bacteremia risk (0.5-6.0 episodes per 1,000 catheter-days) and are associated with increased mortality.31137-0/fulltext) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/) Guidelines advocate minimizing CVC duration, targeting less than 10% prevalent use, with ultrasound guidance for insertion to reduce complications like pneumothorax.31137-0/fulltext)\n\nPeritoneal access for peritoneal dialysis utilizes specialized catheters to infuse and drain dialysate into the peritoneal cavity, with Tenckhoff cathetersâ€”straight or curled tip, often double-cuffedâ€”being the most common type for secure fixation and reduced migration.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/) Insertion techniques include open surgical (midline laparotomy under general anesthesia), laparoscopic (with visualization for adhesiolysis), and percutaneous (Seldinger method under local anesthesia or fluoroscopy), each with comparable long-term success but varying procedural risks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/) Guidelines recommend a 2-week break post-insertion before full dialysis to minimize early complications like dialysate leakage (5-10% incidence).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/)\n\nCommon peritoneal catheter complications encompass early issues such as bowel perforation (1%), bleeding, and malpositioning, alongside late problems including exit-site infections (0.4-0.6 episodes per patient-year), tunnel infections, and outflow obstruction from fibrin or omental plugging, potentially necessitating removal in 10-20% of cases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/) Prophylactic measures, like burying the external cuff initially or using antibiotic creams, reduce infection rates, while imaging or laparoscopy aids in dysfunction management.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/) Patient selection, including avoidance in cases of abdominal adhesions or obesity, optimizes outcomes.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf)\n\n### Session Protocols and Monitoring\n\n![Hemodialysis machine](./_assets_/Hemodialysismachine.jpg)\n\nHemodialysis sessions typically occur three times per week, with each session lasting 3.5 to 5 hours to achieve a minimum of 12 hours weekly dialysis time in patients with minimal residual kidney function.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3) [](https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf) Protocols begin with vascular access preparation, including cannulation of arteriovenous fistula or graft, administration of anticoagulation such as unfractionated heparin to prevent clotting, and programming the dialysis machine for blood flow rates of 300-500 mL/min and dialysate flow of 500-800 mL/min.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3) Ultrafiltration rates are prescribed to remove excess fluid while minimizing hemodynamic instability, often targeting a single-pool Kt/V of at least 1.2 per session.[](https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf)\n\nIntra-session monitoring includes continuous assessment of machine parameters such as arterial and venous pressures, transmembrane pressure, blood pump speed, and conductivity alarms, alongside patient vital signs checked every 30 minutes, encompassing blood pressure, heart rate, and temperature to detect complications like hypotension.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3) Pre-dialysis evaluations involve recording dry weight, blood pressure, and access patency, while post-dialysis protocols confirm target weight achievement, final vital signs, and access site hemostasis to prevent bleeding.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3) Adequacy is verified monthly via equilibrated Kt/V measurements, with adjustments for residual renal function assessed quarterly if present.[](https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf)\n\nFor peritoneal dialysis, protocols differ by modality: continuous ambulatory peritoneal dialysis (CAPD) involves 3-5 manual exchanges daily with dwell times of 4-6 hours, while automated peritoneal dialysis (APD) uses cyclic machine-driven exchanges overnight, typically 8-10 cycles with shorter dwells of 1.5-3 hours for high transporters.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/) Monitoring emphasizes daily self-assessment of body weight, blood pressure, and dialysate effluent for clarity and volume to ensure ultrafiltration of at least 750 mL/day in anuric adults, with peritoneal equilibration testing performed at 6 weeks post-initiation and annually thereafter to evaluate membrane function.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/) Solute clearance targets include a weekly Kt/V urea of 1.7 or creatinine clearance of 50 L/1.73 mÂ², measured semiannually, alongside residual renal function tracking to guide prescription adjustments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/)\n\n### Home versus In-Center Delivery\n\nHome hemodialysis (HHD) and peritoneal dialysis (PD), the primary home-based modalities, enable patients to perform treatments independently or with caregiver assistance after extensive training, contrasting with in-center hemodialysis (ICHD), which occurs under professional supervision at facilities three times weekly for approximately four hours per session. HHD training typically spans 4-8 weeks, covering vascular access management, dialysate preparation, and complication recognition, while PD requires instruction in catheter care and manual or automated dialysate exchanges performed daily.[](https://www.kidney.org/kidney-topics/choosing-dialysis-which-type-right-me)[](https://nephrology.medicine.ufl.edu/patient-care/renal-replacement-therpay/home-dialysis/)\n\n| Aspect                  | Home Dialysis (HHD/PD) Advantages/Outcomes | In-Center HD Advantages/Outcomes | Key Evidence/Limitations |\n|-------------------------|--------------------------------------------|---------------------------------|------------------------|\n| **Survival**           | Lower all-cause mortality (e.g., 3.76 vs. 6.27 deaths/100 patient-years for extended HHD vs. ICHD; HR 0.60, 95% CI 0.45-0.80); PD advantage persists 1.5-2 years before equalizing. | Higher standardized mortality in observational data, though supervised care mitigates acute issues. | Selection bias favors healthier home patients (younger, fewer comorbidities); no RCTs due to recruitment challenges.[](https://www.sciencedirect.com/science/article/pii/S2468024923014845)[](https://pubmed.ncbi.nlm.nih.gov/22098661/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6628511/) |\n| **Quality of Life**    | Greater flexibility reduces travel (up to 52 days/year saved), enables more frequent/shorter sessions, improves life participation and satisfaction. | Structured social interaction; immediate staff intervention for complications. | Mixed results on mental/physical components; home burnout or isolation possible.[](https://www.kidney.org.uk/home-dialysis-the-advantages)[](https://www.hsrd.research.va.gov/publications/esp/kidney-dialysis-REPORT.pdf) |\n| **Clinical Control**   | Better blood pressure, phosphate, and nutrition management; fewer hospitalizations. | Consistent monitoring reduces procedural errors. | Home requires patient adherence; PD peritonitis risk higher if hygiene lapses.[](https://www.sciencedirect.com/science/article/pii/S2468024923014845) |\n| **Costs**              | More cost-effective (e.g., PD yields higher QALYs at lower cost than ICHD); potential savings from reduced facility overhead. | Higher overall due to staffing/transport; initial home setup offset by long-term gains. | Upfront home equipment/training barriers; PD consumables ongoing.30271-5/fulltext)[](https://link.springer.com/article/10.1007/s40258-025-00976-7) |\n\nHome dialysis demands reliable home infrastructure, electricity, and water quality, with HHD often necessitating nocturnal or daily regimens for optimal clearance, whereas ICHD adheres to standardized protocols minimizing patient burden but limiting personalization. Risks in home settings include technique failure (e.g., PD peritonitis rates ~0.2-0.5 episodes/year despite improvements) and vascular access issues without immediate oversight, though ICHD exposes patients to facility-acquired infections. Empirical data favor home modalities for suitable candidatesâ€”those with adequate support and dexterityâ€”due to causal links between treatment frequency/intensity and cardiovascular stability, yet broader adoption is hindered by training demands and socioeconomic factors.[](https://pubmed.ncbi.nlm.nih.gov/22098661/)[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03264-5)\n\n## Clinical Outcomes\n\n### Survival Rates and Mortality Data\n\nFor patients with end-stage renal disease (ESRD) initiating dialysis in the United States, the five-year survival probability after starting hemodialysis (HD) was 40.7% for the 2018 incident cohort, showing minimal improvement from 40.4% in the 2008 cohort.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality) Similarly, five-year survival after peritoneal dialysis (PD) initiation stood at 42.5% for the 2018 cohort, down slightly from 44.5% in 2008.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality) These figures reflect persistent challenges, with overall one-year mortality rates for dialysis patients estimated at 15-20%, driven primarily by cardiovascular events, infections, and comorbidities.[](https://pharm.ucsf.edu/kidney/need/statistics)\n\nAdjusted all-cause mortality rates for prevalent HD patients averaged 185.7 deaths per 1,000 patient-years in 2022, following a spike to 195.9 in 2021 amid the COVID-19 pandemic, which eroded prior declines observed from 179.4 in 2012 to 166.0 in 2019.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality) For PD patients, rates were lower at 149.5 per 1,000 patient-years in 2022 but exhibited a similar pandemic-related increase from 132.1 in 2019.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality) Survival varies markedly by age, with HD mortality rates rising from 92.1 per 1,000 patient-years in those aged 18-44 to 318.3 in those 75 and older in 2022; analogous age-stratified elevations occur in PD cohorts.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality)\n\n| Modality | 5-Year Survival (2008 Cohort) | 5-Year Survival (2018 Cohort) | 2022 Mortality Rate (per 1,000 patient-years) |\n|----------|-------------------------------|-------------------------------|----------------------------------------------|\n| Hemodialysis | 40.4%                        | 40.7%                        | 185.7                                       |\n| Peritoneal Dialysis | 44.5%                   | 42.5%                        | 149.5                                       |\n\nData from USRDS 2024 Annual Data Report.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality)\n\nComorbidities exacerbate mortality, with dialysis patients aged 66-74 exhibiting rates four times higher than those with cancer and three times higher than heart failure in 2022 comparisons.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality) Meta-analyses indicate comparable long-term survival between HD and PD overall, though PD may confer early advantages in select non-diabetic or urgent-start populations, while HD predominates for extended survival in others.[](https://pubmed.ncbi.nlm.nih.gov/39675379)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12407124/) Global trends mirror these patterns, with chronic kidney disease-related mortality influenced by access to dialysis and regional healthcare disparities, though high-income countries report 15-20% one-year mortality post-initiation.[](https://www.nature.com/articles/s41581-024-00820-6) Survival has stagnated over decades despite procedural advances, attributable to rising patient age, diabetes prevalence, and non-renal comorbidities at ESRD onset.[](https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality)\n\n### Quality of Life and Functional Impacts\n\nPatients undergoing kidney dialysis experience substantially diminished health-related quality of life (HRQoL) compared to the general population, with reductions particularly pronounced in physical and mental domains as assessed by standardized tools like the SF-36 questionnaire.[](https://www.cureus.com/articles/205740-quality-of-life-and-complications-among-hemodialysis-patients)[](https://www.nature.com/articles/s41581-024-00820-6) A 2024 study of hemodialysis (HD) patients reported average QoL scores lower than those of healthy individuals, correlating with the presence of complications such as anemia and cardiovascular issues.[](https://www.cureus.com/articles/205740-quality-of-life-and-complications-among-hemodialysis-patients) Longitudinal analyses indicate progressive declines in both physical and mental HRQoL over time for patients on institutional HD or peritoneal dialysis (PD), though PD may preserve slightly better initial HRQoL due to greater scheduling flexibility.[](https://academic.oup.com/ckj/article/18/2/sfae420/7929882)[](https://www.nature.com/articles/s41598-019-46744-1)\n\nFunctional impacts are marked by chronic fatigue, reduced exercise capacity, and limitations in daily activities stemming from uremic symptoms, fluid and dietary restrictions, and the treatment burden itself. Approximately 27% of patients initiating dialysis develop significant functional impairment within the first year, often requiring assistance with activities of daily living.[](https://academic.oup.com/ndt/article/38/11/2528/7172141) HD sessions, typically lasting 3-5 hours three times weekly, impose substantial time constraints, disrupting employment and social engagements; employment rates among dialysis patients remain low at around 20-30%, influenced by physical debility and session logistics.[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1530465/full) In contrast, PD allows home-based treatment but demands rigorous adherence to sterile techniques and may exacerbate abdominal discomfort or hernias, limiting mobility in some cases.[](https://www.nature.com/articles/s41598-019-46744-1)[](https://karger.com/kbr/article/43/6/1813/187988/Hemodialysis-or-Peritoneal-Dialysis-Which-Is)\n\nPsychological burdens further erode QoL, with depression prevalence ranging from 20% to 45% among end-stage renal disease patients on dialysis, exceeding rates in other chronic conditions and linked to biological factors like inflammation alongside psychosocial stressors.[](https://www.mypcnow.org/fast-fact/depression-in-end-stage-renal-disease/)[](https://www.kidney.org/sites/default/files/v40b_a4.pdf) Anxiety co-occurs frequently, affecting up to 50% in some cohorts, and correlates with poorer adherence and higher hospitalization risks.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-03051-8) These mental health challenges, compounded by body image concerns from vascular access and dependency on machines, underscore dialysis's holistic toll, though interventions like exercise programs can modestly improve physical function and mood.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5856029/) Overall, while dialysis sustains life, its functional restrictions often confine patients to a narrowed sphere of activity, with younger cohorts facing amplified disruptions to career and family roles.[](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1530465/full)\n\n### Comparisons to Kidney Transplantation and No Treatment\n\nKidney transplantation generally confers superior long-term survival compared to remaining on dialysis for patients with end-stage renal disease (ESRD). A systematic review of observational studies found that transplantation is associated with lower all-cause mortality rates than chronic dialysis, with adjusted hazard ratios indicating a 50-70% reduction in mortality risk post-transplant.[](https://pubmed.ncbi.nlm.nih.gov/21883901/) Similarly, a meta-analysis of 48 studies reported that 92% demonstrated a survival benefit for transplantation over dialysis beyond one year, with the advantage persisting across age groups and comorbidities.[](https://www.bmj.com/content/376/bmj-2021-068769) However, one-year post-transplant survival rates may approximate those on dialysis (94% versus 95%), as surgical risks and early immunosuppression complications offset initial gains, after which divergence favors transplantation.[](https://www.sciencedirect.com/science/article/pii/S1600613523005786) Deceased-donor transplants extend median survival by years across all candidate ages, even after accounting for waiting times up to five years.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181)\n\nHealth-related quality of life (HRQoL) also improves markedly after successful kidney transplantation relative to dialysis. Multiple studies, including prospective cohorts, show transplant recipients experiencing higher scores in physical functioning, vitality, and social domains on validated instruments like the SF-36, attributable to freedom from frequent treatments and reduced uremic symptoms.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z) [](https://pubmed.ncbi.nlm.nih.gov/21883901/) For older recipients (over 65), transplantation yields significantly better HRQoL than remaining waitlisted on dialysis, with gains in mobility and emotional well-being persisting long-term.[](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12071/full) These benefits stem from restored renal function enabling dietary liberalization and employment resumption, though lifelong immunosuppression introduces infection and malignancy risks not present in dialysis.[](https://www.sciencedirect.com/science/article/pii/S2590059525000226)\n\nIn contrast to conservative management without dialysis or transplantation, dialysis extends survival for most ESRD patients, particularly those under 80 or without severe frailty. A 2024 analysis of over 10,000 patients found dialysis initiation reduced all-cause mortality risk by 40-60% compared to conservative care in advanced chronic kidney disease (CKD5), with median survival on dialysis exceeding conservative management by 12-24 months.[](https://pubmed.ncbi.nlm.nih.gov/39212241/) [](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6) Meta-analyses confirm this survival edge where patients explicitly choose dialysis, though conservative care avoids procedural burdens like vascular access infections.[](https://academic.oup.com/ndt/article-abstract/37/8/1529/6534933) For patients over 80 or with life expectancy under six months, survival differences narrow, and conservative managementâ€”focusing on symptom palliation and holistic supportâ€”may preserve HRQoL by preventing dialysis-related fatigue and hospitalizations without meaningfully prolonging life.[](https://www.capc.org/blog/rethinking-kidney-care-the-role-of-conservative-kidney-management/) [](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790040) Untreated ESRD typically leads to uremic death within weeks to months, underscoring dialysis as a bridge to transplantation or stabilization when feasible.[](https://www.kidneymedicinejournal.org/article/S2590-0595%2820%2930268-5/fulltext)\n\n## Complications and Risks\n\n### Acute Complications\n\nIntradialytic hypotension, defined as a drop in systolic blood pressure by at least 20 mm Hg or to below 90 mm Hg during hemodialysis, represents the most frequent acute complication, occurring in 10-30% of sessions and linked to increased cardiovascular mortality and hospitalization risks.[](https://www.ajkd.org/article/S0272-6386%2805%2900436-1/fulltext)[](https://academic.oup.com/ckj/article/13/6/981/5868598) This event arises primarily from rapid fluid removal via ultrafiltration exceeding vascular refilling, compounded by autonomic neuropathy common in end-stage renal disease, left ventricular dysfunction, and dialysate composition factors such as low sodium levels.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/) Symptomatic episodes manifest as dizziness, nausea, or syncope, with severe cases precipitating ischemia or arrhythmias; preventive strategies include adjusted ultrafiltration rates and midodrine administration, though evidence for long-term outcome improvement remains limited.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7851674/)\n\nMuscle cramps, affecting up to 20% of hemodialysis sessions, typically occur in the lower extremities during the latter half of treatment and correlate strongly with predialysis fluid overload and intradialytic hypotension.[](https://www.intechopen.com/chapters/85615) These cramps stem from electrolyte shifts, particularly hypocalcemia or hypomagnesemia induced by diffusive losses, and muscle ischemia from hypoperfusion; interventions such as hypertonic saline boluses or quinine have shown variable efficacy, with cramps resolving post-session in most cases but contributing to treatment discontinuation in 1-2% of patients annually.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/)\n\nOther intradialytic events in hemodialysis include nausea and vomiting (5-15% incidence), often tied to rapid urea removal causing osmotic disequilibrium, and pruritus from residual uremia or mast cell degranulation.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01806-9) Arrhythmias, encompassing ventricular ectopy or atrial fibrillation, arise in 10-20% of sessions among at-risk patients with underlying cardiac disease, exacerbated by electrolyte fluctuations like hyperkalemia reversal or hypocalcemia; continuous ECG monitoring detects these, with beta-blockers or pacing as acute management.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7851674/) Rare but critical complications encompass air embolism from venous air ingress (mortality up to 20% if untreated) and hemolysis from hypotonic dialysate or overheated solutions, both necessitating immediate session termination and supportive care.[](https://www.ajkd.org/article/S0272-6386%2821%2900001-9/pdf)\n\nIn peritoneal dialysis, acute complications predominantly involve infectious peritonitis, with an incidence of 0.2-0.5 episodes per patient-year, presenting as abdominal pain, cloudy effluent, and fever within hours of contamination during catheter exchanges.[](https://www.ajkd.org/article/S0272-6386%2823%2900649-2/fulltext) Mechanical issues, such as dialysate leaks or catheter malposition, occur in 5-10% of early sessions, leading to subcutaneous edema, reduced ultrafiltration, or hydrothorax from pleuroperitoneal communication, often requiring temporary cessation and surgical revision.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11168815/) Exit-site bleeding or hypotension from excessive fluid shifts can also emerge acutely, though less frequently than in hemodialysis.[](https://www.merckmanuals.com/home/multimedia/table/some-common-complications-of-peritoneal-dialysis) Overall, acute events in both modalities heighten session interruptions and underscore the need for vigilant monitoring, with hemodialysis exhibiting higher cardiovascular acuity while peritoneal dialysis risks center on access integrity.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11952240/)\n\n### Long-Term Complications\n\nLong-term complications of kidney dialysis arise primarily from the incomplete replication of native kidney function, leading to persistent uremia, fluid and electrolyte imbalances, and chronic inflammation, despite regular treatments. Cardiovascular disease remains the predominant cause of morbidity and mortality, accounting for approximately 40-50% of deaths in dialysis patients, driven by accelerated atherosclerosis, left ventricular hypertrophy, and arrhythmias due to factors such as hypertension, anemia, and hyperphosphatemia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6168816/) [](https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686) Dialysis patients exhibit 10-20 times higher cardiovascular mortality compared to the general population, with risks exacerbated by intradialytic hypotension, which promotes regional myocardial ischemia and long-term cardiac remodeling.[](https://www.ncbi.nlm.nih.gov/books/NBK563296/) [](https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2023.1198560/full)\n\n**Mineral and bone disorder (CKD-MBD)** manifests as renal osteodystrophy, characterized by high-turnover bone disease from secondary hyperparathyroidism, adynamic bone disease, or osteomalacia, resulting from phosphate retention, vitamin D deficiency, and disrupted calcium homeostasis.[](https://www.ncbi.nlm.nih.gov/books/NBK560742/) Long-term dialysis intensifies vascular calcification, linking CKD-MBD to increased cardiovascular events and fracture risk, with bone-specific alkaline phosphatase levels at dialysis initiation predicting higher hospitalization rates for cardiovascular, cerebrovascular, and peripheral arterial disease.[](https://www.sciencedirect.com/science/article/pii/S2214762414000140) [](https://my.clevelandclinic.org/health/diseases/24006-renal-osteodystrophy) In hemodialysis patients surviving over 20 years, uremic osteodystrophy persists as a key issue, often requiring parathyroidectomy for severe hyperparathyroidism.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8359961/)\n\nInfections pose a sustained threat, with vascular access sites in hemodialysis predisposing to bacteremia and sepsis, while peritoneal dialysis carries risks of peritonitis and encapsulating peritoneal sclerosis after prolonged use.[](https://www.kidney.org/kidney-topics/dialysis) [](https://pubmed.ncbi.nlm.nih.gov/8320909/) Defects in cellular immunity inherent to uremia compound these risks, elevating overall infection rates beyond those attributable to access alone.[](https://pubmed.ncbi.nlm.nih.gov/8320909/) Neurological complications, including peripheral neuropathy and dialysis-related amyloidosis from beta-2 microglobulin accumulation, emerge after years of therapy, impairing quality of life and mobility.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/) Acquired cystic kidney disease also develops in long-term patients, increasing malignancy risk.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/)\n\nComparisons between hemodialysis and peritoneal dialysis reveal modality-specific patterns: hemodialysis associates more with cardiovascular and access-related issues, while peritoneal dialysis heightens encapsulating sclerosis risk after 5-10 years, though both share systemic burdens like fatigue and reduced survival linked to dialysis vintage.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8359961/) These complications underscore dialysis's role as a bridge therapy, with cumulative risks rising with treatment duration, often necessitating multimodal management including phosphate binders, erythropoietin, and access revisions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5654453/)\n\n## Economic and Systemic Factors\n\n### Treatment Costs and Cost-Effectiveness\n\nIn the United States, the average annual Medicare expenditure per patient for in-center hemodialysis was approximately $99,000 in 2021, while peritoneal dialysis averaged $87,000 per patient, reflecting differences in facility utilization, supply requirements, and associated hospitalizations.[](https://www.cdc.gov/pcd/issues/2024/24_0052.htm) These figures encompass bundled payments under the End-Stage Renal Disease Prospective Payment System, which covers dialysis treatments, medications, and laboratory services, but exclude supplemental costs such as physician fees or extended hospital stays for complications.[](https://www.cms.gov/newsroom/fact-sheets/calendar-year-2024-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1782-f) Peritoneal dialysis generally incurs lower direct costs due to reduced need for clinic infrastructure and transportation, though initial training and home setup expenses can offset some savings in the first year.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7873827/)\n\n| Modality | Average Annual Cost per Patient (US, 2021 Medicare) | Key Cost Drivers |\n|----------|-----------------------------------------------------|------------------|\n| In-Center Hemodialysis | $99,000 | Facility operations, frequent sessions (3x/week), higher drug expenditures (e.g., $20,000/year for injectables)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10344940/) |\n| Peritoneal Dialysis | $87,000 | Home-based supplies, training, lower facility dependency |\n| Kidney Transplantation (first year) | $100,000â€“$130,000 (variable by donor type) | Surgery, immunosuppression; subsequent years ~$20,000â€“$30,000 |\n\nLong-term cost-effectiveness analyses indicate peritoneal dialysis yields superior value compared to hemodialysis, with 10-year cumulative costs averaging $336,000 for peritoneal dialysis versus $353,000 for in-center hemodialysis, driven by fewer hospitalizations and lower overhead.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7873827/) Incremental cost-effectiveness ratios for dialysis modalities often exceed $50,000â€“$100,000 per quality-adjusted life year (QALY) gained relative to conservative management, reflecting modest survival extensions (median 3â€“5 years on dialysis) amid high complication rates.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10060297/) In contrast, kidney transplantation demonstrates dominant cost-effectiveness over dialysis, with first-year costs comparable or higher but lifetime savings of $50,000â€“$70,000 per patient due to improved QALYs (e.g., 0.72 QALYs for transplant vs. 0.55 for hemodialysis in one-year models) and reduced ongoing therapy needs.[](https://www.sciencedirect.com/science/article/pii/S2212109925000342)[](https://www.nature.com/articles/s41598-023-37814-6)\n\nFactors influencing cost-effectiveness include patient comorbidities, which elevate hospitalization expenses (up to 40% of total dialysis costs), and payer mix, as Medicare covers most end-stage renal disease patients but private insurers face 20â€“30% higher reimbursements for hemodialysis sessions.[](https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2342210) Home-based peritoneal dialysis enhances cost savings in resource-constrained settings by minimizing indirect expenses like lost productivity, though adoption remains low (under 10% of US dialysis patients) due to training barriers and peritonitis risks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10060297/) Overall, while dialysis sustains life short-term, its economic burdenâ€”totaling over $50 billion annually in Medicare spendingâ€”underscores the imperative for transplantation prioritization, as evidenced by models showing net QALY gains and cost neutrality after 2â€“3 years post-transplant.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794481)[](https://www.medpac.gov/wp-content/uploads/2024/03/Mar24_Ch5_MedPAC_Report_To_Congress_SEC.pdf)\n\n### Industry Structure and Market Dynamics\n\nThe dialysis industry exhibits a highly concentrated oligopolistic structure, particularly in the United States, where two dominant providersâ€”Fresenius Medical Care AG \u0026 Co. KGaA and DaVita Inc.â€”control approximately 77% of dialysis facilities and account for over 90% of industry revenue as of 2024.[](https://www.healio.com/news/nephrology/20250708/economic-analysis-dialysis-center-duopoly-keeps-commercial-insurance-payments-high)[](https://lpeproject.org/blog/a-dialysis-duopoly-how-public-funding-entrenched-private-power/) This consolidation has intensified over the past two decades, with their combined market share rising from 59% to 77% between the early 2000s and recent years, driven by acquisitions and economies of scale that have marginalized independent centers, whose share fell from 20% to 11%.[](https://www.healio.com/news/nephrology/20250708/economic-analysis-dialysis-center-duopoly-keeps-commercial-insurance-payments-high) Globally, the market includes additional players like Baxter International Inc. and B. Braun Melsungen AG, but vertical integration by leadersâ€”spanning equipment manufacturing, consumables, and service provisionâ€”reinforces barriers to entry for smaller competitors.[](https://www.marketsandmarkets.com/ResearchInsight/dialysis-market.asp) Dialysis chains overall dominate U.S. centers with an 83% share in 2024, benefiting from standardized operations and extensive networks.[](https://www.grandviewresearch.com/industry-analysis/us-dialysis-centers-market-report)\n\nMarket dynamics are shaped by steady demand growth amid structural rigidities. The global dialysis market reached $98.51 billion in 2024 and is forecasted to expand to $181.16 billion by 2032 at a compound annual growth rate (CAGR) of 8.4%, propelled by rising chronic kidney disease (CKD) and end-stage renal disease (ESRD) incidence linked to diabetes, hypertension, and aging demographics.[](https://www.fortunebusinessinsights.com/dialysis-market-102367) In the U.S., where Medicare covers nearly all ESRD patients via the bundled Prospective Payment System (PPS), total payments to facilities are projected to rise with a 2025 base rate adjustment to $273.82 per treatment, though this has incentivized cost containment measures like reduced ancillary services.[](https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f) Reimbursement policies have facilitated consolidation by favoring large chains capable of negotiating higher commercial ratesâ€”up to three times Medicare levelsâ€”while bundling expansions since 2011 have correlated with shifts in care practices, such as anemia management variations by market competition.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7985814/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592119/)\n\nKey trends include a gradual pivot toward home-based dialysis, supported by portable technologies, though in-center treatments still comprise the majority due to patient adherence barriers and infrastructure costs in emerging markets.[](https://meditechinsights.com/dialysis-market/) Barriers persist from high capital requirements for equipment and regulatory compliance, alongside policy-driven pressures like Medicare's PPS, which prioritize efficiency but risk technique failures in peritoneal dialysis promotion.[](https://www.sciencedirect.com/science/article/abs/pii/S016885102300101X) Innovations in dialyzer membranes and continuous therapies offer growth potential, yet oligopolistic pricing power sustains elevated commercial reimbursements, with limited antitrust intervention despite facility divestitures in concentrated areas.[](https://som.yale.edu/sites/default/files/2024-05/Dialysis_Divestitures_6.2.pdf) Overall, while prevalence-driven expansion sustains revenueâ€”U.S. centers at $31.3 billion in 2025â€”systemic dependencies on public funding underscore vulnerabilities to policy reforms targeting over-concentration.[](https://www.ibisworld.com/united-states/industry/dialysis-centers/4038/)\n\n### Access Disparities and Policy Influences\n\nIn the United States, the Medicare End-Stage Renal Disease (ESRD) program, enacted in 1972 as an amendment to the Social Security Act, entitles individuals with ESRD who are fully or currently insured under Social Securityâ€”or their spouses or dependentsâ€”to Medicare coverage for dialysis services, regardless of age or disability status, with benefits typically starting on the first day of the fourth month of dialysis treatments.[](https://www.cms.gov/medicare/coordination-benefits-recovery/overview/end-stage-renal-disease-esrd) [](https://www.medicare.gov/basics/end-stage-renal-disease) This policy has substantially expanded access since its inception, covering all ESRD-related services and contributing to near-universal treatment availability for eligible patients by 1980, when annual expenditures reached $1.2 billion.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11090145/) However, implementation through the prospective payment system (PPS), updated annuallyâ€”such as the 2025 revisionsâ€”aims to control costs via bundled reimbursements but has not eliminated disparities in treatment modality and quality.[](https://www.federalregister.gov/documents/2024/11/12/2024-25486/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis)\n\nRacial, ethnic, and socioeconomic disparities persist within this framework. Non-Hispanic Black and Hispanic patients initiate dialysis at younger ages and face barriers to home-based modalities, with large gaps in access to home dialysis and living donor kidney transplantation compared to non-Hispanic White patients, as documented in the US Renal Data System 2023 and 2024 reports.00048-9/fulltext) 00703-6/fulltext) Low socioeconomic status correlates with higher chronic kidney disease incidence, faster progression to ESRD, inadequate predialysis nephrology care, and reliance on central venous catheters rather than optimal arteriovenous fistulas, exacerbating infection risks and outcomes.[](https://www.nature.com/articles/nrneph.2012.117) [](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838512) Black, Hispanic, and Asian patients with advanced chronic kidney disease also encounter limited specialist access, influenced by social determinants like education and income, which policy expansions such as Medicare Advantage enrollment under the 21st Century Cures Act (effective 2021) have only partially addressed amid rising dual enrollment.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10593311/) [](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823636)\n\nGlobally, access disparities are more pronounced, driven by policy and funding variations. In 2023, an estimated 3.57 million people received dialysis worldwide, but availability at kidney failure onset exceeds 50% of needs in only 74% of countries with services, dropping to 32% in low-income countries (LICs) where private out-of-pocket funding predominates and temporary catheters comprise over 75% of hemodialysis initiations in 57% of cases.00198-6/fulltext) 00570-3/fulltext) [](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03593-z) Men are 47% more likely than women to access dialysis or transplantation, reflecting gender biases in resource allocation across regions.[](https://www.nature.com/articles/s41581-024-00820-6) High-income countries achieve broader coverage through public funding models akin to the U.S. ESRD program, while LICs' limited infrastructure and cost barriers lead to treatment withdrawal and higher mortality from access-related infections.01737-6/fulltext) The International Society of Nephrology's 2023 Global Kidney Health Atlas highlights how national policies prioritizing universal kidney replacement therapy correlate with reduced inequities, though only 6% of responding countries fully cover all needs at onset.[](https://www.theisn.org/wp-content/uploads/media/ISN%2520Atlas_2023%2520Digital.pdf)\n\n## Special Populations\n\n### Pediatric Dialysis\n\nPediatric dialysis refers to renal replacement therapy administered to children with end-stage renal disease (ESRD), typically those under 18 years of age, to remove waste products and excess fluid from the blood when kidneys fail. In the United States, approximately 1,500 children younger than 18 receive dialysis annually, with congenital anomalies of the kidney and urinary tract accounting for about 50% of cases, followed by glomerular diseases. Peritoneal dialysis (PD) is often the initial modality for infants and young children due to its feasibility for home use and continuous nature, which supports growth and minimizes hemodynamic instability compared to intermittent hemodialysis (HD).[](https://www.healthychildren.org/English/health-issues/conditions/genitourinary-tract/Pages/dialysis-in-children.aspx)[](https://link.springer.com/book/10.1007/978-3-030-66861-7)\n\nVascular access poses significant challenges in pediatric HD, as small vessel sizes complicate arteriovenous fistula (AVF) creation, leading to reliance on central venous catheters (CVCs) in up to 70-80% of cases initially, which increases infection risks and thrombosis. Guidelines from the American Society of Pediatric Nephrology recommend AVF as the preferred permanent access for maintenance HD when feasible, but maturation rates are lower in children under 10 years due to anatomical limitations. PD avoids vascular access issues but carries risks of peritonitis (incidence 0.5-1 episode per patient-year) and mechanical complications like catheter malfunction, particularly in active toddlers.[](https://pubmed.ncbi.nlm.nih.gov/32891312/)[](https://www.ajkd.org/article/S0272-6386%2806%2900666-4/fulltext)[](https://link.springer.com/article/10.1007/s00467-025-06713-5)\n\nOutcomes in pediatric dialysis vary by age, modality, and comorbidities, with 1-year patient survival rates ranging from 82-96% and 5-year rates from 51-84%, influenced by factors such as effluent flow adequacy in continuous therapies and timely transition to transplantation. Cardiovascular complications remain the leading cause of mortality, accounting for up to 30% of deaths, while non-infectious issues like growth impairment and neurocognitive delays affect long-term quality of life. Psychosocial burdens are pronounced, with children on PD experiencing higher rates of anxiety (up to 40%) and academic disruption due to treatment demands on families. Multidisciplinary care, including nutritional support and psychological interventions, is essential to mitigate these effects.[](https://academic.oup.com/ndt/article/23/4/1336/1874466)[](https://journals.lww.com/sjkd/fulltext/2023/34010/outcomes_of_maintenance_peritoneal_dialysis_in.6.aspx)[](https://journaljpri.com/index.php/JPRI/article/view/7512)[](https://journals.sagepub.com/doi/10.1177/08968608241273633)\n\n### Dialysis in the Elderly and Frail\n\nElderly patients initiating dialysis, typically defined as those aged 75 years and older, exhibit substantially reduced survival compared to younger cohorts. A 2019 analysis of U.S. Medicare data for adults aged 65 and older found one-year mortality rates of 54.5% following dialysis start, with 22.5% dying within 30 days and 44.2% within 180 days.[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730766) For patients over 80 on chronic hemodialysis, approximately one-third survive 12-24 months and another third 24-60 months, influenced by comorbidities such as cardiovascular disease and diabetes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3998852/) Peritoneal dialysis in this group yields even lower survival, with rates of 79% at one year and 30% at five years, versus 97% and 73% in younger patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4033330/)\n\nFrailty, characterized by diminished strength, endurance, and physiologic reserve, profoundly worsens prognosis in dialysis-dependent elderly patients. Frail individuals face 2- to 6-fold higher risks of mortality, hospitalization, infections, cardiovascular events, and dialysis-related complications like technique failure.[](https://www.sciencedirect.com/science/article/pii/S2468024923016455) Prevalence of frailty exceeds 70% in advanced chronic kidney disease progressing to dialysis, escalating with age and correlating with accelerated functional decline post-initiation.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03303-1) A 2009 New England Journal of Medicine study of patients aged 70 and older documented marked deterioration in functional statusâ€”measured by activities of daily livingâ€”within one year of starting dialysis, independent of age or baseline function, attributing this to treatment burdens including vascular access issues and fatigue.[](https://www.nejm.org/doi/full/10.1056/NEJMoa0904655)\n\nQuality of life often diminishes rather than improves with dialysis in frail elderly patients, due to procedural demands, frequent hospitalizations, and symptom persistence. Longitudinal assessments show no significant gains in health-related quality of life metrics post-dialysis initiation, with frail patients reporting higher pain, reduced mobility, and dependency.[](https://pubmed.ncbi.nlm.nih.gov/30922246/) A 2024 Stanford-led study of frail older adults with kidney failure indicated that delaying or forgoing dialysis resulted in only nine days shorter median survival but substantially more days spent at home versus in facilities, highlighting dialysis's limited life-prolonging benefit against its logistical strains.[](https://news.stanford.edu/stories/2024/08/for-some-older-adults-with-kidney-failure-dialysis-may-not-be-the-best-option)\n\nConservative kidney managementâ€”focusing on symptom palliation, blood pressure control, and anemia correction without dialysisâ€”emerges as a viable alternative for frail elderly with end-stage renal disease. Median survival under conservative care ranges from 1 to 45 months, with one-year rates of 29-82%, often comparable to dialysis in highly comorbid subgroups where treatment intensity yields marginal gains.[](https://www.kidneymedicinejournal.org/article/S2590-0595%2822%2900059-0/fulltext) While dialysis may confer a slight overall mortality advantage in selected elderly cohorts, conservative approaches preserve quality of life by avoiding dialysis-associated disruptions, with evidence from comparative studies showing equivalent or superior symptom control in frail patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/) Shared decision-making, incorporating frailty indices like the Fried phenotype, is essential, as patient preferences for longevity versus autonomy influence outcomes; guidelines emphasize discussing these trade-offs pre-initiation to align with realistic expectations.[](https://academic.oup.com/ndt/article/39/5/742/7281724)\n\n## Historical Development\n\n### Early Innovations and Ethical Challenges\n\nIn 1913, American physiologist John Jacob Abel, collaborating with Leonard G. Rowntree and Benjamin B. Turner, developed the first experimental artificial kidney apparatus. This device employed semipermeable collodion tubes as dialysis membranes and hirudin derived from leeches as an anticoagulant to remove urea and other waste from animal blood ex vivo, marking the initial demonstration of diffusive clearance mimicking renal filtration.[](https://karger.com/ajn/article/17/3-4/289/326285/History-of-the-Science-of-Dialysis) The system operated by circulating blood through the tubes immersed in a saline bath, achieving measurable toxin reduction but limited by clotting and membrane fragility, restricting it to short-term laboratory use.[](https://edren.org/ren/unit/history/milestones-in-nephrology/)\n\nBuilding on these principles, German physician Georg G. Haas conducted the first human dialysis experiments in 1924 at the University of Giessen. Haas adapted collodion tubing and hirudin anticoagulation to treat uremic patients, performing sessions that reduced blood urea levels, though outcomes were hampered by inconsistent anticoagulation, membrane rupture, and patient comorbidities, with no long-term survivals.[](https://pubmed.ncbi.nlm.nih.gov/9189249/) These efforts highlighted technical barriers like biocompatibility and vascular access but established dialysis as a feasible, albeit rudimentary, intervention for acute uremia.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/)\n\nPractical advancements accelerated during World War II under Dutch physician Willem J. Kolff, who in 1943 constructed the first functional hemodialyzerâ€”a rotating drum machine using 30 meters of cellophane sausage casing wrapped around a wooden cylinder rotating in a dialysate bath. Kolff treated 16 patients with acute kidney injury in Nazi-occupied Netherlands, sustaining one leather tanner for 24 hours beyond expectations, though most succumbed to underlying conditions or complications like hemorrhage.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/) Postwar refinements, including distribution of Kolff's designs to centers like the U.S. Naval Medical Center, enabled broader acute applications, with survival rates improving to 10-50% in selected cases by the late 1940s.[](https://freseniusmedicalcare.com/en/media/insights/company-features/the-history-of-dialysis/)\n\nEthical challenges emerged concurrently as dialysis transitioned from experimental salvage therapy to potential life-sustaining treatment, raising questions of consent, futility, and equitable access amid resource scarcity. Early human trials involved terminal patients with minimal informed consent protocols, prioritizing physiological restoration over quality-of-life assessments, which later drew scrutiny for overlooking psychological burdens like dependency and survival with disabilities.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/) By the early 1960s, innovations such as Belding Scribner's external arteriovenous shunt in 1960 permitted repeated access for chronic therapy, but limited machinesâ€”often one per centerâ€”necessitated selection criteria favoring younger, employed, socially stable individuals, as determined by ad hoc hospital committees.[](https://journalofethics.ama-assn.org/article/god-panels-and-history-hemodialysis-america-cautionary-tale/2012-11) These \"God committees\" provoked public outcry, exemplified by a 1962 Life magazine feature and 1965 NBC documentary \"Who Shall Live?\", exposing utilitarian judgments on human worth and catalyzing bioethics discourse on rationing without democratic oversight.[](https://www.ajkd.org/article/S0272-6386%2807%2900116-3/fulltext) Such practices underscored causal tensions between technological promise and societal capacity, influencing later policy shifts toward universal access under the 1972 U.S. End-Stage Renal Disease program.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/)\n\n### Modern Advancements and Milestones\n\nThe introduction of **continuous ambulatory peritoneal dialysis (CAPD)** in 1976 by Popovich and colleagues marked a pivotal shift toward outpatient and home-based renal replacement therapy, enabling patients to perform exchanges manually without specialized equipment, thereby reducing reliance on hospital-based hemodialysis.[](https://journals.lww.com/sjkd/fulltext/1995/06010/continuous_ambulatory_peritoneal_dialysis__capd_.8.aspx) [](https://www.ccjm.org/content/ccjom/47/4/285.full.pdf) This modality expanded access for chronic kidney disease patients, with widespread adoption in the 1980s demonstrating improved quality of life through greater flexibility, though peritonitis rates initially posed challenges addressed via refined connection systems.[](https://karger.com/books/book/120/chapter/5059608/Historical-Milestones-in-Peritoneal-Dialysis)\n\nBuilding on CAPD, **automated peritoneal dialysis (APD)** emerged in 1981, utilizing cyclers to automate fluid exchanges overnight, which minimized daytime disruptions and suited patients with physical limitations or high transporters.[](https://clinicaltrials.gov/study/NCT01209273) Baxter's APD cycler, introduced in 1984, facilitated programmed regimens like continuous cycling PD, enhancing solute clearance and ultrafiltration while lowering infection risks compared to manual methods.[](https://www.linkedin.com/posts/arun-bhim-singh-_apd-baxter-this-activity-7370391987830599680-G_pv) Concurrently, hemodialysis advanced with **high-flux dialyzers** in the early 1980s, such as the 1980 F60 polysulfone model, which permitted greater removal of middle-molecular-weight toxins like beta-2 microglobulin, reducing amyloidosis incidence and improving long-term outcomes over low-flux predecessors.[](https://www.researchgate.net/figure/Evolution-of-discoveries-enabling-development-of-hemodialysis-for-renal-failure-in-the_tbl1_5458717)\n\nA landmark pharmacological milestone occurred on June 1, 1989, when the U.S. FDA approved recombinant human erythropoietin (epoetin alfa) for treating anemia in dialysis patients, dramatically decreasing transfusion dependence from over 50% to under 10% in the first years of use by stimulating endogenous red blood cell production.[](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa) This innovation addressed a core complication of end-stage renal disease, with studies confirming hemoglobin stabilization and reduced cardiovascular strain, though later dose adjustments were needed to mitigate risks like thrombosis.[](https://www.ncbi.nlm.nih.gov/books/NBK554547/)\n\nIn the 2000s, **portable home hemodialysis systems** like the NxStage System One gained traction, cleared for home use to enable short, frequent sessions (e.g., 2.5-3 hours, 5-6 times weekly), yielding superior phosphate control and vascular access preservation versus conventional thrice-weekly in-center treatments.[](https://ww3.nxstage.com/wp-content/uploads/2017/12/introducing_the_nxstage_system_one.pdf) Recent developments include sorbent-based regeneration for reduced fluid volumes and wearable prototypes, such as the AWAK PD device, which recycles peritoneal dialysate for continuous ambulatory use; clinical trials since 2018 have shown feasibility for mobility, though scalability and regulatory hurdles persist.[](https://journals.lww.com/imna/fulltext/2024/06000/wearable_artificial_kidneys__the_first_choice_for.9.aspx) These innovations collectively extend survivalâ€”dialysis patient life expectancy rose from under 5 years in the 1980s to over 10 years by the 2020sâ€”driven by iterative engineering and biocompatibility gains, albeit with ongoing needs for infection mitigation and personalization.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7391926/)\n\n## Controversies and Debates\n\n### Resource Allocation and Rationing\n\nIn the early 1960s, scarcity of hemodialysis machines in Seattle, Washington, led to the formation of an anonymous committee at Swedish Hospital, informally known as the \"God Committee,\" to allocate access to treatment among patients with end-stage renal disease (ESRD).[](https://journalofethics.ama-assn.org/article/god-panels-and-history-hemodialysis-america-cautionary-tale/2012-11) The committee, comprising seven lay members including a minister, labor leader, housewife, and government official, evaluated candidates using criteria such as medical suitability, income, marital status, family responsibilities, community contributions, and perceived social worth, effectively deciding life-or-death outcomes for dozens of applicants amid only 10-16 available machines nationwide.[](https://www.aei.org/articles/the-god-committee/) This process, initiated in 1962, sparked public outrage over subjective judgments and inspired journalistic scrutiny, including Shana Alexander's 1962 *Life* magazine exposÃ©, which highlighted cases like the denial of treatment to a wheat farmer deemed insufficiently \"intellectually stimulating.\"[](https://www.realclearpolicy.com/2020/12/09/the_god_committee_652383.html)\n\nThe Seattle experience catalyzed broader policy reforms, culminating in the U.S. Social Security Amendments of 1972, which established Medicare entitlement for all ESRD patients regardless of age, effectively eliminating explicit rationing by federalizing funding for dialysis and transplantation at an initial cost of $240 million annually, rising to billions over decades.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/) This \"end-stage renal disease program\" prioritized universal access over cost containment, averting committee-style triage but straining resources, as demand exceeded supply projections; by 2023, over 550,000 U.S. patients received dialysis at costs exceeding $50 billion yearly.[](https://www.kidney.org/sites/default/files/v36b_a4.pdf) Critics argue this approach deferred rationing to implicit forms, such as withholding treatment from noncompliant or frail patients based on clinical futility, though empirical data show lower mortality benefits in elderly cohorts with comorbidities, raising stewardship questions.[](https://www.ncbi.nlm.nih.gov/books/NBK234421/)\n\nGlobally, explicit rationing persists in low- and middle-income countries (LMICs), where dialysis capacity covers less than 10% of needs in sub-Saharan Africa and South Asia, often prioritizing younger patients or transplant candidates over the elderly or poor due to limited machines and funding.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11296549/) In resource-constrained settings like Pakistan and parts of Africa, up to 60% of ESRD patients are denied treatment owing to poverty or social factors, with informal triage by clinicians leading to moral distress; for instance, a 2006 South African study found economic barriers excluded most applicants.[](https://www.researchgate.net/publication/6904071_The_dangers_of_rationing_dialysis_treatment_The_dilemma_facing_a_developing_country) The 2023 International Society of Nephrology Global Kidney Health Atlas documents stark disparities, with only 20-30% of LMICs providing comprehensive kidney replacement therapy, necessitating rationing by ability to pay or prognostic utility rather than egalitarian principles.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11010612/)\n\nPandemic-induced shortages, as during COVID-19, exposed vulnerabilities even in high-income systems; in New York City hospitals in April 2020, machine and fluid deficits forced reductions in continuous renal replacement therapy sessions from 24 to 12 hours daily or outright triage, prioritizing acute over chronic cases.[](https://www.npr.org/2020/04/19/837727691/doctors-at-hard-hit-hospitals-say-theyre-facing-shortage-of-dialysis-equipment) Advocates subsequently urged inclusion of dialysis equipment in U.S. national stockpiles, absent since the 1980s, to mitigate future crises, though no standardized ESRD-specific guidelines emerged, leaving decisions to ad hoc clinical judgment.[](https://www.statnews.com/2023/08/07/kidney-failure-dialysis-stockpile/) Ethical debates center on balancing utility (e.g., quality-adjusted life years gained) against equity, with evidence from LMICs indicating age- or comorbidity-based rationing maximizes population-level outcomes but risks discrimination, while high-income avoidance of explicit criteria may inflate costs without proportional survival gains.[](https://www.tandfonline.com/doi/full/10.1080/15265161.2020.1777346)[](https://www.nature.com/articles/s41581-021-00404-8)\n\n### Optimal Timing of Dialysis Initiation\n\nThe optimal timing for initiating dialysis in patients with advanced chronic kidney disease (CKD) remains a topic of debate, with evidence indicating that decisions should prioritize clinical symptoms over glomerular filtration rate (GFR) thresholds alone. Randomized controlled trials, such as the Initiating Dialysis Early and Late (IDEAL) study published in 2010, demonstrated no survival benefit from starting dialysis at a higher eGFR (10-14 mL/min/1.73 mÂ²) compared to a lower threshold (5-7 mL/min/1.73 mÂ²), with median survival times of 6.0 years versus 5.8 years, respectively.[](https://www.nejm.org/doi/full/10.1056/NEJMoa1000552) [](https://www.nejm.org/doi/full/10.1056/NEJMoa1000552) This trial, involving 828 participants, also found no differences in cardiovascular events, infections, or quality of life, challenging prior observational data suggesting early initiation improved outcomes, which were likely confounded by lead-time and survivor biases.[](https://www.nejm.org/doi/full/10.1056/NEJMoa1000552)\n\nSubsequent analyses and guidelines reinforce a symptom-guided approach, recommending initiation when uremia impairs daily function, uncontrollable fluid overload occurs, or persistent hyperkalemia or acidosis develops, typically at eGFR levels below 10 mL/min/1.73 mÂ² in symptomatic patients.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf) KDIGO controversies conference reports from 2019 explicitly advise against routine preemptive dialysis in asymptomatic individuals, as early starts do not reduce mortality or cardiac risks and may hasten residual renal function decline.[](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf) [](https://kdigo.org/wp-content/uploads/2017/02/10.-Harris-DialysisInitiationKDIGO1216a.pdf) A 2023 systematic review of 23 studies confirmed that GFR at initiation does not independently predict mortality, with planned starts (versus urgent) associated with better survival due to better access preparation rather than timing per se.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03184-4)\n\nEarly initiation carries risks including higher rates of dialysis-related complications, such as infections from temporary catheters and accelerated loss of native kidney function, without offsetting gains in longevity.[](https://pubmed.ncbi.nlm.nih.gov/36158157/) [](https://www.nejm.org/doi/full/10.1056/NEJMoa1000552) In contrast, delayed initiation in carefully monitored patients allows for conservative management, potentially avoiding dialysis altogether in some with slow progression, though urgent starts risk higher short-term mortality from complications like volume overload.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03184-4) Patient-specific factors, including frailty, comorbidities, and access maturity (e.g., arteriovenous fistula formation requiring 6 months for maturation), must inform timing to minimize harm.[](https://kdigo.org/wp-content/uploads/2017/02/Polkinghorne_KDIGO-Dialysis-Initiation-Presentation.pdf) Post-IDEAL practice shifts in regions like Canada showed reduced mean eGFR at start from 11.0 to 8.5 mL/min/1.73 mÂ² without worsening outcomes, supporting later, deliberate initiation.[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2733562)\n\n### Barriers to Home Dialysis Adoption\n\nDespite evidence that home dialysis modalities, such as peritoneal dialysis and home hemodialysis, can improve patient quality of life and potentially reduce costs compared to in-center treatments, adoption remains low, comprising less than 10% of dialysis patients in the United States as of 2023.[](https://www.renalandurologynews.com/news/home-dialysis-hampered-by-barriers-despite-financial-incentives/) Patient-level fears represent a primary obstacle, with surveys indicating that fear of self-performing dialysisâ€”particularly self-cannulation for home hemodialysisâ€”and concerns over handling medical emergencies at home rank as the top barriers cited by patients and caregivers.[](https://www.ajkd.org/article/S0272-6386%2824%2900790-X/fulltext) These apprehensions are compounded by inadequate home space for equipment and supplies, which affects up to 20-30% of potential candidates in urban or low-income settings.[](https://ldi.upenn.edu/our-work/research-updates/6-major-barriers-that-stop-patients-from-doing-home-dialysis/)\n\nCaregiver and family burden further deters uptake, as home dialysis often requires assistance from relatives, imposing physical, emotional, and time demands that many households cannot sustain without support.[](https://onlinelibrary.wiley.com/doi/10.1111/hdi.13213?af=R) Qualitative studies highlight psychosocial factors, including patients' physical limitations, cognitive impairments, and negative attitudes toward self-management, which systematically exclude frail or elderly individuals despite their potential eligibility.[](https://www.kidney.org/sites/default/files/v36a_a1.pdf) Deficient patient education exacerbates these issues; providers report that insufficient training programs and low awareness of home options lead patients to default to familiar in-center care, where professional oversight alleviates perceived risks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12531936/)\n\nFrom a systemic perspective, reimbursement structures fail to adequately cover home modifications, ongoing support visits, or caregiver respite, even following policy incentives like the U.S. Advancing American Kidney Health Initiative launched in 2019, which aimed to boost home dialysis to 80% of new patients by 2025 but has seen limited progress.[](https://www.renalandurologynews.com/news/home-dialysis-hampered-by-barriers-despite-financial-incentives/) [](https://www.ajkd.org/article/S0272-6386%2824%2900790-X/fulltext) Economic disparities amplify this, with socioeconomically disadvantaged patients facing upfront costs for home setups and supply storage that in-center dialysis avoids, particularly in peritoneal dialysis where modality-specific infrastructure demands strain low-resource environments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9161798/) Providers also cite operational hurdles, such as the scarcity of dedicated home dialysis clinics with transitional care units, which are essential for initial training but absent in many regions.[](https://www.mdpi.com/2673-8236/5/2/18)\n\nIn Europe and other regions, policy fragmentation contributes to inequities, with home dialysis often restricted to patients with high autonomy and financial stability, sidelining broader implementation despite modifiable barriers like standardized training protocols.[](https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04188-y) [](https://academic.oup.com/ckj/article/17/7/sfae180/7705608) Addressing these requires targeted interventions, including enhanced financial alignments and education, though entrenched provider preferences for in-center modelsâ€”driven by revenue stabilityâ€”persist as unaddressed incentives.[](https://www.sciencedirect.com/science/article/abs/pii/S0272638611011437)\n\n## Future Directions\n\n### Technological Innovations\n\nEfforts to develop wearable artificial kidneys focus on enhancing patient mobility and enabling more frequent, continuous treatment to mimic natural renal function. Devices like the Automated Wearable Artificial Kidney (AWAK) for peritoneal dialysis regenerate dialysate using sorbent technology, reducing fluid volume requirements and allowing ambulatory use under clothing, with prototypes demonstrating feasibility in preclinical models as of 2023.[](https://www.sciencedirect.com/science/article/pii/S0272638625000538) Similarly, Seoul National University researchers advanced a portable peritoneal dialysis system in April 2025 that continuously purifies and reinfuses dialysate, potentially enabling home-based, water-efficient therapy without large infrastructure.[](https://www.eurekalert.org/news-releases/1079258) These innovations address limitations of stationary hemodialysis by prioritizing dialysate regeneration and miniaturization, though clinical trials remain ongoing to validate long-term efficacy and biocompatibility.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7812841/)\n\nBioartificial kidneys represent a paradigm shift toward implantable devices integrating synthetic filtration with living cellular components for autonomous waste removal and metabolic regulation. The Kidney Project at the University of California, San Francisco, develops a silicon nanopore membrane-based hemofilter paired with a bioreactor of human renal tubule cells, aiming for 24/7 implantation without immunosuppression or anticoagulation; prototypes achieved proof-of-concept filtration in large animal models by 2023, earning a $1 million KidneyX prize in 2023 for milestone advancements.[](https://pharm.ucsf.edu/kidney/device) The Implantable Bio-Artificial Kidney (iBAK), a soda-can-sized device with porcine renal cells, supports continuous ultrafiltration and reabsorption, with preclinical data from 2023 indicating stable function without dialysis dependency in animal studies.[](https://www.kidneyx.org/prize-winners/implantable-bioartificial-kidney/) These hybrid approaches leverage tissue engineering to restore endocrine functions absent in conventional dialysis, but human trials are pending resolution of immune rejection and scaling challenges.[](https://www.kidney.org/news-stories/future-artificial-kidneys)\n\nIntegration of artificial intelligence (AI) and machine learning promises precision dialysis through predictive analytics and automated adjustments. Machine learning models trained on intradialytic data predict hypotension episodes with high accuracy, enabling preemptive interventions to reduce cardiovascular risks during sessions, as demonstrated in systematic reviews of studies up to 2024.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11344373/) AI-driven systems analyze real-time patient metrics like fluid status and urea levels to optimize dose adequacy, outperforming traditional Kt/V metrics in retrospective datasets from 2021 onward.[](https://www.nature.com/articles/s41598-021-94964-1) Future smart dialyzers could incorporate AI for personalized regimens, learning from aggregated treatment data to minimize complications, though validation requires prospective trials to confirm causality beyond correlations.[](https://www.sciencedirect.com/science/article/pii/S2590059524000797)\n\nNanotechnology enhances hemodialysis membranes by improving selectivity, antifouling, and biocompatibility. Incorporation of nanoparticles, such as gold or graphene oxide, into polymeric matrices boosts permeability for middle-molecule clearance while preventing protein adsorption and bacterial adhesion, with lab-tested membranes showing up to 50% higher flux without albumin loss as of 2021-2023 studies.[](https://www.sciencedirect.com/science/article/abs/pii/S1383586625023159) Nano-porous alumina membranes exhibit superior solute rejection and hemocompatibility compared to polysulfone standards, enabling efficient uremic toxin removal in ex vivo setups reported in 2009 but refined in recent nanocomposites.[](https://pubmed.ncbi.nlm.nih.gov/19293709/) These modifications support compact, high-efficiency filters for wearable applications, yet biocompatibility in chronic human use demands further randomized evidence to mitigate potential nanoparticle leaching risks.[](https://www.tandfonline.com/doi/full/10.1080/15583724.2025.2512945)\n\n### Research and Potential Breakthroughs\n\nOngoing research into kidney dialysis focuses on developing implantable and bioartificial kidneys to replace conventional hemodialysis and peritoneal dialysis, aiming to restore natural filtration without frequent sessions or vascular access complications. The Kidney Project, a collaboration between UCSF and Vanderbilt University, is advancing a bioartificial kidney that integrates silicon nanopore membranes for glomerular filtration and living kidney cells for bioactivity, with preclinical large-animal studies demonstrating sustained function as of 2024.[](https://www.kidney.org/news-stories/future-artificial-kidneys) Similarly, UCLA's Implantable Artificial Kidney program is engineering a waterless, dialysis-free device mimicking the renal glomerulus using silicon nanopore technology, which filters blood continuously without anticoagulants or pumps, supported by National Institutes of Health funding and entering advanced prototyping in 2023.[](https://www.uclahealth.org/medical-services/nephrology/clinical-programs/implantable-artificial-kidney) These efforts address dialysis limitations like infection risks and poor quality of life, with projections for human trials in the late 2020s if biocompatibility hurdles are overcome.[](https://www.preprints.org/manuscript/202505.1959/v1)\n\nWearable and portable dialysis devices represent nearer-term innovations to enhance mobility and reduce clinic dependence. Devices like the Wearable Artificial Kidney (WAK), weighing about 2 kg and belt-mounted, perform sorbent-based hemodialysis using body fluids for regeneration, enabling continuous treatment with lower fluid volumes than standard machines; clinical trials in 2023-2024 confirmed safety and efficacy in small cohorts, though energy efficiency and membrane durability remain challenges.[](https://journals.lww.com/imna/fulltext/2024/06000/wearable_artificial_kidneys__the_first_choice_for.9.aspx) Next-generation peritoneal dialysis systems, such as automated portable cyclers with sorbent technology, are under development to minimize dialysate use and infrastructure needs, with European prototypes tested in 2025 showing improved ultrafiltration rates.[](https://www.kidney.org.uk/news/kidney-technologies-on-the-horizon) These technologies could expand home-based therapy, potentially lowering costsâ€”estimated at $90,000 annually per patient for in-center dialysisâ€”and cardiovascular strain from intermittent treatment, per modeling from the National Kidney Foundation.[](https://www.kidney.org/news-stories/dream-starting-to-come-true-wearable-kidneys)\n\nRegenerative approaches, including stem cell and cell therapies, seek to repair kidney tissue and delay or obviate dialysis initiation. Mesenchymal stem cell infusions have shown promise in preclinical models for reducing inflammation and fibrosis in chronic kidney disease (CKD), with a 2024 review indicating improved glomerular filtration rates in rodent acute kidney injury studies, though human translation is limited by engraftment issues.[](https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01751-2) A phase 1/2 trial launched by UC Davis Health in April 2025 tests allogeneic cell therapy in type 2 diabetes-associated CKD patients on or nearing dialysis, aiming to restore tubular function via paracrine effects; early data from similar mesenchymal trials report stabilized creatinine levels in 30-50% of participants after 12 months.[](https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04) Bioengineered kidney organoids from induced pluripotent stem cells offer platforms for disease modeling and potential transplantation, but scalability and vascularization barriers persist, with no clinical dialysis-alternative applications as of 2025.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11669058/) These therapies complement dialysis by targeting underlying pathology, yet experts emphasize the need for randomized controlled trials to validate long-term outcomes amid risks like immune rejection.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1619291/full)\n\nIntegration of precision medicine, such as biomarkers like suPAR for predicting dialysis need, is accelerating through omics research, with NIH-funded studies in 2024-2025 identifying genetic variants influencing dialysis response to guide personalized regimens.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/) While xenotransplantation trials, including genetically modified pig kidneys sustaining function in brain-dead humans for over 60 days in 2023, primarily target transplantation, they indirectly inform bioartificial designs by validating cross-species compatibility.[](https://www.uab.edu/news/health-medicine/new-study-pig-kidneys-for-the-first-time-demonstrate-life-sustaining-kidney-function-in-a-human) Overall, these advancements could transform end-stage renal disease management by 2050, potentially halving reliance on chronic dialysis through hybrid renal replacement therapies, contingent on regulatory approval and equitable access.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998293/)"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887036795,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Dialysis - hemodialysis: MedlinePlus Medical Encyclopedia\",\"description\":\"Mar 31, 2024 Â· Dialysis treats end-stage kidney disease also called kidney failure. It removes waste from your blood when your kidneys can no longer do their job.\",\"url\":\"https://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000707.htm\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Hemodialysis - NIDDK\",\"description\":\"Hemodialysis is a treatment to filter wastes and water from your blood, as your kidneys did when they were healthy.\",\"url\":\"https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"In brief: How does dialysis work? - InformedHealth.org - NCBI - NIH\",\"description\":\"Mar 8, 2018 Â· The two main types of dialysis are hemodialysis and peritoneal dialysis. Go to: What is diffusion? In order to understand what diffusion is, itÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK492981/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Hemodialysis | Peritoneal dialysis - MedlinePlus\",\"description\":\"May 7, 2018 Â· Hemodialysis and Peritoneal Dialysis are two types of dialysis that filter your blood to rid your body of harmful waste.\",\"url\":\"https://www.nlm.nih.gov/medlineplus/dialysis.html\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Dialysis Modalities for the Treatment of End-Stage Kidney Disease ...\",\"description\":\"Hemodialysis (HD) and peritoneal dialysis (PD) are the two main types of dialysis provided under Canadian kidney care programs.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK532006/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Hemodialysis - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"There are three primary types of dialysis: hemodialysis, peritoneal dialysis, and hemofiltration. ... The patient care technician performs the dialysis treatmentÂ ...Introduction Â· Equipment Â· Technique or Treatment Â· Complications\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK563296/\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Peritoneal Dialysis - NIDDK\",\"description\":\"Peritoneal dialysis is a treatment for kidney failure that uses the lining of your abdomen, or belly, to filter your blood inside your body.\",\"url\":\"https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/peritoneal-dialysis\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Dr. Willem Kolff: The Father of the Artificial Kidney - PMC - NIH\",\"description\":\"Sep 10, 2024 Â· Kolff's introduction of dialysis in 1943 marks the dawn of modern nephrology. Keywords: artificial kidney, general nephrology dialysis andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11466315/\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"KOLFF, WILLEM J. | Encyclopedia of Cleveland History\",\"description\":\"During the 1950s, Kolff developed the twin-coil kidney (TCK) and patented it in 1955 through Baxter Travenol. This invention was revolutionary as it was theÂ ...\",\"url\":\"https://case.edu/ech/articles/k/kolff-willem-j\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"End-Stage Renal Disease - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Jun 22, 2025 Â· The 5-year survival rate for a patient undergoing long-term dialysis in the US is approximately 35% and about 25% in patients with diabetes. GoÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK499861/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"The Hemodialysis Access Surveillance Controversy Continues - PMC\",\"description\":\"Oct 2, 2020 Â· The dialysis access complications account for 12% to 25% of hospital admissions. More importantly, a dysfunctional vascular access remains aÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7529591/\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Medicare Costs Associated With Arteriovenous Fistulas Among US ...\",\"description\":\"Mar 28, 2018 Â· Thus, vascular access management in patients with ESRD costs an estimated $5 billion annually in total direct expenditures by public and privateÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2818%2930124-0/fulltext\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Dialysis: A Review of the Mechanisms Underlying Complications in ...\",\"description\":\"There are two types of dialysis procedures; it may be hemodialysis (using a machine/artificial kidney-like apparatus) or peritoneal dialysis (using aÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5654453/\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Ultrafiltration - National Kidney Foundation\",\"description\":\"Ultrafiltration is the process of removing fluid from the body during dialysis. It helps achieve target dry weight by removing excess fluid safely.\",\"url\":\"https://www.kidney.org/kidney-topics/ultrafiltration\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Countercurrent Flow - an overview | ScienceDirect Topics\",\"description\":\"Dialysis is a diffusive process that also requires a semipermeable membrane to separate blood from an aqueous solution (called dialysate). This semipermeableÂ ...\",\"url\":\"https://www.sciencedirect.com/topics/nursing-and-health-professions/countercurrent-flow\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Dialysate Composition for Hemodialysis: Changes and Changing Risk\",\"description\":\"Jan 8, 2017 Â· In this review, we examine the current epidemiological evidence guiding selection of dialysate bicarbonate, calcium, magnesium and potassium.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7645386/\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Optimal composition of the dialysate, with emphasis on its influence ...\",\"description\":\"The usual average dialysate concentration is 35 mmol/l, obtained from proportioning dialysis stations that mix bicarbonate from solution or dry powder to waterÂ ...\",\"url\":\"https://academic.oup.com/ndt/article/19/4/785/1810632\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Peritoneal Dialysis Fluid - an overview | ScienceDirect Topics\",\"description\":\"PD solutions all have the following approximate electrolyte composition: sodium 132 meq/L; chloride 95 to 105 meq/L; calcium 2.5 to 3.5 meq/L; and magnesium 0.5Â ...\",\"url\":\"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/peritoneal-dialysis-fluid\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Diffusion as a mechanism of solute removal - Deranged Physiology\",\"description\":\"Dec 18, 2023 Â· Diffusion is the transport of solute across a membrane, along a concentration gradient. This is how small molecules are cleared during haemodialysis.\",\"url\":\"https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-111/diffusion-mechanism-solute-removal\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"The History of Dialysis | DaVita\",\"description\":\"Dr. Willem Kolff is considered the father of dialysis. This young Dutch physician constructed the first dialyzer (artificial kidney) in 1943.\",\"url\":\"https://davita.com/treatment-options/articles/the-history-of-dialysis/\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"History of Innovation - Nephrology - University of Washington\",\"description\":\"With the creation of the Scribner Shunt, ongoing dialysis treatment became a reality, and patients with chronic kidney disease could live with the disease.\",\"url\":\"https://nephrology.uw.edu/about/history\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"The scientific principles and technological determinants of ...\",\"description\":\"Dec 27, 2021 Â· In haemodialysis (HD), the semipermeable membrane is in a tubular geometry in the form of miniscule pipes (hollow fibres) and separationÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8711766/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"The Impact of Hemodialysis Frequency and Duration on Blood ...\",\"description\":\"Sep 2, 2017 Â· According to the 2015 US Renal Data System Annual Data Report, in 2014, 87.9% of all incident cases began renal replacement therapy withÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5618180/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Hemodialysis Vascular Access: Core Curriculum 2025\",\"description\":\"Dec 3, 2024 Â· This Core Curriculum reviews the major forms of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter)\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2824%2900976-4/fulltext\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Types of Arteriovenous Fistulas - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"There are multiple types of arteriovenous (AV) hemodialysis access, though autogenous AV access has higher patency rates, a lower risk of complications.Continuing Education Activity Â· Indications Â· Technique or Treatment Â· Complications\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK493195/\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"Arteriovenous Access for Hemodialysis: A Review - JAMA Network\",\"description\":\"Mar 18, 2024 Â· Autogenous arteriovenous fistulas require 3 to 6 months to mature, whereas standard arteriovenous grafts can be used 2 to 4 weeks after beingÂ ...\",\"url\":\"https://jamanetwork.com/journals/jama/article-abstract/2816266\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"Hemodialysis Access | Fistula, Graft, \u0026 Catheter National Kidney ...\",\"description\":\"Hemodialysis access is a way to reach the blood for dialysis. Types include fistula, graft, and catheter. Care includes hygiene and checking for problems.\",\"url\":\"https://www.kidney.org/kidney-topics/hemodialysis-access\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Frequency, predictors and outcomes of intradialytic complications in ...\",\"description\":\"Raja SM, et al reported the frequency of intradialytic complications to be around 30%whereby hypotension was the most common complications [12]. Halle MP, et alÂ ...\",\"url\":\"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300823\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Long Interdialytic Interval and Mortality among Patients Receiving ...\",\"description\":\"Sep 22, 2011 Â· The rate of cardiac arrest was 7 per 100,000 hemodialysis sessions, equivalent to 1.1 per 100 person-years with a typical thrice-weeklyÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa1103313\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Extended-hours hemodialysis is associated with lower mortality risk ...\",\"description\":\"The average treatment time per session for extended-hours hemodialysis was 399 minutes compared to 211 minutes for conventional therapy. The crude mortalityÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0085253816303222\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Survival on four compared with three times per week haemodialysis ...\",\"description\":\"Dec 28, 2020 Â· Observational data suggest that 3Ã—WHD with a longer session length is associated with improved overall survival, but increases in mortalityÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/14/2/665/6054266\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Peritoneal Dialysis - StatPearls - NCBI Bookshelf\",\"description\":\"Both surgical and percutaneous procedures have low complication rates when performed by experienced operators. Obese patients who have had previous abdominalÂ ...Missing:  efficacy | Show results with:efficacy\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK532979/\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Peritoneal dialysis - National Kidney Foundation\",\"description\":\"Peritoneal dialysis uses the lining of your belly to filter blood when kidneys fail. Learn about the process, types, pros and cons, and payment options.Missing:  principles efficacy\",\"url\":\"https://www.kidney.org/kidney-topics/peritoneal-dialysis\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"\",\"description\":\"\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39675379/\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Long-term mortality and technique survival in peritoneal dialysis ...\",\"description\":\"Jul 8, 2025 Â· A total of 204 patients (41%) transitioned from PD to HD, 137 patients (27.5%) died, 92 (18.5%) received kidney transplant and 64 (13%) remainedÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/18/8/sfaf215/8193697\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Comparing Mortality of Peritoneal and Hemodialysis Patients in an ...\",\"description\":\"Crude 2-year mortality was 27.6% for patients dialyzing via HD and 16.7% for patients on PD. In adjusted models, there was no evidence of mortality differencesÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7855236/\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Mortality of Peritoneal Dialysis versus Hemodialysis in Older Adults\",\"description\":\"Feb 7, 2024 Â· Pooled analysis showed that PD had a higher mortality rate than HD in older dialysis population (HR 1.17, 95% CI: 1.10â€“1.25). When stratified byÂ ...Abstract Â· Introduction Â· Results Â· Discussion\",\"url\":\"https://karger.com/ger/article/70/5/461/896692/Mortality-of-Peritoneal-Dialysis-versus\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Patient survival and maintenance dialysis - UpToDate\",\"description\":\"Aug 5, 2025 Â· After initiation of maintenance hemodialysis or peritoneal dialysis, the five-year survival rate is approximately 40 percent [2]. HoweverÂ ...\",\"url\":\"https://www.uptodate.com/contents/patient-survival-and-maintenance-dialysis\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Continuous Renal Replacement Therapy - StatPearls - NCBI - NIH\",\"description\":\"Mar 10, 2024 Â· CRRT comprises techniques that manage solute removal and fluid balance over 24 hours. CRRT filters blood through a semipermeable membrane using various soluteÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK556028/\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Continuous Kidney Replacement Therapies: Core Curriculum 2025\",\"description\":\"Mar 9, 2025 Â· Continuous KRT (CKRT) is used across many ICUs as the therapy of choice for hemodynamically unstable patients with kidney failure. ThoughÂ ...Missing:  evidence- | Show results with:evidence-\",\"url\":\"https://www.ajkd.org/article/S0272-63862401120-X/fulltext\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Continuous Renal Replacement Therapy: Who, When, Why, and How\",\"description\":\"Continuous renal replacement therapy (CRRT) is commonly used to provide renal support for critically ill patients with acute kidney injury.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6435902/\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Continuous Renal Replacement Therapy: What Have We Learned ...\",\"description\":\"Continuous renal replacement therapy (CRRT) is the main extracorporeal kidney support therapy used in critical ill patients in the intensive care unit (ICU)Â ...Missing:  advantages | Show results with:advantages\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0034837625001639\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Intensive care unit continuous kidney replacement therapy - PubMed\",\"description\":\"Oct 17, 2024 Â· The KDIGO AKI clinical guidelines recommend delivering effluent volumes of 20-25 ml/kg/hour for CKRT in the ICU setting, with the caveat that higher prescribedÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39417967/\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"Renal replacement therapy in an intensive care unit: guidelines from ...\",\"description\":\"Jul 16, 2025 Â· RRT should not be initiated before 72 h in adults with AKI classified as KDIGO 3 in the absence of emergency criteria (e.g., hyperkalemia,Â ...Question 1 Â· Question 2 Â· Question 4\",\"url\":\"https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-025-01517-0\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Efficacy of Continuous Renal Replacement Therapy and Intermittent ...\",\"description\":\"Apr 17, 2023 Â· The results of meta-analysis showed that the length of in-hospital stay was significantly shorter in the CRRT group than that of the IHDÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10125730/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Comparing Renal Replacement Therapy Modalities in Critically Ill ...\",\"description\":\"The results of this network meta-analysis suggest there is no difference in mortality between continuous renal replacement therapy and intermittent hemodialysisÂ ...\",\"url\":\"https://journals.lww.com/ccejournal/fulltext/2021/05000/comparing_renal_replacement_therapy_modalities_in.3.aspx\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Study protocol and statistical plan for the ICRAKI trial\",\"description\":\"The ICRAKI trial will inform the choice of RRT modalities in critically ill patients with severe AKI. More than 300 patients were already included.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1441277225000110\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"A wearable artificial kidney for patients with end-stage renal disease\",\"description\":\"We conducted a FDA-approved human trial of a wearable artificial kidney, a miniaturized, wearable hemodialysis machine, based on dialysate-regenerating sorbentÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/27398407/\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Primary Clinical Evaluation of Wearable Filtrating Artificial Kidney ...\",\"description\":\"Jun 15, 2023 Â· The purpose of this study is to evaluation of the precision, security, and operability of wearable filtrating artificial kidney device for on-Â ...\",\"url\":\"https://clinicaltrials.gov/study/NCT05906355\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Device and Research Â· The Kidney Project Â· UCSF\",\"description\":\"The bioartificial kidney is a compact, surgically implanted, free-standing device to treat kidney failure. It performs the vast majority of the biologicalÂ ...Frequently Asked Questions... Â· Development Plan Â· Selected Publications\",\"url\":\"https://pharm.ucsf.edu/kidney/device\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Cell therapy, new PD devices, bioartificial kidneys set a new ... - Healio\",\"description\":\"Oct 14, 2024 Â· In 2023, the Kidney Project was awarded a $1 million Artificial Kidney Prize from KidneyX for advancing its prototype bioartificial kidney ...\",\"url\":\"https://www.healio.com/news/nephrology/20241008/cell-therapy-new-pd-devices-bioartificial-kidneys-set-a-new-direction-for-kidney-care\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Implantable Artificial Kidney - Nephrology - UCLA Health\",\"description\":\"In approximately two years we anticipate having completed the proof-of-concept phase of animal testing in preparation for the FDA and clinical trials. The novelÂ ...\",\"url\":\"https://www.uclahealth.org/medical-services/nephrology/clinical-programs/implantable-artificial-kidney\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"A Narrative Review of an Emerging Dialysis Modality - PMC\",\"description\":\"Sep 3, 2025 Â· Intermittent infusion hemodiafiltration (I-HDF) is an emerging, hybrid dialysis technique that combines standard hemodialysis with the cyclicÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12474070/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Portable, wearable and implantable artificial kidney systems - Nature\",\"description\":\"Jun 5, 2023 Â· The researchers concluded that hollow fibres with a wavy design would outperform those with a flat surface; however, experimental studies shouldÂ ...Missing:  experimental | Show results with:experimental\",\"url\":\"https://www.nature.com/articles/s41581-023-00726-9\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"[PDF] KDIGO Clinical Practice Guideline for Acute Kidney Injury\",\"description\":\"Jul 2, 2012 Â· Acute Dialysis Quality Initiative. AHCPR. Agency for Health Care ... Injury Network (AKIN) criteria and studies on risk relationships.\",\"url\":\"https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"When to start dialysis in patients with acute kidney injury? When ...\",\"description\":\"Initiating dialysis in AKI should be based on clinical criteria and not on serum creatinine or another serum/urine-based biomarker.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3387587/\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Timing of Initiation of Renal-Replacement Therapy in Acute Kidney ...\",\"description\":\"Jul 15, 2020 Â· Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015;41:1411-1423. Go toÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2000741\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Timing of Renal-Replacement Therapy in Patients with Acute Kidney ...\",\"description\":\"Oct 10, 2018 Â· Renal-Replacement Therapy for AKI ... Acute kidney injury is a frequent complication in patients hospitalized in the intensive care unit (ICU) forÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa1803213\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Acute kidney injury, when to dialyze - NephJC\",\"description\":\"May 27, 2016 Â· BUN \u003e 112 mg/dL Â· Potassium \u003e 6 mmol/L (or \u003e 5.5 despite medical treatment) Â· pH \u003c 7.15 with either PaCO2 \u003c 35 mm Hg or PaCO2 \u003e 50 mm Hg withoutÂ ...\",\"url\":\"http://www.nephjc.com/news/2016/5/26/acute-kidney-injury-when-to-dialyze\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"When to start a renal replacement therapy in acute kidney injury (AKI ...\",\"description\":\"In the JAMA study, indications to start RRT were: KDIGO stage 2; plasma neutrophil gelatinase-associated lipocalin (NGAL) \u003e150 ng/mL; one of the following:Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5066036/\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"When to start renal replacement therapy in acute kidney injury - NIH\",\"description\":\"Mar 7, 2024 Â· ... Research Investigating Biomarker Endpoints AKI ... Delayed versus early initiation of renal replacement therapy for severe acute kidney injuryÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11258500/\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Timing of Renal Replacement Therapy for Severe Acute Kidney ...\",\"description\":\"Oct 11, 2018 Â· Acute kidney injury (AKI) affects many ICU patients and is responsible for increased morbidity and mortality. Although lifesaving in manyÂ ...\",\"url\":\"https://www.atsjournals.org/doi/full/10.1164/rccm.201810-1906CP\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"When to start dialysis: updated guidance following publication of the ...\",\"description\":\"May 5, 2011 Â· Dialysis should be instituted whenever the glomerular filtration rate (GFR) is \u003c15 mL/min and there is one or more of the following: symptoms orÂ ...Introduction Â· The IDEAL study Â· Other studies published since...\",\"url\":\"https://academic.oup.com/ndt/article/26/7/2082/1896753\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Timing of Dialysis Initiation - What Has Changed Since IDEAL? - PMC\",\"description\":\"With the intent-to-defer strategy, patients with an eGFR of less than 15 mL/ min per 1.73 m2 are monitored closely by a nephrologist, and dialysis is initiatedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5407409/\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"When to initiate dialysis for end-stage kidney disease - PubMed\",\"description\":\"Sep 17, 2018 Â· It is suggested that in asymptomatic patients with stage 5 chronic kidney disease, dialysis may be safely delayed until the eGFR is at least as low as 5-7 mL/Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/30208820/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"[PDF] Dialysis initiation, modality choice, access, and prescription - KDIGO\",\"description\":\"Apr 13, 2019 Â· Recommendations for â€œtimely referralâ€ to a nephrologist, particularly for access creation, are mostly based on time to dialysisâ€”for example, 6Â ...\",\"url\":\"https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Dialysis-Initiation-conf-report-FINAL.pdf\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"[PDF] KDOQI Clinical Practice Guideline Hemodialysis Update\",\"description\":\"First, there is no compelling evidence that initiation of dialysis based solely on measurement of kidney function leads to improvement in clinical outcomes,Â ...\",\"url\":\"https://www.kidney.org/sites/default/files/KDOQI-Clinical-Practice-Guideline-Hemodialysis-Update_Public-Review-Draft-FINAL_20150204.pdf\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"News - When Should I Start Dialysis? | National Kidney Foundation\",\"description\":\"Once dialysis or transplantation is felt to be necessary, this is called End Stage Renal Disease (ESRD). If your eGFR is less than 20, you can be evaluated andÂ ...\",\"url\":\"https://www.kidney.org/news-when-should-i-start-dialysis\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"An update on absolute and relative indications for dialysis treatment ...\",\"description\":\"Sep 13, 2023 Â· Absolute contraindications are uncommon and, in most cases, where modality prejudice exists, e.g. obesity, Adult Polycystic Kidney Disease, andÂ ...\",\"url\":\"https://doi.org/10.1093/ckj/sfad062\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"End-Stage Renal Disease: Medical Management - AAFP\",\"description\":\"End-stage renal disease (ESRD) is when kidney function is no longer adequate for long-term survival without kidney transplantation or dialysis.\",\"url\":\"https://www.aafp.org/pubs/afp/issues/2021/1100/p493.html\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Conservative Care for Kidney Failureâ€”The Other Side of the Coin\",\"description\":\"Mar 14, 2022 Â· In reality, dialysis is viewed as the default treatment for kidney failure, and the option to forgo dialysis treatment is often not explicitlyÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790050\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Survival of patients who opt for dialysis versus conservative care - NIH\",\"description\":\"Patients opting for dialysis have an overall lower mortality risk compared with patients opting for CC. However, a high risk of bias and heterogeneous reportingÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9317173/\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"Conservative Kidney Management Versus Dialysis Initiation\",\"description\":\"Dec 28, 2020 Â· Overall, this study confirms that among patients who opt for dialysis over conservative management, dialysis works: those selecting dialysis onÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.kidneymedicinejournal.org/article/S2590-0595%2820%2930268-5/fulltext\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Does conservative kidney management offer a quantity or quality of ...\",\"description\":\"Sep 11, 2021 Â· In general, patients with CKD5 who have chosen or are on CKM live for a shorter time than patients who have chosen or are on dialysis.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02516-6\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Using Conservative Management as an Alternative to Dialysis for ...\",\"description\":\"â€œResearch shows that conservative management may be comparable to dialysis in terms of outcomes, but with a different quality of life,â€ says Dr. Koncicki,Â ...\",\"url\":\"https://reports.mountsinai.org/article/neph2021-04-conservative-management-of-esrd\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"End-Stage Renal Disease in the Elderly: Dialysis or Conservative ...\",\"description\":\"May 3, 2022 Â· Patients choosing dialysis were younger compared with those opting for conservative management and were less functionally impaired. Survival wasÂ ...\",\"url\":\"https://academic.oup.com/ndt/article/37/Supplement_3/gfac071.013/6578311\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Conservative Management in End-Stage Kidney Disease between ...\",\"description\":\"Dec 21, 2023 Â· Both CM and dialysis remain valid alternatives in the management of ESKD. However, assessing comorbidities, disabilities, and social contextÂ ...\",\"url\":\"https://www.mdpi.com/2077-0383/13/1/41\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Conservative Kidney Management Practice Patterns and Resources ...\",\"description\":\"This study is a cross-sectional analysis of data from US nephrology clinics enrolled in the chronic kidney disease Outcomes and Practice Patterns Study (CKDopps)Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2590059523001449\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"KDOQI 2019 Vascular Access Guidelines: What Is New - PMC\",\"description\":\"The targets focus on the patient and the key complications associated with the use of AV access (AVF and AVG) and CVC ( Table 3 ). The second target isÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8856770/\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Peritoneal dialysis catheter placement technique and complications\",\"description\":\"This review describes the peritoneal dialysis (PD) catheter implantation techniques for the treatment of PD.Missing:  kdigo. | Show results with:kdigo.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4421142/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Renal Association Clinical Practice Guideline on Haemodialysis\",\"description\":\"Oct 17, 2019 Â· It aims to provide guidance on how to look after patients and how to run dialysis units, and provides standards which units should in general aim to achieve.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1527-3\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Renal Association Clinical Practice Guideline on peritoneal dialysis ...\",\"description\":\"We recommend that peritoneal membrane function should be monitored regularly (6 weeks after commencing treatment and at least annually or when clinicallyÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5691857/\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Choosing Dialysis: Which type is right for me?\",\"description\":\"There are 3 main types of dialysis: in-center hemodialysis, home hemodialysis, and peritoneal dialysis. Learn the pros and cons of each treatment.\",\"url\":\"https://www.kidney.org/kidney-topics/choosing-dialysis-which-type-right-me\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Home Hemodialysis and Peritoneal Dialysis\",\"description\":\"Needs a caregiver at least for the duration of dialysis 5-6 times a week Â· Higher commitment compared to hemodialysis Â· Need to weave into lifestyle Â· NeedsÂ ...\",\"url\":\"https://nephrology.medicine.ufl.edu/patient-care/renal-replacement-therpay/home-dialysis/\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Patient Survival With Extended Home Hemodialysis Compared to In ...\",\"description\":\"These results indicate that extended HHD is associated with higher survival and better outcomes compared to ICHD.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2468024923014845\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Peritoneal dialysis versus hemodialysis: risks, benefits, and access ...\",\"description\":\"The survival advantage of PD continues for 1.5-2 years but, over time, the risk of death with PD equals or becomes greater than with in-center HD, depending onÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/22098661/\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Survival Comparisons of Home Dialysis Versus In-Center ... - NIH\",\"description\":\"Jul 13, 2019 Â· Many observational studies have demonstrated a survival benefit with home dialysis compared with in-center dialysis; however, results have been conflicting.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6628511/\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Home dialysis the advantages - National Kidney Federation\",\"description\":\"Mar 27, 2019 Â· Home haemodialysis patients can save up to 52 days per year, with less dialysis recovery time, time spent travelling to the centre and waitingÂ ...\",\"url\":\"https://www.kidney.org.uk/home-dialysis-the-advantages\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"[PDF] Comparative Effectiveness of Home-based Kidney Dialysis versus In ...\",\"description\":\"Mixed results were reported for quality of life outcomes including mental and physical health components, quality of life utilities, and life participationÂ ...\",\"url\":\"https://www.hsrd.research.va.gov/publications/esp/kidney-dialysis-REPORT.pdf\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"The Cost-Effectiveness of Initiating Patients on Home Dialysis ...\",\"description\":\"May 25, 2025 Â· Home dialysis therapy (HDT) has an 82% probability of being cost-effective. Alleviating staff capacity stresses and implementing qualityÂ ...\",\"url\":\"https://link.springer.com/article/10.1007/s40258-025-00976-7\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Home hemodialysis technique survival: insights and challenges\",\"description\":\"Jul 11, 2023 Â· Home hemodialysis (HHD) offers several clinical, quality of life and cost-saving benefits for patients with end-stage kidney disease.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03264-5\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"6. Mortality - Annual Data Report | USRDS\",\"description\":\"Survival probabilities over 5 years by year of ESRD onset, stratified by dialysis modality or by kidney transplant source (living versus deceased donor kidney)Â ...\",\"url\":\"https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Statistics Â· The Kidney Project Â· UCSF\",\"description\":\"After one year of treatment, those on dialysis have a 15-20% mortality rate, with a 5-year survival rate of under 50%. ... 2018 USRDS annual data report:Â ...\",\"url\":\"https://pharm.ucsf.edu/kidney/need/statistics\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Comparison of survival outcomes in haemodialysis versus ... - PubMed\",\"description\":\"Long-term survival rates were comparable between ISPD and HD groups. The survival benefit was more pronounced in the non-diabetic population.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39675379\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Outcomes of Initiating Peritoneal Dialysis versus Hemodialysis ... - NIH\",\"description\":\"Thirty patients (29.1%) in the hemodialysis group and 25 (20.8%) in the PD group died at 90 days (risk difference, 8.3%; 95% confidence interval [CI], 3.1 toÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12407124/\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Chronic kidney disease and the global public health agenda - Nature\",\"description\":\"Apr 3, 2024 Â· Even in HICs, 15â€“20% of patients die within 12 months of starting dialysis. Millions more develop kidney failure and require KRT but lack accessÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.nature.com/articles/s41581-024-00820-6\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Quality of Life and Complications Among Hemodialysis Patients\",\"description\":\"Oct 8, 2024 Â· The average QoL score for HD patients was lower than that of healthy individuals. There was a statistically significant relationship betweenÂ ...\",\"url\":\"https://www.cureus.com/articles/205740-quality-of-life-and-complications-among-hemodialysis-patients\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Quality of life trajectories for different dialysis modalitiesâ€”a ...\",\"description\":\"Dec 20, 2024 Â· Our aim was to compare longitudinal changes in health-related physical and mental quality of life between patients on institutional hemodialysis (IHD),Â ...Missing:  peer- | Show results with:peer-\",\"url\":\"https://academic.oup.com/ckj/article/18/2/sfae420/7929882\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Better Quality of Life of Peritoneal Dialysis compared to ... - Nature\",\"description\":\"Jul 16, 2019 Â· Both patients on HD and PD experienced significant decreases in different HRQOL domains over two years and the degree of changes in HRQOL overÂ ...\",\"url\":\"https://www.nature.com/articles/s41598-019-46744-1\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Patient-focused outcomes after initiation of dialysis for ESRD\",\"description\":\"One-year mortality for ESRD patients initiating dialysis was 33.8%. Functional impairment occurred in 27.1% of patients, while 82.8% of patients requiredÂ ...\",\"url\":\"https://academic.oup.com/ndt/article/38/11/2528/7172141\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"Real experience of young and middle-aged hemodialysis patients\",\"description\":\"Apr 6, 2025 Â· Data show that about 40% ~ 60% of dialysis patients are young and middle-aged. Hemodialysis significantly impacts the daily life andÂ ...\",\"url\":\"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1530465/full\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Hemodialysis or Peritoneal Dialysis, Which Is Better for Patients with ...\",\"description\":\"Nov 30, 2018 Â· Compared with PD, hemodialysis (HD) has a higher dialysis efficacy and better capacity control, but a greater impact on hemodynamics and anÂ ...\",\"url\":\"https://karger.com/kbr/article/43/6/1813/187988/Hemodialysis-or-Peritoneal-Dialysis-Which-Is\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Depression in End-Stage Renal Disease\",\"description\":\"Aug 14, 2020 Â· ... dialysis irrespective of GFR (1). Depression is common in patients with ESRD, with estimated prevalence rates between 20% and 40%, yet it isÂ ...\",\"url\":\"https://www.mypcnow.org/fast-fact/depression-in-end-stage-renal-disease/\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"[PDF] Depression Among Dialysis Patients - National Kidney Foundation\",\"description\":\"Cohen and colleagues reported prevalence of depression among dialysis patients in the United States as 45% (Cohen, Norris, Acquaviva, Peterson, \u0026 Kimmel, 2007).\",\"url\":\"https://www.kidney.org/sites/default/files/v40b_a4.pdf\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Depression and anxiety symptoms among patients receiving ...\",\"description\":\"Dec 31, 2022 Â· Depression and anxiety may be likely to occur among patients undergoing MHD and impact their quality of life.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-022-03051-8\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Anxiety and depression in patients with end-stage renal disease - NIH\",\"description\":\"Mar 12, 2018 Â· 4 Within patients undergoing dialysis, the prevalence rates of depression were found to be 22.8% using clinical interviews (eg, SCID andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5856029/\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Systematic review: kidney transplantation compared with dialysis in ...\",\"description\":\"Individual studies indicate that kidney transplantation is associated with lower mortality and improved quality of life compared with chronic dialysis treatmentÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/21883901/\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Survival for waitlisted kidney failure patients receiving ... - The BMJ\",\"description\":\"Mar 1, 2022 Â· 92% (n=44/48) of studies reported a long term (at least one year) survival benefit associated with transplantation compared with dialysis.\",\"url\":\"https://www.bmj.com/content/376/bmj-2021-068769\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Survival after kidney transplantation compared with ongoing dialysis ...\",\"description\":\"One-year survival rates were comparable between the 2 groups (kidney recipients 94% vs remaining on dialysis 95%); however, after the first year, a clear andÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S1600613523005786\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"Survival Benefit of First Single-Organ Deceased Donor Kidney ...\",\"description\":\"Oct 7, 2022 Â· The findings of this study suggest that kidney transplant prolongs the survival time of persons with kidney failure across all candidate ages and waiting times.\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797181\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Quality of life for kidney transplant recipients and hemodialysis ...\",\"description\":\"Jun 3, 2021 Â· A comparative analysis of survival of patients on dialysis and after kidney transplantation. Clin Kidney J. 2018;11(3):389â€“93. https://doiÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02412-z\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Kidney Transplantation Improves Health-Related Quality of Life in ...\",\"description\":\"Apr 14, 2024 Â· In conclusion, HRQoL is significantly higher among older KTR after kidney transplantation compared to older waitlisted patients.\",\"url\":\"https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12071/full\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Insights Into Health-Related Quality of Life of Kidney Transplant ...\",\"description\":\"Health-related quality of life (HRQoL) after kidney transplantation is notably better than before kidney transplantation and surpasses HRQoL of patients treatedÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2590059525000226\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Survival rates in comprehensive conservative care compared to ...\",\"description\":\"Aug 30, 2024 Â· The higher mortality rate in the comprehensive conservative care group remained significantly higher than in the hemodialysis group amongÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39212241/\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Survival of patients who opt for dialysis versus conservative care\",\"description\":\"This systematic review and meta-analysis aims at comparing survival outcomes between dialysis and CC in studies where patients made an explicit treatment choiceÂ ...\u003c|separator|\u003e\",\"url\":\"https://academic.oup.com/ndt/article-abstract/37/8/1529/6534933\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"The Role of Conservative Kidney Management - CAPC Blog\",\"description\":\"Feb 19, 2025 Â· Studies show that dialysis does not significantly prolong survival in patients with an estimated life expectancy of less than six months. CKMÂ ...\",\"url\":\"https://www.capc.org/blog/rethinking-kidney-care-the-role-of-conservative-kidney-management/\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Long-term Outcomes Among Patients With Advanced Kidney ...\",\"description\":\"Mar 14, 2022 Â· Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? ï»¿ ClinÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790040\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Hemodialysis Complications - American Journal of Kidney Diseases\",\"description\":\"Intradialytic complications. Hypotension. â€¢. Most common acute complication of hemodialysis (incidence, 15% to 30%). â€¢. More common in older patients and womenÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2805%2900436-1/fulltext\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"An update review of intradialytic hypotension: concept, risk factors ...\",\"description\":\"Jul 8, 2020 Â· Intradialytic hypotension (IDH) is a frequent and serious complication of chronic haemodialysis, linked to adverse long-term outcomes.\",\"url\":\"https://academic.oup.com/ckj/article/13/6/981/5868598\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Management of acute intradialytic cardiovascular complications\",\"description\":\"Chronic hemodialysis patients manifest acute cardiovascular complications such as intradialytic hypotension, intradialytic hypertension, arrhythmias, acuteÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7851674/\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Acute Complication during Hemodialysis - IntechOpen\",\"description\":\"The common complications include intradialytic hypotension, hypertension, arrhythmias, muscle cramps, sudden cardiac death, headache, etc.\",\"url\":\"https://www.intechopen.com/chapters/85615\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"Intradialytic complications among patients on twice-weekly ...\",\"description\":\"May 5, 2020 Â· The most commonly associated complications include hypotension, muscle cramps, nausea and vomiting, headache, pruritus, fever and chills.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-020-01806-9\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Hemodialysis Emergencies: Core Curriculum 2021\",\"description\":\"Mar 23, 2021 Â· Patients may present with hypo- tension, tachycardia, muffled heart sounds, and elevated jugular venous pressure.\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2821%2900001-9/pdf\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Updates on Infectious and Other Complications in Peritoneal Dialysis\",\"description\":\"Jul 12, 2023 Â· Infectious Complications. PD-related infections include peritonitis, exit site infections, and tunnel infections. According to the 2022 US RenalÂ ...Infectious Complications Â· Noninfectious Complications Â· Peritoneal Dialysis Catheter...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2823%2900649-2/fulltext\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"Complications of Peritoneal Dialysis Part I - NIH\",\"description\":\"This review covers mechanical complications, including leaks, PD hydrothorax, hernias, dialysate flow problems, PD-related pain, and changes in respiratoryÂ ...Dialysate Leaks Â· Pd Hydrothorax Â· Clinical Presentation And...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11168815/\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"Some Common Complications of Peritoneal Dialysis - Merck Manuals\",\"description\":\"Low blood pressure. Loss of too much fluid and salt during dialysis ; Bleeding. Unintentional perforation of an internal organ during placement of the catheter.\",\"url\":\"https://www.merckmanuals.com/home/multimedia/table/some-common-complications-of-peritoneal-dialysis\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Frequency, predictors and outcomes of intradialytic complications in ...\",\"description\":\"Mar 28, 2025 Â· Most common intra-dialytic complications encountered in patients undergoing maintenance hemodialysis are blood pressure changes (Hypotension andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11952240/\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Cardiovascular disease in dialysis patients - PMC - PubMed Central\",\"description\":\"Oct 3, 2018 Â· Cardiovascular disease (CVD) is a highly common complication and the first cause of death in patients with end-stage renal disease (ESRD) on haemodialysis (HD).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6168816/\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Cardiovascular Disease in Chronic Kidney Disease | Circulation\",\"description\":\"Mar 15, 2021 Â· Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk manifesting as coronary artery disease, heart failure,Â ...\",\"url\":\"https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Pathophysiological concepts and screening of cardiovascular ...\",\"description\":\"Dialysis patients experience 10â€“20 times higher cardiovascular mortality than the general population. The high burden of both conventional and nontraditionalÂ ...\",\"url\":\"https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2023.1198560/full\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - NCBI\",\"description\":\"These disruptions lead to alterations in bone morphology (renal osteodystrophy), vascular calcification, and cardiovascular death in patients with chronicÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK560742/\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"Impact of the serum bone-specific alkaline phosphatase level at the ...\",\"description\":\"Patients undergoing dialysis have significantly higher rates of hospitalization for cardiovascular (CV), cerebrovascular, and peripheral arterial disease (PAD)Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2214762414000140\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Renal Osteodystrophy: Causes, Symptoms \u0026 Treatment\",\"description\":\"Bone damage becomes more severe after kidney failure and long-term dialysis. Symptoms and Causes. What causes renal osteodystrophy? Chronic kidney diseaseÂ ...\",\"url\":\"https://my.clevelandclinic.org/health/diseases/24006-renal-osteodystrophy\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"Clinical and dialysisâ€related characteristics of extremely longâ€term ...\",\"description\":\"Mar 21, 2021 Â· Longâ€term hemodialysis survivors suffer from a number of complications, in particular uremic osteodystrophy and Î²2â€microglobulinâ€associatedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8359961/\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Dialysis - Types, effectiveness, side effects\",\"description\":\"In peritoneal dialysis, your blood is filtered inside your own body instead of using a dialyzer machine. For this type of dialysis, the lining of your abdomenÂ ...Missing:  principles mechanism\",\"url\":\"https://www.kidney.org/kidney-topics/dialysis\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Long-term complications of dialysis: infection - PubMed\",\"description\":\"It is widely accepted that patients with renal failure have an increased risk of infection. Laboratory studies have established defects in cellular immunityÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/8320909/\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"Comparison of Long-term Complications in Patients on ... - NIH\",\"description\":\"The most frequent long-term dialysis complications relate to cardiovascular disease, peripheral neuropathy, parathyroid adenoma, parathroidectomy and acquiredÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4800559/\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"Dialysis More Available Than Patient Education in Counties ... - CDC\",\"description\":\"Aug 15, 2024 Â· Its annual cost in 2021 was estimated at approximately $99,000 per patient for hemodialysis and $87,000 for peritoneal dialysis (8). DSMESÂ ...\",\"url\":\"https://www.cdc.gov/pcd/issues/2024/24_0052.htm\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"Calendar Year 2024 End-Stage Renal Disease (ESRD) Prospective ...\",\"description\":\"Oct 27, 2023 Â· The final CY 2024 ESRD PPS base rate is $271.02, which is an increase of $5.45 to the current CY 2023 base rate of $265.57.\",\"url\":\"https://www.cms.gov/newsroom/fact-sheets/calendar-year-2024-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1782-f\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"The Cost-effectiveness of Peritoneal Dialysis Is Superior to ...\",\"description\":\"The total 10-year average cost of all dialysis (both in-center HD and PD) was $350,774, and PD cost $16,000 less than in-center HD ($336,309 vs $352,712).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7873827/\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"Hemodialysis Versus Peritoneal Dialysis Drug Expenditures\",\"description\":\"Between matched pairs, the average annual injectable dialysis drug expenditures were $20,000 for in-center hemodialysis and $10,000 for PD. (Table 2) ThisÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10344940/\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"A systematic review of the cost-effectiveness of renal replacement ...\",\"description\":\"This study aimed to assess existing cost-effectiveness analyses of dialysis modalities and consider whether the methods applied and results obtained reflectÂ ...Missing:  USRDS | Show results with:USRDS\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10060297/\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Cost-Effectiveness of the Kidney Transplant Compared With ...\",\"description\":\"Jun 18, 2024 Â· Research has shown that compared with dialysis, adult patients who have kidney transplants have lower costs per QALY. Dubai HealthÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2212109925000342\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Healthcare costs after kidney transplantation compared to dialysis ...\",\"description\":\"Jul 3, 2023 Â· The current study indicates a â‚¬72,000 saving in healthcare costs associated with KTx compared to dialysis over the first three years after KTx.\",\"url\":\"https://www.nature.com/articles/s41598-023-37814-6\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"Exploring kidney dialysis costs in the United States: a scoping review\",\"description\":\"The median MA payment for a hemodialysis treatment was $300, 29% higher than the Medicare FFS payment that would be made under the bundled ESRD PPSCitation.\",\"url\":\"https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2342210\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"Net Benefit and Costs of Preemptive Adult Deceased Donor Kidney ...\",\"description\":\"Jul 22, 2022 Â· The net cost of preemptive transplantation was $54 100 (95% CI, $44 100-$64 100) more than transplantation to a waitlisted patient. If the rateÂ ...\u003c|separator|\u003e\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794481\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"[PDF] Outpatient dialysis services - MedPAC\",\"description\":\"Nov 2, 2023 Â· In 2021, average Medicare spending for patients on dialysis (nearly $98,000) was more than twice the annual spending of those who had a.\",\"url\":\"https://www.medpac.gov/wp-content/uploads/2024/03/Mar24_Ch5_MedPAC_Report_To_Congress_SEC.pdf\",\"favicon\":\"\"},{\"id\":\"148\",\"title\":\"Economic analysis: Dialysis center duopoly keeps commercial ...\",\"description\":\"Jul 8, 2025 Â· Market share of DaVita and Fresenius grew from 59.1% to 77.1%, and that of independent centers declined from 20.4% to 10.6%, according to theÂ ...Missing:  industry oligopoly\",\"url\":\"https://www.healio.com/news/nephrology/20250708/economic-analysis-dialysis-center-duopoly-keeps-commercial-insurance-payments-high\",\"favicon\":\"\"},{\"id\":\"149\",\"title\":\"A Dialysis Duopoly: How Public Funding Entrenched Private Power\",\"description\":\"Aug 7, 2025 Â· DaVita and Fresenius control over two-thirds of the 6,700 facilities that dot the country, and account for 90% of the industry's revenue. TheÂ ...Missing:  oligopoly | Show results with:oligopoly\",\"url\":\"https://lpeproject.org/blog/a-dialysis-duopoly-how-public-funding-entrenched-private-power/\",\"favicon\":\"\"},{\"id\":\"150\",\"title\":\"Top Companies in Hemodialysis and Peritoneal Dialysis Market\",\"description\":\"Apr 17, 2024 Â· Some of the prominent players operating in the market include Fresenius Medical Care AG \u0026 Co. KGaA (Germany), Baxter International, Inc. (US),Â ...\",\"url\":\"https://www.marketsandmarkets.com/ResearchInsight/dialysis-market.asp\",\"favicon\":\"\"},{\"id\":\"151\",\"title\":\"U.S. Dialysis Centers Market Size | Industry Report, 2030\",\"description\":\"The U.S. dialysis centers market size was estimated at USD 29.51 billion in 2024 and is projected to grow at a CAGR of 5.4% from 2025 to 2030.Dialysis Insights Â· Regional Insights Â· Recent Developments\",\"url\":\"https://www.grandviewresearch.com/industry-analysis/us-dialysis-centers-market-report\",\"favicon\":\"\"},{\"id\":\"152\",\"title\":\"Dialysis Market Size, Share \u0026 Growth | Analysis Report [2032]\",\"description\":\"The global dialysis market size was $98.51 billion in 2024 \u0026 is projected to grow from $103.15 billion in 2025 to $181.16 billion by 2032, at a CAGR of 8.4%Missing:  2024-2030 | Show results with:2024-2030\",\"url\":\"https://www.fortunebusinessinsights.com/dialysis-market-102367\",\"favicon\":\"\"},{\"id\":\"153\",\"title\":\"Calendar Year 2025 End-Stage Renal Disease (ESRD) Prospective ...\",\"description\":\"Nov 1, 2024 Â· For CY 2025, CMS is increasing the ESRD PPS base rate to $273.82, which CMS expects will increase total payments to all ESRD facilities, both freestanding andÂ ...\",\"url\":\"https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f\",\"favicon\":\"\"},{\"id\":\"154\",\"title\":\"Payment for Dialysis Services in the Individual Market - PMC\",\"description\":\"Mar 22, 2021 Â· Individual market plans paid approximately 3 times what Medicare paid for dialysis services, underscoring the incentive for facilities toÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7985814/\",\"favicon\":\"\"},{\"id\":\"155\",\"title\":\"Market Competition and Anemia Management in the United States ...\",\"description\":\"We examined whether changes in anemia management following the expansion of Medicare's dialysis payment bundle varied with market competition.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10592119/\",\"favicon\":\"\"},{\"id\":\"156\",\"title\":\"Dialysis Market Size: Trends, Challenges, and Opportunities by 2030\",\"description\":\"The dialysis market is projected to grow at a CAGR of approximately 8% during the forecast period. This growth is driven by the increasing prevalence ofÂ ...\",\"url\":\"https://meditechinsights.com/dialysis-market/\",\"favicon\":\"\"},{\"id\":\"157\",\"title\":\"Impact of dialysis reimbursement policies on care outcomes in ...\",\"description\":\"The results indicate the increase in PD utilization during this period was also accompanied by increases in both technique failure and mortality.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S016885102300101X\",\"favicon\":\"\"},{\"id\":\"158\",\"title\":\"[PDF] Yale University - Thurman Arnold Project\",\"description\":\"May 16, 2024 Â· Fresenius' and DaVita's market shares have grown considerably over the past two decades. In the early 2000s, Fresenius and DaVita possessed 24.3Â ...\",\"url\":\"https://som.yale.edu/sites/default/files/2024-05/Dialysis_Divestitures_6.2.pdf\",\"favicon\":\"\"},{\"id\":\"159\",\"title\":\"Dialysis Centers in the US Industry Analysis, 2025 - IBISWorld\",\"description\":\"The dialysis industry is dominated by just two companies, Fresenius and DaVita. The two companies account for most of the available market. Together, they setÂ ...\",\"url\":\"https://www.ibisworld.com/united-states/industry/dialysis-centers/4038/\",\"favicon\":\"\"},{\"id\":\"160\",\"title\":\"End-Stage Renal Disease (ESRD) - CMS\",\"description\":\"Sep 10, 2024 Â· Beneficiaries may become entitled to Medicare based on ESRD. Benefits on the basis of ESRD are for all covered services, not only those related to the kidneyÂ ...\",\"url\":\"https://www.cms.gov/medicare/coordination-benefits-recovery/overview/end-stage-renal-disease-esrd\",\"favicon\":\"\"},{\"id\":\"161\",\"title\":\"End-Stage Renal Disease (ESRD) - Medicare\",\"description\":\"If you're on dialysis: Medicare coverage usually starts on the first day of the fourth month of your dialysis treatments.Kidney transplants Â· Dialysis services \u0026 supplies Â· Children and ESRD\",\"url\":\"https://www.medicare.gov/basics/end-stage-renal-disease\",\"favicon\":\"\"},{\"id\":\"162\",\"title\":\"Fifty Years of a National Program for the Treatment of Kidney Failure\",\"description\":\"By 1980, Medicare was spending $1.2 billion per year on the ESRD program. An initial attempt to control increasing dialysis costs occurred in 1981 when MedicareÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11090145/\",\"favicon\":\"\"},{\"id\":\"163\",\"title\":\"Medicare Program; End-Stage Renal Disease Prospective Payment ...\",\"description\":\"Nov 12, 2024 Â· This final rule updates and revises the End-Stage Renal Disease (ESRD) Prospective Payment System for calendar year 2025.\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.federalregister.gov/documents/2024/11/12/2024-25486/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis\",\"favicon\":\"\"},{\"id\":\"164\",\"title\":\"Influence of race, ethnicity and socioeconomic status on kidney ...\",\"description\":\"Low SES is associated with increased incidence of chronic kidney disease, progression to end-stage renal disease, inadequate dialysis treatment, reduced accessÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.nature.com/articles/nrneph.2012.117\",\"favicon\":\"\"},{\"id\":\"165\",\"title\":\"Predialysis Nephrology Care and Incident Vascular Access Among ...\",\"description\":\"Sep 5, 2025 Â· This cohort study examines the association of lack of access to predialysis nephrology care with incident vascular access outcomes amongÂ ...Missing:  global | Show results with:global\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838512\",\"favicon\":\"\"},{\"id\":\"166\",\"title\":\"Social Determinants of Health Impacting Access to Renal Dialysis ...\",\"description\":\"Sep 23, 2023 Â· Black, Hispanic, and Asian patients with CKD are more likely to experience limited access to kidney specialists. Awareness is needed in areasÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10593311/\",\"favicon\":\"\"},{\"id\":\"167\",\"title\":\"Medicare Advantage Enrollment Following the 21st Century Cures ...\",\"description\":\"Sep 12, 2024 Â· In this cross-sectional time-trend study of Medicare beneficiaries with ESRD, MA enrollment continued to increase in the second year of the Cures Act.\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823636\",\"favicon\":\"\"},{\"id\":\"168\",\"title\":\"Global variations in funding and use of hemodialysis accesses\",\"description\":\"May 8, 2024 Â· In low-income countries, there is a higher use of temporary dialysis catheters and private funding models for access creation.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03593-z\",\"favicon\":\"\"},{\"id\":\"169\",\"title\":\"[PDF] Global Kidney Health Atlas - International Society of Nephrology\",\"description\":\"In 74% of countries with available dialysis services, \u003e50% of people needing KRT can access dialysis at kidney failure onset; only in 6% of countries areÂ ...\",\"url\":\"https://www.theisn.org/wp-content/uploads/media/ISN%2520Atlas_2023%2520Digital.pdf\",\"favicon\":\"\"},{\"id\":\"170\",\"title\":\"Dialysis in Children - HealthyChildren.org\",\"description\":\"Apr 7, 2023 Â· Chronic Kidney Disease in Children Â· What is a Pediatric Nephrologist? Â· American Society of Pediatric Nephrology Â· National Kidney FoundationÂ ...\",\"url\":\"https://www.healthychildren.org/English/health-issues/conditions/genitourinary-tract/Pages/dialysis-in-children.aspx\",\"favicon\":\"\"},{\"id\":\"171\",\"title\":\"Pediatric Dialysis | SpringerLink\",\"description\":\"Overview Â· Bradley A. Warady Â· Steven R. Alexander Â· Franz Schaefer. Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University ofÂ ...\",\"url\":\"https://link.springer.com/book/10.1007/978-3-030-66861-7\",\"favicon\":\"\"},{\"id\":\"172\",\"title\":\"Challenges of Vascular Access in the Pediatric Population - PubMed\",\"description\":\"A well-functioning vascular access is required for effective hemodialysis and choosing the best vascular access option for pediatric patients can be difficult.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/32891312/\",\"favicon\":\"\"},{\"id\":\"173\",\"title\":\"Clinical practice recommendation 8: Vascular access in pediatric ...\",\"description\":\"Permanent access in the form of a fistula or graft is the preferred form of vascular access for most pediatric patients on maintenance HD therapy. 8.1.2.\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2806%2900666-4/fulltext\",\"favicon\":\"\"},{\"id\":\"174\",\"title\":\"Non-infectious complications of peritoneal dialysis in children\",\"description\":\"Mar 3, 2025 Â· Mechanical issues, such as catheter malposition and dysfunction, are common and can lead to discomfort and diminished dialysis efficiency. AÂ ...\u003c|separator|\u003e\",\"url\":\"https://link.springer.com/article/10.1007/s00467-025-06713-5\",\"favicon\":\"\"},{\"id\":\"175\",\"title\":\"The outcome of chronic dialysis in infants and toddlersâ€”advantages ...\",\"description\":\"The survival of 1-, 3-, 5- and 8-year-old patients was 96%, 88%, 84% and 84% respectively. Severe co-morbidities were present in almost half of those who died.\",\"url\":\"https://academic.oup.com/ndt/article/23/4/1336/1874466\",\"favicon\":\"\"},{\"id\":\"176\",\"title\":\"Outcomes of Maintenance Peritoneal Dialysis in Children - LWW\",\"description\":\"Kaplanâ€“Meier analysis showed that the 1-year patient survival rate was 81.8%, the 2-year patient survival rate was 51.7%, and the 5-year patient survival rateÂ ...\",\"url\":\"https://journals.lww.com/sjkd/fulltext/2023/34010/outcomes_of_maintenance_peritoneal_dialysis_in.6.aspx\",\"favicon\":\"\"},{\"id\":\"177\",\"title\":\"Challenges and Outcomes of Chronic Dialysis in Children\",\"description\":\"Apr 13, 2024 Â· However, it comes with difficult challenges, cardiovascular ones being the most significant and fatal.\",\"url\":\"https://journaljpri.com/index.php/JPRI/article/view/7512\",\"favicon\":\"\"},{\"id\":\"178\",\"title\":\"Peritoneal dialysis in children, what's different: Your questions ...\",\"description\":\"Sep 23, 2024 Â· Children on PD and their families face many psychosocial challenges including high rates of anxiety and depression, academic impairment, andÂ ...\",\"url\":\"https://journals.sagepub.com/doi/10.1177/08968608241273633\",\"favicon\":\"\"},{\"id\":\"179\",\"title\":\"One-Year Mortality After Dialysis Initiation Among Older Adults\",\"description\":\"Apr 22, 2019 Â· Death occurred in 88 patients (22.5%) within 30 days after starting dialysis, 173 (44.2%) within 180 days, and 213 (54.5%) within 365 days. At 1Â ...\",\"url\":\"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730766\",\"favicon\":\"\"},{\"id\":\"180\",\"title\":\"Survival of chronic hemodialysis patients over 80 years of age - PMC\",\"description\":\"In our study, almost one-third of patients that were â‰¥80 years of age survived 12â€“24 months; and one-third of them survived between 24â€“60 months.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3998852/\",\"favicon\":\"\"},{\"id\":\"181\",\"title\":\"Clinical Outcome in Elderly Patients on Chronic Peritoneal Dialysis\",\"description\":\"Survival rates were 97%, 92%, 88%, and 73% in the younger age group and 79%, 67%, 56%, and 30% in the elderly group. Mean patient survival was 57.4 months (95%Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4033330/\",\"favicon\":\"\"},{\"id\":\"182\",\"title\":\"Narrative Review: Clinical Implications and Assessment of Frailty in ...\",\"description\":\"Frailty predicts an approximately 2- to 6-fold increase in risk of death, hospitalization, and progression to dialysis.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2468024923016455\",\"favicon\":\"\"},{\"id\":\"183\",\"title\":\"Prevalence of physical frailty and impact on survival in patients with ...\",\"description\":\"Sep 3, 2023 Â· Frailty is common in chronic kidney disease (CKD) patients and becomes more prevalent as kidney disease progresses.\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03303-1\",\"favicon\":\"\"},{\"id\":\"184\",\"title\":\"Functional Status of Elderly Adults before and after Initiation of Dialysis\",\"description\":\"Oct 15, 2009 Â· Moreover, the extent to which dialysis extends life and its effect on the quality of life in elderly patients who are frail or disabled remainÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa0904655\",\"favicon\":\"\"},{\"id\":\"185\",\"title\":\"Quality of life after the initiation of dialysis or maximal conservative ...\",\"description\":\"Quality of life after the initiation of dialysis or maximal conservative ... Baseline data included demographics, frailty as measured with a geriatricÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/30922246/\",\"favicon\":\"\"},{\"id\":\"186\",\"title\":\"Dialysis may not be the best option for older adults with kidney failure\",\"description\":\"Aug 19, 2024 Â· A Stanford Medicine-led study found that frail older patients who waited to start dialysis died only nine days earlier on average â€“ and spent more time at home.\",\"url\":\"https://news.stanford.edu/stories/2024/08/for-some-older-adults-with-kidney-failure-dialysis-may-not-be-the-best-option\",\"favicon\":\"\"},{\"id\":\"187\",\"title\":\"Survival of Older Patients With Advanced CKD Managed Without ...\",\"description\":\"Mar 11, 2022 Â· Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease? Clin JÂ ...\",\"url\":\"https://www.kidneymedicinejournal.org/article/S2590-0595%2822%2900059-0/fulltext\",\"favicon\":\"\"},{\"id\":\"188\",\"title\":\"Shared decision making in elderly patients with kidney failure\",\"description\":\"Among a cohort of 3418 elderly patients who underwent pre-dialysis VA creation, 67.4% started dialysis, 15.1% died and 17.5% survived without requiring dialysisÂ ...WHICH CHOICE BETWEEN... Â· IF DIALYSIS IS CHOSEN... Â· CALL TO ACTION\u003c|separator|\u003e\",\"url\":\"https://academic.oup.com/ndt/article/39/5/742/7281724\",\"favicon\":\"\"},{\"id\":\"189\",\"title\":\"History of the Science of Dialysis | American Journal of Nephrology\",\"description\":\"Oct 28, 2008 Â· Unaware of Abel's work, Georg Haas (1886-1971) performed the first human dialysis in the German town of Giessen in 1924. But it was notÂ ...\",\"url\":\"https://karger.com/ajn/article/17/3-4/289/326285/History-of-the-Science-of-Dialysis\",\"favicon\":\"\"},{\"id\":\"190\",\"title\":\"Milestones in dialysis and transplantation - edren.org\",\"description\":\"Apr 3, 2019 Â· 1913, Artificial kidney developed â€“ John Abel (Baltimore) â€“ More ; 1924, First human dialysis â€“ George Haas (Giessen) â€“ More ; 1943, Rotating drumÂ ...\",\"url\":\"https://edren.org/ren/unit/history/milestones-in-nephrology/\",\"favicon\":\"\"},{\"id\":\"191\",\"title\":\"History of the science of dialysis - PubMed\",\"description\":\"In 1913, John Abel and coworkers reported the first application of the principles of diffusion to remove substances from the blood of living animals. UnawareÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/9189249/\",\"favicon\":\"\"},{\"id\":\"192\",\"title\":\"The history of dialysis - Fresenius Medical Care\",\"description\":\"In fall 1945, Willem Kolff, of the Netherlands, made the breakthrough that had stubbornly eluded Haas. Kolff used a rotating drum kidney he had developed toÂ ...\",\"url\":\"https://freseniusmedicalcare.com/en/media/insights/company-features/the-history-of-dialysis/\",\"favicon\":\"\"},{\"id\":\"193\",\"title\":\"The Evolving Ethics of Dialysis in the United States - NIH\",\"description\":\"beneficence, nonmaleficence, autonomy and justice â€” have been weightedÂ ...Missing:  peer- | Show results with:peer-\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4822659/\",\"favicon\":\"\"},{\"id\":\"194\",\"title\":\"God Panels and the History of Hemodialysis in America\",\"description\":\"Nov 1, 2012 Â· Introduced with the noble intentions of restoring patient dignity and autonomy, the ESRD program has mushroomed into an unsustainable behemoth.\",\"url\":\"https://journalofethics.ama-assn.org/article/god-panels-and-history-hemodialysis-america-cautionary-tale/2012-11\",\"favicon\":\"\"},{\"id\":\"195\",\"title\":\"The Early History of Dialysis for Chronic Renal Failure in the United ...\",\"description\":\"In 1959, Richard Ruben in San Francisco was the first to use peritoneal dialysis (PD) successfully for a patient with chronic renal failure who survived for 6Â ...\u003c|separator|\u003e\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2807%2900116-3/fulltext\",\"favicon\":\"\"},{\"id\":\"196\",\"title\":\"Continuous Ambulatory Peritoneal Dialysis (CAPD) - LWW\",\"description\":\"Continuous ambulatory peritoneal dialysis (CAPD) was first described in 1976 by Popovich et al. They called the procedure \\\"equilibrium peritoneal dialysisÂ ...\",\"url\":\"https://journals.lww.com/sjkd/fulltext/1995/06010/continuous_ambulatory_peritoneal_dialysis__capd_.8.aspx\",\"favicon\":\"\"},{\"id\":\"197\",\"title\":\"[PDF] Continuous ambulatory peritoneal dialysis\",\"description\":\"Introduced by Popovich et al,1 in 1976, continu- ous ambulatory peritoneal dialysis (CAPD) has the potential for affecting the extent to which perito-.\",\"url\":\"https://www.ccjm.org/content/ccjom/47/4/285.full.pdf\",\"favicon\":\"\"},{\"id\":\"198\",\"title\":\"Historical Milestones in Peritoneal Dialysis - Karger Publishers\",\"description\":\"This chapter will describe the various milestones in the field of PD achieved over the years. These include the understanding of solute and water transportÂ ...\",\"url\":\"https://karger.com/books/book/120/chapter/5059608/Historical-Milestones-in-Peritoneal-Dialysis\",\"favicon\":\"\"},{\"id\":\"199\",\"title\":\"Comparison of Quality of Life on Automated Peritoneal Dialysis and ...\",\"description\":\"Automated peritoneal dialysis (APD) was first described in 1981, 5 years after the introduction of continuous ambulatory peritoneal dialysis (CAPD).\",\"url\":\"https://clinicaltrials.gov/study/NCT01209273\",\"favicon\":\"\"},{\"id\":\"200\",\"title\":\"Baxter introduces Automated Peritoneal Dialysis Cycler in 1984\",\"description\":\"Sep 7, 2025 Â· A milestone in dialysis history â€“ The Automated Peritoneal Dialysis (#APD) Cycler Back in 1984, #Baxter (then Travenol Laboratories)Â ...\",\"url\":\"https://www.linkedin.com/posts/arun-bhim-singh-_apd-baxter-this-activity-7370391987830599680-G_pv\",\"favicon\":\"\"},{\"id\":\"201\",\"title\":\"Evolution of discoveries enabling development of hemodialysis for ...\",\"description\":\"In 1980, the F60 polysulfone dialyzer/ultrafilter was developed as a highflux dialyzer with a capability to minimize the diminution of white blood cellÂ ...\",\"url\":\"https://www.researchgate.net/figure/Evolution-of-discoveries-enabling-development-of-hemodialysis-for-renal-failure-in-the_tbl1_5458717\",\"favicon\":\"\"},{\"id\":\"202\",\"title\":\"Information for Epogen/Procrit (Epoetin alfa) - FDA\",\"description\":\"Apr 13, 2017 Â· Epogen/Procrit was approved on June 1, 1989 for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients notÂ ...\",\"url\":\"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa\",\"favicon\":\"\"},{\"id\":\"203\",\"title\":\"Epoetin Alfa - StatPearls - NCBI Bookshelf\",\"description\":\"Jun 8, 2024 Â· The Food and Drug Administration (FDA) approved epoetin alfa in 1989 for treating anemia in patients with chronic kidney disease (CKD),Â ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK554547/\",\"favicon\":\"\"},{\"id\":\"204\",\"title\":\"[PDF] System One - NxStage.com\",\"description\":\"Home dialysis with NxStage makes more frequent dialysis practical. NxStage patients usually dialyze 5 to 6 times a week, 2Â½ to 3 hours per treatment. But unlikeÂ ...\",\"url\":\"https://ww3.nxstage.com/wp-content/uploads/2017/12/introducing_the_nxstage_system_one.pdf\",\"favicon\":\"\"},{\"id\":\"205\",\"title\":\"Wearable Artificial Kidneys: The First Choice for Portable Renal ...\",\"description\":\"Automated wearable artificial kidney (AWAK) is a leading medical innovation technology in which two products have been developedâ€“AWAK-peritoneal dialysis (AWAKÂ ...\",\"url\":\"https://journals.lww.com/imna/fulltext/2024/06000/wearable_artificial_kidneys__the_first_choice_for.9.aspx\",\"favicon\":\"\"},{\"id\":\"206\",\"title\":\"The current and future landscape of dialysis - PMC - PubMed Central\",\"description\":\"Jul 30, 2020 Â· This Review describes the current landscape of dialysis therapy from an epidemiological, economic, ethical and patient-centred framework.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7391926/\",\"favicon\":\"\"},{\"id\":\"207\",\"title\":\"The God Committee | American Enterprise Institute - AEI\",\"description\":\"Jun 17, 2008 Â· In 1962, Seattle's Swedish Hospital established what later came to be called the â€œGod Committee.â€ Formally known as the Admissions and PolicyÂ ...\",\"url\":\"https://www.aei.org/articles/the-god-committee/\",\"favicon\":\"\"},{\"id\":\"208\",\"title\":\"The God Committee - RealClearPolicy\",\"description\":\"Dec 9, 2020 Â· They convened in the summer of 1961 in Seattle because a professor of medicine at the University of Washington had invented a new method ofÂ ...\",\"url\":\"https://www.realclearpolicy.com/2020/12/09/the_god_committee_652383.html\",\"favicon\":\"\"},{\"id\":\"209\",\"title\":\"[PDF] Dialysis rationing and the just allocation of resources\",\"description\":\"The federal government avoided the ethical question of who was to receive an expensive, scarce resource, and instead provided the resource to everyone whoÂ ...\",\"url\":\"https://www.kidney.org/sites/default/files/v36b_a4.pdf\",\"favicon\":\"\"},{\"id\":\"210\",\"title\":\"Ethical Issues - Kidney Failure and the Federal Government - NCBI\",\"description\":\"Three types of patients raise ethical problems for ESRD caregivers today: the noncompliant, self-destructive dialysis patient; the hostile, abusive dialysisÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK234421/\",\"favicon\":\"\"},{\"id\":\"211\",\"title\":\"The Future of Kidney Care in Low- and Middle-Income Countries\",\"description\":\"Often dialysis has to be rationed to allow only those who can undergo kidney transplants. Most countries in Africa lack data on KRT.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11296549/\",\"favicon\":\"\"},{\"id\":\"212\",\"title\":\"The dangers of rationing dialysis treatment: The dilemma facing a ...\",\"description\":\"Aug 6, 2025 Â· Almost 60% of patients were denied renal replacement treatment because of social factors related to poverty. In a developing country, whereÂ ...\",\"url\":\"https://www.researchgate.net/publication/6904071_The_dangers_of_rationing_dialysis_treatment_The_dilemma_facing_a_developing_country\",\"favicon\":\"\"},{\"id\":\"213\",\"title\":\"report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)\",\"description\":\"Apr 8, 2024 Â· Globally, there remain significant disparities in the capacity and quality of kidney care, as evidenced by the third edition of theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11010612/\",\"favicon\":\"\"},{\"id\":\"214\",\"title\":\"Doctors At Hard-Hit Hospitals Say They're Facing Shortage Of ... - NPR\",\"description\":\"Apr 19, 2020 Â· MOGUL: Doctors at at least two hospitals in the city say they're coping with the shortage by taking patients off 24-hour continuous dialysis.\",\"url\":\"https://www.npr.org/2020/04/19/837727691/doctors-at-hard-hit-hospitals-say-theyre-facing-shortage-of-dialysis-equipment\",\"favicon\":\"\"},{\"id\":\"215\",\"title\":\"Doctors push to include dialysis machines in emergency stockpile\",\"description\":\"Aug 7, 2023 Â· Some advocates have begun pushing for dialysis equipment to once again be included in the US Strategic National Stockpile (SNS), a cache of essential medicalÂ ...\",\"url\":\"https://www.statnews.com/2023/08/07/kidney-failure-dialysis-stockpile/\",\"favicon\":\"\"},{\"id\":\"216\",\"title\":\"A Call for Dialysis-Specific Resource Allocation Guidelines During ...\",\"description\":\"Jul 27, 2020 Â· Notably absent, however, is consideration of ethical issues in the provision of care for people with end-stage kidney disease (ESKD) during theÂ ...\",\"url\":\"https://www.tandfonline.com/doi/full/10.1080/15265161.2020.1777346\",\"favicon\":\"\"},{\"id\":\"217\",\"title\":\"The realities of rationing in health care | Nature Reviews Nephrology\",\"description\":\"Feb 15, 2021 Â· Rationing is seldom required in high-income settings but is often necessary in low-income settings. Global solidarity and health systemÂ ...\",\"url\":\"https://www.nature.com/articles/s41581-021-00404-8\",\"favicon\":\"\"},{\"id\":\"218\",\"title\":\"A Randomized, Controlled Trial of Early versus Late Initiation of ...\",\"description\":\"Jun 27, 2010 Â· In this study, planned early initiation of dialysis in patients with stage V chronic kidney disease was not associated with an improvement in survival orÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa1000552\",\"favicon\":\"\"},{\"id\":\"219\",\"title\":\"[PDF] Level of Renal Function at the Time of Dialysis Initiation ... - KDIGO\",\"description\":\"Early start (vs. late start) dialysis does NOT: â€“ Reduce mortality. â€“ Improve cardiac outcomes. â€“ Improve nutritional status. â€“ Decrease infections.Missing:  chronic | Show results with:chronic\",\"url\":\"https://kdigo.org/wp-content/uploads/2017/02/10.-Harris-DialysisInitiationKDIGO1216a.pdf\",\"favicon\":\"\"},{\"id\":\"220\",\"title\":\"Update of dialysis initiation timing in end stage kidney disease patients\",\"description\":\"Jun 7, 2023 Â· The optimal start was defined when all the following criteria were met: a planned dialysis start, a minimum of 6-month follow-up by aÂ ...\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-023-03184-4\",\"favicon\":\"\"},{\"id\":\"221\",\"title\":\"The impact of early versus late initiation of renal replacement ...\",\"description\":\"May 12, 2022 Â· Early RRT initiation does not improve the 28-day and overall mortality, nor the likelihood of RRF, and increases the risk for RRT-associated adverse events.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/36158157/\",\"favicon\":\"\"},{\"id\":\"222\",\"title\":\"[PDF] Appropriate Dialysis Access - KDIGO\",\"description\":\"KHA/CARI Guidelines 2013. â€“ All patients, especially those with co-morbid conditions, should be referred to a vascular access.Missing:  methods | Show results with:methods\",\"url\":\"https://kdigo.org/wp-content/uploads/2017/02/Polkinghorne_KDIGO-Dialysis-Initiation-Presentation.pdf\",\"favicon\":\"\"},{\"id\":\"223\",\"title\":\"Association Between the IDEAL Trial and Dialysis Initiation Timing\",\"description\":\"May 28, 2019 Â· The Initiating Dialysis Early and Late trial appeared to be associated with an immediate and sustained change in the timing of dialysis initiation in Canada.\",\"url\":\"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2733562\",\"favicon\":\"\"},{\"id\":\"224\",\"title\":\"Home Dialysis Hampered by Barriers Despite Financial Incentives\",\"description\":\"Jul 8, 2024 Â· Financial incentives to increase the use of home dialysis and kidney transplantation in the US have not sped up adoption, the latest data show.\",\"url\":\"https://www.renalandurologynews.com/news/home-dialysis-hampered-by-barriers-despite-financial-incentives/\",\"favicon\":\"\"},{\"id\":\"225\",\"title\":\"Identifying Major Barriers to Home Dialysis (The IM-HOME Study)\",\"description\":\"Jun 6, 2024 Â· The top 3 barriers listed by patients and care partners were (1) fear of performing dialysis at home; (2) limited space at home for the dialysisÂ ...\",\"url\":\"https://www.ajkd.org/article/S0272-6386%2824%2900790-X/fulltext\",\"favicon\":\"\"},{\"id\":\"226\",\"title\":\"6 Major Barriers That Stop Patients from Doing Home Dialysis\",\"description\":\"Jul 29, 2024 Â· 1. Fear of Performing Dialysis at Home Â· 2. Limited Space at Home Â· 3. Need for More Home-Based Support.\",\"url\":\"https://ldi.upenn.edu/our-work/research-updates/6-major-barriers-that-stop-patients-from-doing-home-dialysis/\",\"favicon\":\"\"},{\"id\":\"227\",\"title\":\"Unveiling Challenges Hindering the Growth of Home Dialysis in ...\",\"description\":\"Mar 6, 2025 Â· From the patient's perspective, the financial burden and the impact of home dialysis on the assistant or relative constitute critical barriers.\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/hdi.13213?af=R\",\"favicon\":\"\"},{\"id\":\"228\",\"title\":\"[PDF] Psychosocial Barriers to Home Dialysis: A Literature Review\",\"description\":\"The literature identified multiple psychosocial barriers to successful home dialysis: physical ability, cognition, patient attitudes toward home dialysis,.\",\"url\":\"https://www.kidney.org/sites/default/files/v36a_a1.pdf\",\"favicon\":\"\"},{\"id\":\"229\",\"title\":\"A Systematic Review of the Qualitative Research on Barriers ... - NIH\",\"description\":\"The most significant capabilities barrier to home HD was a lack of knowledgeâ€”for both patients and healthcare providers [16, 17, 18, 19, 20]. Patients cannotÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12531936/\",\"favicon\":\"\"},{\"id\":\"230\",\"title\":\"Cost Barriers to More Widespread Use of Peritoneal Dialysis in ... - NIH\",\"description\":\"A survey New Zealand found that participants who were socioeconomically disadvantaged faced substantial economic barriers to home dialysis, including unsuitableÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9161798/\",\"favicon\":\"\"},{\"id\":\"231\",\"title\":\"Annotated Barriers to Peritoneal and Home Hemodialysis in the U.S.\",\"description\":\"It requires designated equipment, space, and staff. The lack of a transitional care program is a barrier to the growth of PD. Home dialysis clinics must haveÂ ...\",\"url\":\"https://www.mdpi.com/2673-8236/5/2/18\",\"favicon\":\"\"},{\"id\":\"232\",\"title\":\"Addressing the inequity of access to home Dialysis in Europe\",\"description\":\"Jun 3, 2025 Â· Several, predominantly modifiable barriers have been described that explain this inequity of access, but as yet no recommendations have beenÂ ...\u003c|separator|\u003e\",\"url\":\"https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04188-y\",\"favicon\":\"\"},{\"id\":\"233\",\"title\":\"Home dialysis: advantages and limitations | Clinical Kidney Journal\",\"description\":\"Jul 3, 2024 Â· The main financial barriers to home dialysis are the high initial setup costs for HHD equipment and ongoing consumable costs for PD, along withÂ ...\",\"url\":\"https://academic.oup.com/ckj/article/17/7/sfae180/7705608\",\"favicon\":\"\"},{\"id\":\"234\",\"title\":\"Systematic Barriers to the Effective Delivery of Home Dialysis in the ...\",\"description\":\"Sep 9, 2011 Â· However, many systematic barriers exist to the successful delivery of home dialysis. ... All stakeholders share the goal of delivering homeÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0272638611011437\",\"favicon\":\"\"},{\"id\":\"235\",\"title\":\"An Update on Portable, Wearable, and Implantable Artificial Kidneys\",\"description\":\"We provide a nonexhaustive overview of promising ways to increase the mobility of technology-based KRTs by dialysate regeneration, chip-based nanoporous ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0272638625000538\",\"favicon\":\"\"},{\"id\":\"236\",\"title\":\"SNU researchers develop portable artificial kidney, paving the way ...\",\"description\":\"Apr 3, 2025 Â· A wearable peritoneal dialysis device could be realized by continuously purifying used dialysis fluid externally and reinfusing it into the peritoneal cavity.\",\"url\":\"https://www.eurekalert.org/news-releases/1079258\",\"favicon\":\"\"},{\"id\":\"237\",\"title\":\"The Wearable Artificial Kidney - PMC - NIH\",\"description\":\"An implantable artificial kidney (IAK) is under development but not yet tested in humans. In this approach, a small manmade kidney would be surgically insertedÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7812841/\",\"favicon\":\"\"},{\"id\":\"238\",\"title\":\"iBAK - Implantable Bio-Artificial Kidney for Continuous Renal ...\",\"description\":\"This compact device will provide kidney failure patients with continuous treatment without being tethered to an external machine.\u003c|separator|\u003e\",\"url\":\"https://www.kidneyx.org/prize-winners/implantable-bioartificial-kidney/\",\"favicon\":\"\"},{\"id\":\"239\",\"title\":\"The Future of Artificial Kidneys - National Kidney Foundation\",\"description\":\"Jul 25, 2024 Â· The Kidney Project's artificial kidney is an implantable biomedical device that will work like a natural kidney and provide 24/7 treatment.\",\"url\":\"https://www.kidney.org/news-stories/future-artificial-kidneys\",\"favicon\":\"\"},{\"id\":\"240\",\"title\":\"Artificial Intelligence and Machine Learning in Predicting Intradialytic ...\",\"description\":\"The findings of this systematic review highlight the potential of leveraging AI/ML techniques for predicting IDH in hemodialysis patients. The included studiesÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11344373/\",\"favicon\":\"\"},{\"id\":\"241\",\"title\":\"Dialysis adequacy predictions using a machine learning method\",\"description\":\"Jul 29, 2021 Â· This study used machine learning models to predict dialysis adequacy in chronic hemodialysis patients using repeatedly measured data during hemodialysis.Results Â· Model Performances Â· Feature Importance\",\"url\":\"https://www.nature.com/articles/s41598-021-94964-1\",\"favicon\":\"\"},{\"id\":\"242\",\"title\":\"Precision Dialysis: Leveraging Big Data and Artificial Intelligence\",\"description\":\"The introduction of more physiologic and smart dialysis systems equipped with AI approaches can enable learning from individual and collective treatment dataÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S2590059524000797\",\"favicon\":\"\"},{\"id\":\"243\",\"title\":\"Advancements in membrane materials for hemodialysis\",\"description\":\"Nanoparticles incorporation enhances the mechanical strength, permeability, fouling resistance, and antimicrobial properties of the membranes. For instance,Â ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S1383586625023159\",\"favicon\":\"\"},{\"id\":\"244\",\"title\":\"Evaluation of nano-porous alumina membranes for hemodialysis ...\",\"description\":\"Alumina membrane has higher solute clearances and no albumin leakage, which makes it an effective replacement for current dialysis membranes.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/19293709/\",\"favicon\":\"\"},{\"id\":\"245\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.tandfonline.com/doi/full/10.1080/15583724.2025.2512945\",\"favicon\":\"\"},{\"id\":\"246\",\"title\":\"Development of the Implantable Artificial Kidney - Preprints.org\",\"description\":\"May 24, 2025 Â· The implantable artificial kidney combines multiple technological advances, such as silicon nanoporous membranes, cellular bioreactors, ...\",\"url\":\"https://www.preprints.org/manuscript/202505.1959/v1\",\"favicon\":\"\"},{\"id\":\"247\",\"title\":\"Kidney Technologies on the Horizon\",\"description\":\"Jun 6, 2025 Â· The VIVANCE system (formerly AWAK) from Singapore uses innovative technology to regenerate dialysis fluid, making it portable enough to carry inÂ ...\",\"url\":\"https://www.kidney.org.uk/news/kidney-technologies-on-the-horizon\",\"favicon\":\"\"},{\"id\":\"248\",\"title\":\"A Dream Starting to Come True: Wearable Kidneys\",\"description\":\"The only device to have been tested in humans is the WAK (wearable artificial kidney). Three human studies have been done so far with good success, and thereÂ ...\",\"url\":\"https://www.kidney.org/news-stories/dream-starting-to-come-true-wearable-kidneys\",\"favicon\":\"\"},{\"id\":\"249\",\"title\":\"Stem cells: a potential treatment option for kidney diseases\",\"description\":\"Jun 25, 2020 Â· Stem cell therapy opens new avenues for the development of renal function and structural repair in kidney diseases.\",\"url\":\"https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01751-2\",\"favicon\":\"\"},{\"id\":\"250\",\"title\":\"UC Davis Health launches new cell therapy trial for chronic kidney ...\",\"description\":\"Apr 3, 2025 Â· Novel therapy could restore kidney function in some patients with renal disease due to type 2 diabetes. (SACRAMENTO). About one in seven peopleÂ ...\",\"url\":\"https://health.ucdavis.edu/news/headlines/uc-davis-health-launches-new-cell-therapy-trial-for-chronic-kidney-disease-patients/2025/04\",\"favicon\":\"\"},{\"id\":\"251\",\"title\":\"Cell therapy in kidney diseases: advancing treatments for renal ...\",\"description\":\"Dec 11, 2024 Â· A longitudinal study spanning a decade has demonstrated that episodes of AKI can result in persistent renal dysfunction, with many patientsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11669058/\",\"favicon\":\"\"},{\"id\":\"252\",\"title\":\"Worldwide hotspots and trends in stem cell therapy for kidney ...\",\"description\":\"This 'disease-in-a-dish' model affords an unprecedented platform for the systematic investigation of pathogenesis in individual-specific renal diseases, servingÂ ...\",\"url\":\"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1619291/full\",\"favicon\":\"\"},{\"id\":\"253\",\"title\":\"Emerging Biomarkers and Advanced Diagnostics in Chronic Kidney ...\",\"description\":\"May 13, 2025 Â· As research continues to validate its role in kidney disease progression, suPAR is expected to become an integral part of personalizedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/\",\"favicon\":\"\"},{\"id\":\"254\",\"title\":\"New study: Pig kidneys â€” for the first time â€” demonstrate â€œlife ...\",\"description\":\"Aug 16, 2023 Â· ... kidney-disease person on chronic dialysis. About 5 to 15 percent of dialysis patients die yearly, and the eight-year survival rate is onlyÂ ...\",\"url\":\"https://www.uab.edu/news/health-medicine/new-study-pig-kidneys-for-the-first-time-demonstrate-life-sustaining-kidney-function-in-a-human\",\"favicon\":\"\"},{\"id\":\"255\",\"title\":\"The future of nephrology in 2050 - PMC - PubMed Central - NIH\",\"description\":\"Mar 31, 2025 Â· By 2050, breakthroughs in kidney disease prevention, dialysis, transplantation, and omics-driven precision medicine could redefine patient care and outcomes.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11998293/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"999f6156f494\",\"caption\":\"Hemodialysis machine\",\"url\":\"./_assets_/Hemodialysismachine.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"48c7f6f5a63a\",\"caption\":\"Key principles of dialysis\",\"url\":\"./_assets_/Osmosis_Diffusion_Ultrafiltration_and_Dialysis.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"48c7f6f5a63a\",\"caption\":\"Illustration of dialysis mechanisms\",\"url\":\"./_assets_/Osmosis_Diffusion_Ultrafiltration_and_Dialysis.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"bc45ea639d64\",\"caption\":\"Hemodialysis schematic\",\"url\":\"./_assets_/Hemodialysis-en.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"999f6156f494\",\"caption\":\"Hemodialysis machine\",\"url\":\"./_assets_/Hemodialysismachine.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"fcdb60c3bba4\",\"caption\":\"Peritoneal dialysis exchange\",\"url\":\"./_assets_/Peritoneal_dialysis.gif\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"5bb42f31e94d\",\"caption\":\"Arteriovenous fistula in the arm\",\"url\":\"./_assets_/Dialysis_-_arm_-_01.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"999f6156f494\",\"caption\":\"Hemodialysis machine\",\"url\":\"./_assets_/Hemodialysismachine.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Kidney_dialysis\",\"title\":\"Kidney dialysis\",\"content\":\"$1f\",\"description\":\"Kidney dialysis\\n\\nHemodialysis machine \\nKidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose...\",\"metadata\":{\"categories\":[\"dialysis\",\"renal dialysis\"],\"lastModified\":\"1761583233\",\"contentLength\":\"117782\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"262343\",\"recentViews\":\"262343\",\"dailyAvgViews\":8744.7666015625,\"qualityScore\":1,\"lastViewed\":\"1761887036\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887036788,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Kidney_dialysis\"],\"queryHash\":\"[\\\"page\\\",\\\"Kidney_dialysis\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Kidney dialysis\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury. The procedure mimics the kidneys' natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences. The two main...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"dialysis, renal dialysis\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Kidney_dialysis\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Kidney dialysis\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury. The procedure mimics the kidneys' natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences. The two main...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Kidney_dialysis\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Kidney dialysis\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:43.233Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Kidney dialysis\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Kidney dialysis is a renal replacement therapy that artificially removes waste products, excess fluids, and electrolytes from the blood of patients whose kidneys can no longer perform these functions adequately, primarily due to end-stage renal disease or acute kidney injury. The procedure mimics the kidneys' natural filtration processes of diffusion and ultrafiltration, using a semipermeable membrane to separate solutes based on concentration gradients and pressure differences. The two main...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZWJlODRiZTctOTViNi00M2U3LThiMDgtMTNmOTgyNGFiYWEy">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Kidney_dialysis\"}]}]\n"])</script></body></html>